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TB	   tuberculosis	  
TB	  Sup	   filter-­‐sterilised	  supernatant	  of	  M.	  tuberculosis	  
TIMP	   tissue	  inhibitor	  of	  metalloproteinase	  
TNFα	   tumour	  necrosis	  factor	  alpha	  
TST	   tuberculin	  skin	  test	  
UV	   ultra-­‐violet	  
UVTB	   ultra-­‐violet	  killed	  M.	  tuberculosis,	  resuspended	  in	  original	  supernatant	  
WHO	   World	  Health	  Organization	  
wUVTB	   washed	  ultra-­‐violet	  killed	  M.	  tuberculosis,	  resuspended	  in	  fresh	  7H9	  media	  
XDR	   extensively-­‐drug	  resistant	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Tuberculosis	  kills	  more	  people	  than	  any	  other	  bacterial	  disease.	  The	  characteristic	  tissue	  destruction	  
that	   occurs	   during	   infection	   contributes	   to	  morbidity,	   mortality,	   and	   transmission.	   Tissue	   damage	  
limits	  antibiotic	  effectiveness,	  and	  generates	  regions	  of	   immune	  privilege.	  Therefore,	  therapies	  that	  
target	  tissue	  destruction	  may	  improve	  treatment	  outcomes.	  
	  
Currently,	  modelling	  tissue	  destruction	   in	  vivo	  requires	  the	   infection	  of	   large	  animals	  for	  prolonged	  
periods.	  These	  models	  are	  highly	  variable	  in	  outcome.	  This	  makes	  experimentation	  challenging,	  and	  
limits	   there	   use	   in	   testing	   therapeutic	   strategies,	   which	   in	   turn	   limits	   the	   progression	   of	   potential	  
therapies	  to	  clinical	  trials.	  
	  
This	  thesis	  outlines	  the	  development	  of	  a	  highly	  consistent	  rabbit	  model	  of	  cavitary	  tuberculosis,	   in	  
which	   novel	   therapies	   can	   be	   investigated,	   using	   small	   groups	   of	   animals.	   A	   method	   to	   assess	  
pathology	   in	   vivo	   by	   breath-­‐hold	   computed	   tomography	   was	   also	   developed.	   Matrix	  
metalloproteinase-­‐1	   is	   confirmed	   as	   a	   potential	  mediator	   of	   tissue	   destruction,	   and	   cathepsin	   K	   is	  
newly	  identified	  as	  a	  potential	  mediator	  of	  tissue	  destruction.	  These	  collagenases	  are	  targetable	  with	  
the	  drugs	  Cipemastat	  and	  Odanacatib	  respectively,	  both	  of	  which	  are	  safe	  in	  man.	  
	  
This	  thesis	  provides	  a	  novel	  system	  for	  trialling	  treatments	  for	  tuberculosis	  in	  the	  context	  of	  human-­‐	  
like,	   tissue-­‐destructive	   pathology.	   This	   may	   facilitate	   the	   selection	   of	   both	   antibiotic	   and	   non-­‐	  
antibiotic	  treatment	  strategies	   for	  tuberculosis.	  This	  model	  will	  allow	  for	  a	  better	  understanding	  of	  
the	   physical,	   chemical,	   molecular,	   genetic	   and	   immunological	   characteristics	   and	   determinants	   of	  
cavitary	  tuberculosis.	  




This	  chapter	  gives	  a	  brief	  overview	  of	  the	  tuberculosis	  (TB)	  epidemic,	  and	  describes	  why	  basic	  science	  
is	  essential	   to	  TB	  eradication.	   I	  suggest	   that	  by	  defining	  disease	  by	  the	  pathology	   involved,	  we	  may	  
identify	   specific	   preventative,	   diagnostic,	   and	   curative	   measures.	   I	   then	   describe	   TB	   pathology,	  
focussing	   on	   the	   importance	   of	   tissue	   destruction	   in	   active	   disease.	   This	   forms	   the	   conceptual	  
framework	  for	  understanding	  the	  reasons	  for	  pursuing	  this	  research.	   I	   then	  discuss	  the	  benefits	  and	  
limitations	   of	   current	   animal	  models	   of	   TB,	   and	   how	   the	   rabbit	   may	   specifically	   help	   us	   to	   better	  
understand	   tissue	   destruction.	   I	   summarise	   current	   evidence	   that	   suggests	   that	   matrix-­‐ degrading	  
enzymes,	   especially	   matrix	   metalloproteinase-­‐1	   (MMP-­‐1),	   are	   important	   in	   TB	   related	   tissue	  
destruction.	   I	   explain	  why,	   in	  order	   to	   understand	   therapeutics	   in	   the	   context	   of	   tissue	  destruction,	  
and	  understand	  the	  mechanisms	  that	  cause	  tissue	  destruction,	  we	  must	  develop	  a	  reliable	  model	  of	  
tissue	  destruction,	  in	  which	  experiments	  can	  be	  carried	  out.	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1.1. Tuberculosis;	  a	  challenging	  pandemic	  
	  
1.1.1. Tuberculosis	   is	   a	   major	   global	   health	   concern,	   complicated	   by	   HIV	   co-­‐infection	  
and	  antibiotic	  resistance	  
TB	  	  	  kills	  	  	  more	  	  	  people	  	  	  than	  	  	  any	  	  	  other	  	  	  bacterial	  	  	  disease.	  	  	  The	  	  	  majority	  	  	  of	  	  	  its	  	  	  victims	  	  	  are	  
immunocompetent	   individuals	  of	  working	  age,	  with	   fully-­‐treatable	  pulmonary	  disease.	   In	  2011,	  the	  
World	  Health	  Organization	   (WHO)	  estimated	   that;	   1.45	  million	  people	   died	   from	   infection,	   8.5-­‐9.2	  
million	  new	  cases	  occurred,	  and	  11-­‐14	  million	  people	  were	  living	  with	  active	  disease	  (1).	  
	  
At	  the	  individual	  level,	  TB	  causes	  a	  debilitating	  disease,	  personal	  suffering	  and	  death.	  Within	  a	  family	  
it	  often	  targets	  the	  bread-­‐winners	  and	  parents	  of	  young	  children	  –	  in	  2010,	  nearly	  10	  million	  children	  
were	   orphaned	   by	   TB	   (2).	   In	   a	   community	   it	   evokes	   fear,	   which	   leads	   to	   discrimination	   and	   even	  
persecution	  (3).	  It	  causes	  the	  loss	  of	  working	  hours	  in	  productive	  populations,	  and	  is	  a	  huge	  burden	  
on	  healthcare	  systems	  in	  developing	  countries	  (1).	  TB	  affects	  global	  politics;	  it	  determines	  travel	  and	  
immigration	  policies,	   foreign	   aid	   requirements	   and	  policy,	   not	   only	   in	   endemic	   countries,	   but	   also	  
those	  seeking	  to	  interact	  with	  them.	  On	  an	  economic	  level	  the	  World	  Bank	  has	  estimated	  that	  TB	  has	  
a	  total	  economic	  cost	  of	  519	  billion	  dollars	  in	  sub	  Saharan	  Africa	  alone	  (4).	  The	  effect	  of	  this	  bacterial	  
disease	  is	  felt	  at	  every	  level	  –	  the	  ‘TB	  problem’	  is	  both	  global	  and	  personal.	  
	  
Mycobacterium	   tuberculosis	   (M.	   tb),	   the	   bacteria	   that	   causes	   TB,	   has	   also	   proven	   a	   deadly	  
pathogen	  in	  Human	  Immunodeficiency	  Virus	  (HIV)	   infected	   individuals.	  M.	  tb	   infection	   is	  estimated	  
to	  be	   responsible	   for	  20%	  of	  HIV-­‐related	  deaths,	  and	  HIV	  contributes	   to	  13%	  of	  all	  deaths	   from	  TB	  
(1).	  
	  
Finally,	   as	   with	   all	   bacterial	   infections,	   the	   increasing	   prevalence	   of	   antibiotic	   resistance	   is	  
concerning,	  especially	  because	  TB	  treatment	  options	  are	  already	   limited.	   It	   is	  estimated	  that	  4%	  of	  
new	   TB	   cases	   are	   resistant	   to	   two	   or	   more	   first	   line	   drugs	   (i.e.	   multi-­‐drug	   resistant	   tuberculosis;	  
MDR-­‐TB)	   (1).	  Worryingly,	  MDR-­‐TB	  appears	   to	  be	  epidemic	   in	  certain	  regions	   in	  Eastern	  Europe,	   for	  
example,	  in	  Russia,	  it	  accounts	  for	  20%	  of	  the	  140,000	  cases	  per	  annum	  (5).	  The	  last	  decade	  has	  also	  
seen	   the	   emergence	   of	   extensively	   drug-­‐resistant	   TB	   (XDR-­‐TB),	   which	   has	   now	   been	   reported	   in
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nearly	  every	  region	  where	  TB	  is	  diagnosed	  (1).	  Fatality	  rates	  of	  up	  to	  97%	  in	  HIV-­‐positive	  individuals	  
with	  XDR-­‐TB	  have	  been	  reported	  (6).	  
	  
In	   1995,	   the	   WHO	   declared	   the	   TB	   epidemic	   a	   global	   emergency,	   resulting	   in	   an	   increase	   of	  
investment	   of	   resources	   for	   research	   and	   eradication	   programs.	   The	   results’	   of	   new	   policies	   and	  
research	  have	  been	  modest,	  although,	  rates	  of	  disease	  are	  beginning	  to	  decline	  (1).	  There	  have	  been	  
no	   specific	   innovations	   that	   have	   aided	   this	   reduction	   in	   disease.	   In	   order	   to	   further	   reduce	   the	  
global	   burden	   of	   this	   disease,	   a	   co-­‐ordinated	   effort	   between	   public-­‐health	   experts,	   governments,	  
industry,	  scientists	  and	  the	  public	  is	  required.	  
	  
1.1.2. Is	  TB	  eradication	  a	  real	  possibility?	   A	  simple	  comparison	  with	  smallpox	  
Undoubtedly,	  the	  benchmark	  for	  global	  infectious	  disease	  eradication	  is	  smallpox.	  In	  1967	  the	  WHO	  
estimates	   that	   there	   were	   15	   million	   people	   infected	   with	   the	   disease	   and	   that	   2	   million	   deaths	  
resulted.	  Incredibly,	  by	  1979,	  smallpox	  was	  eradicated	  (7).	  Why	  hasn’t	  this	  been	  the	  case	  with	  TB?	  
	  
Simply,	   the	   challenge	   is	   much	   more	   complex.	   The	   technology	   required	   to	   identify,	   eradicate	   and	  
prevent	   smallpox	  was	   very	   simple	   and	   easily	   deployable.	   There	  was	   a	   highly	   effective	   vaccine	   for	  
prevention,	  and	  a	  simple	   diagnosis	  achieved	  	  by	  merely	   	  observing	  	  an	  	   infected	  	   individuals	   	  outer	  
appearance	   (8).	   Unfortunately	   with	   TB,	   there	   is	   no	   effective	   vaccine,	   diagnosis	   is	   challenging,	  
transmission	   can	   occur	   from	   asymptomatic	   carriers,	   symptoms	   are	   non-­‐specific,	   and	   disease	   can	  
remain	  dormant	  for	  a	  lifetime	  or	  can	  reactivate	  unexpectedly	  (9,	  10).	  This	  being	  said,	  TB	  is	  very	  rare	  
in	   the	  developed	  world,	  and	  TB	  mortality	   rarer	   still	   (1).	  We	   therefore	  have	  good	  reason	  to	  believe	  
that	   very	   significant	   reductions	   in	   TB	   rates	   are	   possible,	   if	   we	   can	   only	   understand	   what	  
interventions	  are	  programmatically	  useful.	  
	  
1.1.3. What	  can	  be	  learned	  from	  successes	  in	  TB	  eradication?	  
China	   has	   implemented	   a	   successful	   campaign	   against	   TB,	   with	   a	   50%	   reduction	   in	   prevalence	  
between	   1990	   and	   2010,	   and	   an	   80%	   reduction	   in	   mortality	   (1).	   This	   was	   likely	   the	   result	   of	  
improved	   co-­‐ordination	   of	   the	   TB	   surveillance	   program	   and	   treatment	   programs,	   following	   the
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outbreak	   of	   severe	   acute	   respiratory	   syndrome	   (SARS)	   in	   2003	   (2).	   Another	   success	   story	   comes	  
from	  Cambodia	  where	  there	  has	  been	  a	  46%	  reduction	  in	  TB	  incidence	  over	  the	  past	  decade	   (1).	  In	  
Cambodia,	   new	   found	  political	   stability	   allowed	   for	   infrastructural	   changes	   and	   implementation	  of	  
surveillance	  and	  treatment	  programs,	  which	  had	  previously	  been	   impossible	   (1).	   In	  both	  cases,	   the	  
application	  of	  current	  technologies	  has	  contributed	  to	  success.	  Similar	  proportional	  reductions	  in	  TB	  
incidence	  were	  also	   seen	  between	  1900	  and	  1950	   in	   the	  United	  States	  of	  America	   (USA)	   (11).	  This	  
decrease	  predates	  any	  specific	  treatment	  for	  the	  patient	  and	  coincides	  with	  reductions	  in	  prevalence	  
of	   other	   infectious	   diseases.	   This	   indicates	   that	   socio-­‐economic	   improvements	   can	   contribute	  
significantly	   to	   reducing	   TB	   burden.	   The	   introduction	   of	   effective	   antibiotics	   did	   not	   substantially	  
alter	   the	   rate	  of	  decline	   in	  prevalence.	   The	  USA	  has	  now	  seen	  a	  greater	   than	  95%	   reduction	   in	  TB	  
incidence	  since	  1900	  (11),	  with	  prevalence	  well	  below	  5	  per	  100,000	  (12).	  The	  lesson	  to	  be	  learned	  is	  
that,	  in	  certain	  contexts,	  current	  technologies	  are	  effective.	  
	  
In	  many	  regions	  of	  the	  world,	  especially	  Sub-­‐Saharan	  Africa,	  the	  situation	  is	  far	  more	  worrisome.	  In	  
South	  Africa,	  TB	  is	  the	  leading	  cause	  of	  death,	  with	  an	  incidence	  200	  times	  greater	  than	  the	  USA	  (1).	  
This	   is	  despite	   the	   fact	   that	   South	  Africa	  has	  a	   relatively	   strong	  economy,	  with	   the	   gross	  domestic	  
product	   (GDP)	  being	  at	   least	   four	  times	  that	  of	  Cambodia	   (13).	  65%	  of	  TB	  cases	   in	  South	  Africa	  are	  
HIV-­‐positive	  (1).	  
	  
It	  is	  clear	  that	  current	  strategies	  have	  not	  been	  effective	  enough	  in	  the	  settings	  where	  they	  are	  most	  
needed.	  Whether	   this	   is	   because	   of	   high	   levels	   of	   HIV,	   modest	   infrastructure,	   political	   instability,	  
economic	   insufficiencies,	   or	   as	   yet	   unidentified	   cultural	   or	   biological	   susceptibilities,	   is	   unclear.	   It	  
must	  be	  remembered	  that	  the	  enormous	  economic	  burden	  attributed	  to	  TB,	  is	   in	  itself	  a	  reason	  for	  
the	  failure	  to	  achieve	  the	  social	  reform	  required	  to	  eradicate	  it	   (14).	  Poverty	  causes	  TB,	  but	  TB	  also	  
causes	  poverty.	  
	  
Promoting	   economic	   development	   may	   help	   eradicate	   TB.	   However,	   strategies	   looking	   at	   cost-­‐	  
effective	   interventions	   to	   facilitate	   growth	   in	   the	   developing	   world,	   include	   the	   expansion	   of
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diagnosis	   and	   treatment	   for	   TB	   (14).	   Clearly	   the	   practical	   solution	   in	   this	   situation	   is	   still	   beyond	  
reach.	  Studying	  the	  socio-­‐economic	  benefit	  of	  healthcare	  interventions	  is	  a	  complex	  and	  burgeoning	  
science	   in	   itself.	   Hopefully,	   sustained	   research	   in	   this	   area	   will	   allow	   for	   directed	   efforts	   to	   solve	  
these	  complex	  problems.	  
	  
1.1.4. Summary:	  The	  eradication	  of	  TB	  is	  dependent	  on	  integration	  of	  innovative	  science	  
and	  policy	  
The	   eradication	   of	   TB	   is	   both	   a	   social	   and	   economic	   necessity.	   It	   will	   require	   the	   simultaneous	  
expansion	   of	   detection,	   and	   treatment,	   coupled	   with	   innovative	   solutions	   to	   prevent	   and	   cure	  
disease.	   The	   smallpox	   eradication	   program	   sets	   a	   precedent	   for	   infectious	   disease	   eradication,	   at	   a	  
relatively	   low	   cost,	   provided	   the	   tools	   required	   for	   targeted	   intervention	   are	   appropriate	   for	   the	  
conditions	   in	  which	  they	  need	  to	  be	  deployed.	  Unfortunately,	  we	   lack	   the	  basic	  understanding	  of	  TB	  
pathogenesis	   required	   to	  make	   targeted	   changes	   in	   TB	   endemic	   regions.	  We	   have	   not	   yet	  met	   the	  
challenge	  of	  providing	  programmatically	  relevant	  to	  combat	  TB.	  	  
	  
It	   is	   the	  duty	  of	  basic	  scientists	   to	  provide	  a	  knowledge	  base	  that	  allows	  TB	  diagnosis	  and	  treatment	  
to	   be	   simplified.	   It	   is	   the	   duty	   of	   economists	   and	   politicians	   to	   ensure	   resources	   are	   correctly	  
allocated	   for	   the	   application	   of	   current	   and	   future	   solutions.	   	   The	   WHO	   has	   been	   successful	   in	  
reversing	  increasing	  rates	  of	  TB	  at	  a	  global	  level	  (1).	  However,	  in	  certain	  parts	  of	  the	  world,	  especially	  
Sub-­‐Saharan	   Africa,	   rates	   of	   TB	   continue	   to	   rise,	   even	   in	   immunocompetent	   individuals,	   despite	  
organised	  programs	  targeting	  TB.	   It	   is	   in	  these	  regions	  especially,	  that	  TB	  is	  having	  its	  greatest	  social	  
and	   economic	   impact,	   and	   that	   we	   are	   in	   most	   need	   of	   innovative	   solutions	   to	   simplify	   the	  
prevention,	  identification	  and	  treatment	  of	  TB.	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1.2. The	  tools	  we	  have	  and	  the	  tools	  we	  need	  
There	  are	  3	  clear	  areas	  where	  the	  TB	  epidemic	  requires	  innovative	  solutions:	  
	  
	  
i)	  	   Prevention:	  Reducing	  the	  number	  of	  new	  infections	  
	  
ii)	   Diagnosis:	  Identifying	  more	  cases,	  more	  quickly	  
	  
iii)	   Treatment:	  Shorter	  treatment,	  with	  less	  side-­‐effects,	  that	  is	  easily	  complied	  with	  
	  
	  
1.2.1. Prevention	  of	  TB	  	  
1.2.1.1.	  Vaccination	  
Vaccination	   is	   the	   ideal	  manner	   with	  which	   to	   prevent	   infectious	   disease.	   However,	   the	   currently	  
used	   vaccine,	   M.	   bovis	   Bacillus	   Calmette-­‐Guérin	   (BCG),	   has	   not	   been	   effective	   in	   curbing	   the	  
epidemic;	   and	   multiple	   studies	   have	   questioned	   its	   efficacy	   (15-­‐17).	   An	   immune	   response	   that	  
protects	   against	   TB	   is	   yet	   to	   be	   described,	   despite	   the	   fact	   that	   an	   estimated	   90%	   of	   individuals	  
exposed	  to	  M.	  tb	  do	  not	  develop	  disease	  (18).	  Novel	  vaccination	  strategies	  have	  been	  shown	  to	  lead	  
to	  long-­‐lasting	  immune	  responses	  (19-­‐21),	  but	  have	  failed	  to	  protect	  from	  disease	  (22).	  Additionally,	  
trials	  are	  programmatically	  challenging,	  because	  vaccination	  strategies	  must	  be	  built	   in	   the	  context	  
of	  BCG	  administration,	  which	  is	  effective	  in	  preventing	  childhood	  disease	  (23).	  
1.2.1.2. Non-­‐vaccine	  preventative	  measures	  
The	  alternatives	  to	  vaccination	  are	  non-­‐specific	  interventions.	  Economic	  development	  was	  discussed	  
in	   section	   1.1.3,	   and	   since	   the	  most	   cost-­‐effective	   measure	   to	   achieve	   development	   is	   infectious	  
disease	   eradication	   (14),	   the	   argument	   is	   circular	   and	   unhelpful.	   Our	   understanding	   of	   disease	  
transmission	  is	  limited,	  and	  hinders	  development	  of	  specific	  prevention	  measures.	  
M.	   tb	   is	   transmitted	   by	   aerosol.	   However,	   we	   still	   do	   not	   have	   more	   than	   a	   preliminary	  
understanding	   of	   the	   infectious	   dose,	   the	   mechanisms	   of	   transmission,	   or	   host	   susceptibility.	   As	  
such,	  modelling	   transmission	   is	   extremely	   challenging,	   and	   identifying	   targets	   that	   are	  most	   likely	  
to	  be	  effective	  at	  reducing	  TB	  burden	   is	  speculative.	  Very	  few	  studies	  have	  been	  completed	   in	  this	  
area.	  Experimentally,	   there	   is	   a	   suggestion	   that	   relatively	   few	   patients	   transmit	   disease	   (24-­‐26).	   A	  
finding	  which	   is	   supported	   by	   a	   number	   of	   sequencing	   studies	   	   (27-­‐29),	   although	   these	   have	  
not	   been	   performed	   in	   endemic	   regions,	   in	   the	   context	   of	   high	   HIV	   prevalence,	   or	   with	   fully	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validated	  data	  analysis	  modalities.	  	  
	  
Lessons	   from	   combating	   HIV	   and	   Malaria	   would	   suggest	   that	   personal	   protection	   (condoms	   and	  
mosquito	  nets	  respectively)	  can	  be	  effective	  (30,	  31).	  Unfortunately,	  diseases	  spread	  by	  aerosol	  are	  
much	   less	   susceptible	   to	   such	   interventions.	   Although	   some	  measures,	   such	   as	  mask-­‐wearing,	   do	  
appear	  to	  be	  of	  benefit	  in	  protecting	  from	  influenza	  (32-­‐34),	  with	  TB,	  masks	  have	  been	  shown	  to	  be	  
ineffective,	   even	   in	   healthcare	   settings	   (35).	   Architectural	   strategies	   have	   also	   been	   trialled	   (24),	  
with	   interventions	   such	   as	   UV	   lighting	   and	   increased	   airflow	   showing	   some	   benefit	   (24,	   36),	   but	  
these	  have	  not	  dramatically	  changed	  TB	  prevalence.	  This	  is	  not	  to	  say	  such	  measures	  are	  ineffective,	  
just	  that	  they	  have	  not	  been	  applied	  in	  a	  way	  that	  has	  significantly	  reduced	   transmission.	  Confined	  
transport	  has	  been	  linked	  to	  increased	  susceptibility,	  suggesting	  that	  simple	  behaviour	  changes,	  such	  
as	  opening	  windows,	  may	  reduce	  transmission,	  however,	  the	  overall	  effect	  of	  such	  measures	  is	  hard	  
to	   ascertain	   (37).	   If	  we	   are	   to	   reduce	   transmission,	   other	   than	  by	   developing	   effective	   vaccines,	   it	  
would	  appear	  that	  basic	  research	  must	  first	  identify	  correlates	  and	  mechanisms	  of	  transmission.	  
1.2.2. Diagnosis	  of	  TB	  
	  
1.2.2.1. Dependence	  on	  self	  presentation	  is	  dangerous	  
Identification	  of	  TB	  is	  usually	  dependent	  on	  self-­‐presentation	  to	  clinicians;	  which	  in	  non-­‐medicalised	  
cultures	  may	  be	  extremely	  late	  during	  the	  disease	  (38).	  Symptoms	  are	  often	  non-­‐specific	  and	  usually	  
mild	  during	  early	  stages	  of	  the	  disease,	  decline	   is	   insidious	  and	  pathology	  may	  be	  extensive	   (9,	  10,	  
39).	  Not	  only	  does	  this	  mean	  that	  individuals	  often	  have	  advanced	  disease	  at	  presentation,	  but	  also	  
that	   they	   may	   have	   transmitted	   the	   infection	   extensively	   (38,	   40).	   The	   absence	   of	   sensitive	   and	  
specific	   screening	  measures	  means	   that	   regional	   surveillance	   is	   labour-­‐intensive	  and	   impractical	   in	  
many	  areas.	  Identification	  of	  the	  bacteria	  is	  required	  for	  diagnosis,	  but	  is	  challenging.	  
1.2.2.2. Bacterial	  detection	  
Diagnosis	  is	  one	  area	  of	  TB	  research	  that	  has	  seen	  the	  translation	  of	   innovative	  solutions	  for	  global	  
use	  (although	  the	  impact	  of	  such	  measures	  is	  yet	  to	  be	  seen).	  Sputum	  smears,	  chest	  radiography	  and	  
bacterial	  culture	  have	  been	  the	  mainstays	  of	  diagnosis,	  but	  none	  are	  both	  sensitive	  and	  specific.	   In	  
2010,	   the	   WHO	   endorsed	   GeneXpert,	   a	   cartridge-­‐based	   polymerase	   chain	   reaction	   (PCR)	   testing	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system	  with	   the	   potential	   to	   diagnose	   TB	   in	   under	   2	   hours	   (41).	   Since	   then	  1.1	  million	   tests	   have	  
been	  conducted	  (1).	  However,	  the	  machine	  is	  costly	  and	  dependent	  on	  electricity,	  therefore,	  its	  use	  
is	  confined	  to	  referral	  centres.	  As	  such,	  while	  reducing	  the	  burden	  of	  diagnosis	  in	  some	  settings,	  this	  
merely	  represents	  a	  step	  on	  the	  path	  to	  a	  point-­‐of-­‐care	  test.	  GeneXpert	  requires	  M.	  tb	  in	  the	  sputum	  
of	  the	  patient	  –	  which	  may	  not	  be	  easily	  produced,	  or	  be	  representative	  of	  the	  entire	  lung.	  We	  still	  
need	   a	   sensitive,	   rapid,	   point-­‐of-­‐care	   test	   to	   help	   identify	   cases.	   At	   present	   there	   is	   no	   reliable	  
screening	  method	  for	  TB.	  
	  
1.2.2.3. Detection	  of	  immune	  correlates	  of	  infection	  
Previous	  exposure	   to	  M.	   tb	   can	  be	  evaluated	   by	   Interferon	  Gamma	  Release	  Assays	   (IGRAs),	  which	  
detect	   Interferon	   gamma	   (IFNɣ)	   release	   by	   blood	   in	   response	   to	  M.	   tb	   specific	   antigens.	   Because	  
there	   is	  no	  way	  of	  predicting	  which	  exposed	   individuals	  will	  develop	  disease,	   this	   information	   is	  of	  
limited	   use	   (especially	   in	   endemic	   regions)	   (42-­‐45).	   Tuberculin	   skin	   tests	   (TSTs)	   use	   the	   induration	  
resulting	   from	   cellular	   recruitment	   and	   inflammation	   that	   occurs	   during	   the	   delayed-­‐type	  
hypersensitivity	  (DTH;	  Type	  IV	  hypersensitivity)	  reaction	  to	  intradermally	  injected	  M.	  tb	  antigens,	  to	  
assess	  previous	  exposure	   to	  M.	  tb.	   This	   test	   is	   significantly	   less	   resource	   intensive	   than	   IGRAs,	  but	  
gives	  a	  positive	  result	  if	  the	  patient	  is	  exposed	  to	  the	  vaccine	  strain,	  M.	  bovis	  BCG.	  In	  addition	  to	  this,	  
persons	   who	   are	   infected	   or	   immunosuppressed	   may	   have	   falsely	   negative	   tests	   by	   either	  
measurement	  (46).	  
	  
A	   highly	   sensitive	   and	   specific	   test	   for	   very	   early	   active	   disease	   and	   antimicrobial	   resistance	   are	  
required.	   It	   must	   be	   point-­‐of-­‐care	   so	   that	   immediate	   action	   can	   be	   taken	   to	   treat	   infected	  
individuals.	  A	  test	  or	  testing	  strategy	  for	  exposure	  in	  immunocompromised	  individuals	  must	  also	  be	  
developed.	  
27	  |	  Page	  
1.2.3. Treatment	  of	  TB	  
TB	   treatment	   consists	   of	   6	   months	   of	   antibiotics,	   comprised	   of	   4	   drugs	   (rifampicin,	   isoniazid,	  
pyrazinamide	  and	  ethambutol)	  for	  2	  months	  followed	  by	  2	  drugs	  (rifampicin	  and	  isoniazid)	  until	  the	  
end	   of	   treatment.	   Patient	   compliance	   during	   such	   a	   lengthy	   regimen	   is	   poor;	   patients	   often	   feel	  
better	  after	   just	  a	  few	  weeks,	  and	  the	  drugs	  have	  unpleasant	  side-­‐effects.	   In	  London,	  despite	  good	  
healthcare	   infrastructure,	   the	  Health	  Protection	  Agency	  (HPA;	  now	  Public	  Health	  England)	  reported	  
only	   85%	   completion	   of	   treatment	   (47).	   This	   suggests	   that	   even	   in	   resource-­‐ready	   settings,	  
application	   of	   this	   complex	   regimen	   is	   problematic.	   Innovations	   are	   clearly	   needed	   to	   rapidly	   and	  
simply	   treat	   TB.	   Novel	   antibiotics	   are	   helping	   to	   combat	   resistant	   disease	   (48-­‐51),	   but	   extensive	  
searches	   have	   failed	   to	   demonstrate	   any	   antibiotics	   likely	   to	   reduce	   treatment	   duration	   of	  
susceptible	   disease	   (52).	   Poor	   antibiotic	   penetration	   into	   diseased	   tissue,	   and	   bacterial	   tolerance,	  
may	  explain	  why	  TB	  treatment	  requires	  prolonged	  antibiotic	  administration	  (53,	  54).	  Identification	  of	  
antibiotics	  which	   overcome	   these	   problems	   is	   challenging	   because	   there	   are	   no	   firmly	   established	  
models	  of	   the	  complex	  bacterial	  microenvironments	   found	   in	  human	  disease	   –	  and	   there	   is	  only	  a	  
limited	   understanding	   of	   which	   microenvironments	   M.	   tb	   may	   be	   persisting	   in.	   It	   should	   be	  
considered	   that	   altering	   these	   microenvironments,	   by	   targeting	   host	   mediators,	   may	   be	   more	  
achievable	   than	   designing	   antibiotics	   that	   can	   function	   in	   these	   complex	   microenvironments,	   or	  
against	  dormant	  bacteria.	  
	  
It	  is	  also	  important	  to	  consider	  that	  the	  duration	  of	  the	  intervention,	  rather	  than	  the	  duration	  of	  the	  
therapy	   itself,	   is	   what	   affects	   compliance.	   A	   single	   therapeutic	   event	   that	   has	   effects	   for	   a	   long	  
duration	   is	   preferable	   to	   a	   shorter	   therapy	   that	   requires	   daily	   administration.	  We	  must	   aim	   for	   a	  
single	   intervention	   strategy,	   which	   is	   simple,	   economical	   and	   safe	   –	   and	   we	   should	   consider	   all	  
possibilities,	  not	  just	  novel	  antibiotics,	  to	  achieve	  this.	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1.2.4. Summary:	   Current	   tools	   are	  only	   partially	   effective,	   innovation	   is	   required	   if	  we	  
are	  to	  tackle	  TB	  in	  the	  developing	  world	  
TB	  kills	  more	  people	  than	  any	  other	  bacterial	  infection.	  Attempts	  to	  reverse	  the	  growing	  burden	  of	  
	  
disease	  have	  proved	  successful	   in	  certain	   socio-­‐economic	  conditions,	  however,	   the	   tools	   that	  have	  
helped	   reduce	   infection	   in	   these	   regions	   are	   not	   accessed	   in	   the	   situations	  where	   disease	   is	  most	  
prevalent.	   Innovations	  as	  well	   as	   increased	  availability	  of	   current	   resources	   are	   required	   to	   relieve	  
the	  burden	  tuberculosis	  in	  the	  developing	  world.	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1.3. Defining	   TB:	   Using	   language	   to	   facilitate	   not	   confuse	   our	  
understanding	  
In	  order	  to	  prevent,	  diagnose	  and	  treat	  TB	  –	  we	  must	  understand	  first	  what	  TB	  is.	  Currently,	  basic	  TB	  
research	  is	  dependent	  on	  clinical	  and	  epidemiological	  definitions,	  which	  are	  not	  directly	  linked	  to	  the	  
diverse	  underlying	  pathological	  processes.	  If	  we	  can	  better	  understand	  the	  phenomena	  that	  surround	  
infection	  and	  disease	  in	  the	  context	  of	  the	  underlying	  pathology,	  we	  may	  reveal	  innovative	  strategies	  
for	  combating	  disease.	  
	  
1.3.1. Tuberculosis	  is	  the	  disease	  of	  humans	  caused	  by	  M.	  tuberculosis	  
TB	   is	   a	   broad-­‐ranging	   term	   that	   describes	   any	   disease	   that	   results	   when	  M.	   tb	   infects	   a	   human.	  
Historically,	   infection	   with	   other	   closely	   related	   mycobacterial	   species	   (M.	   microtii,	   M.	   bovis,	   M.	  
africanum,	   M.	   canettii)	   have	   been	   called	   TB	   –	   but	   this	   adds	   an	   ambiguity	   in	   understanding	   the	  
specific	  mechanisms	  of	  disease	  (that	  cannot	  be	  assumed	  to	  be	   identical	  for	  all	   species),	  and	  so	  this	  
thesis	  will	   refer	   to	   these	   less	   common	  human	   infections	   as	   ‘disease	   caused	  by	  M.	   species’.	   This	   is	  
particularly	   true	  of	  M.	  bovis,	   in	  which	  human-­‐to-­‐human	  transmission	   is	  exceptionally	   rare	   (55,	  56),	  
and	  thus	  has	  nearly	  been	  eradicated	  where	  pasteurisation	  of	  milk	  products	  is	  routine	  (57-­‐59).	  Clearly	  
the	  pathogenesis	  of	  this	  infection	  is	  very	  different	  to	  M.	  tb,	  which	  is	  dependent	  on	  human-­‐to-­‐human	  
transmission.	  
	  
Since	   no	   other	   species	   is	   naturally	   infected	   with	  M.	   tb,	   it	   is	   an	   obligate	   human	   pathogen.	   The	  
symptoms	  and	  disease	  caused	  by	  experimental	  M.	  tb	  infection	  in	  other	  species	  may	  resemble	  human	  
disease	  –	  but	  is	  not	  the	  human	  disease;	  TB.	  
	  
1.3.2. The	   clinical	  picture	   is	   related	   to,	   but	   not	   entirely	   dependent	   on,	   the	  underlying	  
pathology	  
The	   clinical	   manifestations	   of	   TB	   are	   incredibly	   variable	   and	   dependent	   on	   numerous	   host	   and	  
bacterial	   factors,	   as	  well	   as	   the	   anatomical	   location	  of	   the	   infection.	   It	  must	   be	   remembered	   that	  
approximately	  90%	  of	  individuals	  who	  are	  exposed	  to	  M.	  tb	  do	  not	  develop	  symptomatic	  illness	  (18).	  
Additionally,	   the	   clinical	   picture	   does	   not	   necessarily	   reflect	   the	   underlying	   pathology;	   apparently	  
healthy	   individuals	  often	  harbour	  highly	  destructive	   lesions	  and	   those	  with	   limited	   immunity	  often	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have	   the	   highest	   bacterial	   burdens	   and	   the	   fewest	   symptoms	   (9,	   10).	  We	  must	   remember	   that	   a	  
clinical	  picture	   is	  a	  surrogate	  of	   these	  underlying	  processes,	  and	  although	  this	   is	  a	  vital	   resource	  to	  
the	  caregiver,	   it	   is	  academically	   vague,	  because	   it	  does	  not	  detail	   the	  complex,	  varied	  mechanisms	  
involved	   in	   ‘active	   TB’.	   For	   example,	   destructive	   spinal	   TB	   and	   cavitary	   lung	   TB	  may	   have	  more	   in	  
common	   with	   each	   other,	   than	   with	   granulomatous	   disease	   in	   a	   lymph	   node	   –	   yet	   most	   studies	  
would	  group	  the	  extrapulmonary	  diseases	  together,	  independent	  of	  their	  pathology.	  
	  
1.3.3. Active	   TB	   is	   an	   over-­‐arching	   term	   defined	   by	   symptomatic	   disease	   or	  
infectiousness	  
Active	  TB	  is	  traditionally	  defined	  by	  the	  presence	  of	  signs	  or	  symptoms	  of	  tuberculosis;	  cough,	  fever,	  
	  
night-­‐sweats,	  weight-­‐loss,	  anorexia,	  general	  malaise	  or	  a	  positive	  diagnosis	  (via	  either	  microscopy	  or	  
culture)	  of	  M.	  tb	  from	  any	  site	  independent	  of	  symptoms	  (9,	  10,	  60).	  This	  is	  in	  contrast	  to	  latent	  TB,	  
which	  is	  defined	  as	  being	  non-­‐symptomatic,	  but	  having	  an	  active	  immune	  response	  to	  a	  subset	  of	  M.	  
tb	  antigens.	  Active	  TB	  can	  be	  either	  pulmonary	  or	  extra-­‐pulmonary,	  but	  all	  infection	  enters	  through	  
the	   lungs	   (through	   inhalation)	  and	   is	   transmitted	   in	  exhaled	  aerosols	   (9,	  10).	   It	   is	  also	   important	  to	  
remember	  that	  individuals	  without	  any	  symptoms	  or	  signs	  of	  TB,	  may	  well	  be	  transmitting	  M.	  tb	  and	  
so	  contributing	  to	  the	  epidemic	  (40).	  I	  will	  be	  defining	  active	  TB	  by	  either	  the	  ability	  to	  transmit	  M.	  tb	  
to	  another	  person	  or	  symptoms	  and	  signs	  of	  tuberculosis	  with	  clinical	  evidence	  of	  M.	  tb	  infection.	  
	  
With	  this	  definition,	  any	  patient	  who	  does	  not	  transmit,	  and	  does	  not	  have	  symptoms,	  does	  not	  have	  
active	  TB.	  Maintenance	  of	  this	  status	   in	  all	  persons	  globally	  would	  effectively	  be	  the	  eradication	  of	  
TB	  as	  a	  disease.	  Persons	  without	  active	  TB	  may	  still	  contain	  actively	  replicating	  bacilli	   (as	  evidenced	  
by	   the	   reduced	   risk	   of	   active	   disease	   after	   prophylactic	   Isoniazid	   treatment	   (61))	   and	   can	   be	  
considered	   to	   have	   sub-­‐clinical	  M.	   tb	   infection.	   If	   a	   period	   of	   active	   disease	   has	   been	   observed,	  
asymptomatic	  and	  non-­‐transmitting	  patients	  can	  be	  considered	  to	  be	  in	  TB	  remission.	  TB	  remission	  
can	  result	  from	  either	  immune	  containment	  (spontaneous	  remission)	  alone,	  or	   in	  combination	  with	  
antibiotic	   killing	   of	   bacteria	   (treatment	   induced	   remission).	   Cured	   TB	   can	   then	   be	   defined	   as	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individuals	  in	  whom	  remission	  is	  induced	  to	  such	  an	  extent	  that	  their	  risk	  is	  equal,	  or	  less	  than,	  that	  
of	  an	  individual	  with	  similar	  immune	  status,	  who	  has	  not	  previously	  been	  infected	  with	  M.	  tb.	  
	  
1.3.4. Temporal	   definitions	   are	   inadequate:	   The	   problem	  with	   	   ‘primary’,	   	   ‘secondary’	  
and	  ‘latent’	  TB	  
TB	   is	  often	  considered	   in	  a	   temporal	   framework,	  where	   ‘primary’	  disease	  occurs	   immediately	  after	  
infection	  (arbitrarily	  within	  6	  months	  of	  infection)	  and	  ‘secondary’	  disease	  occurs	  after	  a	  prolonged	  
asymptomatic	  period	  (latent	  disease)	  (62).	  These	  temporal	  definitions	  are	  inadequate	  in	  the	  context	  
of	   modern	   disease.	   For	   example,	   disease	   resulting	   from	   immunosuppression	   is	   clinically	   and	  
pathologically	   more	   similar	   to	   progressive	   disseminated	   infection;	   but	   temporal	   definitions	   would	  
deem	  the	  former	  ‘secondary’	  disease	  and	  the	  latter	  ‘primary’	  disease.	  Newly	  acquired	  infection,	  in	  a	  
previously	   exposed	   individual,	   may	   be	   paucibacillary,	   and	   highly	   destructive,	   but	   is	   by	   definition	  
primary	  disease	  even	  though	   this	   same	  clinical	  picture	   is	  extremely	  common	   in	  older	  patients	  who	  
most	   likely	   have	   reactivation	   of	   past	   infections.	   Temporal	   definitions	   are	   clinically	   useful	   for	  
understanding	  the	  risk	  for	  patients	  exposed	  to	  M.	  tb,	  and	  estimating	  the	  time	  of	  exposure	  –	  but	  are	  
academically	   insufficient	   because	   they	   are	   not	   based	   on	   biological	   observations.	   The	   term	   latency	  
will	  be	  avoided	  –	  the	  definition	  is	  imprecise	  and	  unclear.	  Commonly,	  latency	  is	  defined	  as	  a	  period	  of	  
asymptomatic	   infection	   that	  may	   become	   active	   disease.	   The	   strict	   clinical	   definition	   of	   latency	   is	  
TST-­‐	   or	   IGRA-­‐positivity.	   These	   tests	   indicate	   that	   a	   person	   has	   immune	   responses	   to	   M.	   tb	  
antigens.	  The	   assumption	   is	   that	   this	   reactivity	   is	   highly	   correlative	  with	   subclinical	  M.	   tb	   infection	  
and	   that	   this	   subclinical	   infection	   is	   likely	   to	   develop	   to	   become	   active	   disease.	   However,	   since	  
TST-­‐	   or	   IGRA-­‐positive	   individuals	   do	   not	   universally	   develop	   disease,	   even	   under	   high	  
immunosuppression	   (63),	   it	   seems	   likely	   that	   immune	   responses	   may	   be	   maintained	   after	  
exposure,	   without	   subclinical	   infection.	   This	   is	   supported	   by	   the	   observation	   that	   prophylactic	  
treatment	   of	   TST-­‐positive	   individuals	   with	   9	   months	   of	   Isoniazid,	   reduces	   the	   long-­‐term	   risk	   of	  
reactivation	   (to	   the	   levels	  of	  unexposed	  individuals)	  (61,	  64,	  65),	  but	  does	  not	  cause	  reversion	  of	  TST	  
or	  IGRA	  responses	  (66-­‐68).	  It	  follows	  therefore,	   that	   individuals	  with	  positive	  TSTs	  or	  IGRAs	  can	  only	  
be	   assumed	   to	   have	  encountered	  M.	   tb	   (or	  M.	   bovis	   in	   the	   case	   of	   TSTs)	   antigens.	   The	   positive	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tests	   therefore	   indicate	  that	  the	  individual	  may	  have	  subclinical	  infection,	  which	  in	  turn	  carries	  a	  risk	  
of	  becoming	  active	  TB.	  
	  
1.3.5. Resistance	  should	  be	  defined	  by	  the	  likelihood	  of	  developing	  active	  disease	  
Resistance	  to	  disease	  is	  the	  goal	  of	  any	  vaccination	  strategy.	  Usually	  this	  would	  be	  defined	  in	  terms	  
of	   resistance	   to	   infection,	   but	   since	   infection	   with	  M.	   tb	   does	   not	   inevitably	   cause	   disease	   it	   is	  
important	  to	  understand	  that	  resistance	  to	  disease	  is	  also	  a	  valuable,	  and	  perhaps	  more	  achievable,	  
aim.	  I	  will	  define	  resistance	  as	  the	  measure	  of	  likelihood	  that	  a	  person	  will	  develop	  Active	  TB,	  (i.e.	  a	  
more	   resistant	   individual	   is	   less	   likely	   to	   develop	   active	   TB).	   Crucially,	   this	   definition	   makes	   no	  
assumption	  about	  the	  immune	  status	  of	  the	  patient.	  It	  is	  clear	  that	  immunocompromised	  individuals	  
are	   less	   resistant	   to	   infection;	   but	   it	  must	  be	   remembered	   that	  many	  of	   the	  processes	   involved	   in	  
active	   TB	   are	   immune-­‐mediated	   –	   and	   therefore	   a	   balance	   of	   both	   pro-­‐	   and	   anti-­‐inflammatory	  
responses	  must	  be	  achieved	  to	  prevent	  disease.	  
	  
1.3.6. Summary	  
The	   language	   used	   to	   describe	   TB	   is	   unclear,	   and	   although	   useful	   for	   clinical	   studies	   and	  
epidemiological	  data	  collection,	  the	  arbitrary	  nature	  of	  these	  definitions	  must	  not	  be	  broadly	  applied	  
to	  academic	  thinking	  on	  the	  subject.	  By	  clearly	  defining	  terms	  as	  evidenced	  by	  data	  it	  is	  clear	  that:	  
	  
• Cure	  does	  not	   require	   total	  bacterial	  eradication,	  but	   a	   return	   to	   a	   state	  where	   the	   risk	  of	  
disease	  is	  equal	  to	  that	  of	  an	  uninfected	  individual.	  
• Latency	   is	   a	   clinical	   phenomenon,	  most	   likely	   explained	   by	   a	   variety	   of	   pathophysiological	  
scenarios.	  
• ‘Resistance’	   to	  disease	   is	  not	  necessarily	  dependent	  on	   resistance	   to	  M.	   tb	   infection	  alone	  
and	  may	  be	  dependent	  on	  mounting	   the	   right	  balance	  between	  complex	  mediators	  of	   the	  
immune	  response,	  rather	  than	  ‘strong’	  or	  ‘weak’	  immune	  responses.	  
	  
TB	   eradication	   is	   dependent	   on	   the	   treatment	   of	   active	   disease	   (including	   asymptomatic	  
transmission),	  and	  prevention	  of	  active	  disease,	  as	  distinct	  from	  eradication	  and	  prevention	  of	  M.	  tb	  
infection.	  This	  is	  not	  to	  suggest	  that	  M.	  tb	  eradication	  is	  not	  a	  valuable	  therapeutic	  goal	  –	  but	  that	  it	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may	  not	  be	  the	  only	  strategy.	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1.4. The	  pathology	  of	  active	  TB	  
Active	  TB	  encompasses	  a	  spectrum	  of	  disorders	  resulting	  from	  the	  interaction	  between	  the	  host	  and	  
bacteria	   as	  well	   as	   their	   individual	   attributes.	   There	   are	   3	   principal	   contributing	   factors	   to	   disease	  
outcome	  (69):	  
	  
i) The	  immune	  status	  of	  the	  infected	  individual	  
	  
ii) The	  virulence,	  number	  and	  metabolic	  state	  of	  the	  M.	  tuberculosis	  bacilli	  
	  
iii) The	  site	  of	  the	  interaction	  between	  host	  and	  bacteria	  
	  
	  
All	   of	   these	   variables	   are	   continually	   changing	   –	   in	   turn	   altering	   each	   other.	   As	   discussed	   in	   the	  
previous	   section,	   an	   accurate	   understanding	   of	   disease	   processes	   is	   a	   prerequisite	   if	   we	   are	   to	  
develop	  novel	  vaccines,	  diagnostics	  and	  treatments.	  
	  
1.4.1. TB	  and	  the	  granuloma	  
There	   are	   a	   few	   principal	   features	   of	   tuberculosis	   anatomic	   and	   histologic	   pathology,	   none	   are	  
unique,	  but	  in	  combination,	  they	  are	  highly	  indicative	  of	  TB.	  The	  most	  studied	  is	  the	  granuloma.	  
	  
Granulomas	   are	   defined	   as	   ‘...nodular	   inflammatory	   lesions,	   usually	   small	   or	   granular,	   firm,	  
persistent	   and	   containing	   compactly	   grouped	   modified	   macrophages’	   (70).	   Granulomatous	  
responses	   are	   essential	   for	   protection	   against	   larger	   parasites	   and	   foreign	   bodies	   (39).	  
Fundamentally,	  the	  response	  results	  in	  sequestration	  of	  the	  foreign	  body	  or	  parasite,	  and	  allows	  for	  
the	  delivery	  of	  immune	  cells	  which	  can	  become	  highly	  activated	  without	  causing	  significant	  collateral	  
damage	   to	   the	   host.	   Granulomas	   are	   also	   found	   in	   a	   number	   of	   conditions	   of	   unknown	   aetiology	  
(39).	  Tuberculosis	  granulomas	  differ	  from	  granulomas	  found	  in	  other	  conditions;	  the	  main	  distinction	  
is	   the	   presence	   of	   central	   necrosis,	   and	   the	   heterogeneity	   of	   the	   lesions.	   TB	   granulomas	  may	   be	  
found	  at	  autopsy,	   in	  cases	  where	  there	   is	  no	  evidence	  of	  active	  TB,	  however,	  other	  TB	  pathologies	  
are	  exceedingly	  rare	  in	  persons	  without	  active	  disease	  (69,	  71).	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1.4.2. Tissue	   destructive	   pathologies	   are	   the	   defining	   feature	   of	   active	   TB	   in	  
immunocompetent	  hosts	  
The	  majority	  of	  TB	  occurs	  in	  immunocompetent	  adults	  (1);	  in	  which	  tissue	  destruction	  is	  the	  defining	  
feature	   of	   active	   disease	   described	   by	   TB	   pathologists:	   Canetti,	   Laennac,	   Rich	   and	   Hunter,	   whose	  
careers	   collectively	   span	   well	   over	   two	   centuries,	   and	   thousands	   of	   dissections,	   (69,	   71-­‐73)	   all	  
describe	  the	  non-­‐granulomatous	   lesion	  as	  of	  utmost	   importance	   in	  active	  TB.	  This	   literature	   is	  best	  
summarised	   in	   a	   recent	   review	   by	   Hunter	   (73).	   The	   most	   up-­‐to-­‐date	   observations	   of	   human	  
pathology	   describe	   a	   lipoid	   pneumonia	   which	   necrotises	   and	   leads	   to	   cavities	   in	   active	   TB.	   The	  
proposed	   mechanism	   is	   that	   the	   lipoid	   pneumonia	   forms	   after	   proximal	   airway	   occlusion	   (73).	  
Laennec	   describes	   large	   necrotising	   yellow	   tubercles	   and	   ‘yellow	   infiltration’	   preceding	   caseation	  
(72).	   Canetti	   rarely	   used	   the	   terms	   tubercle	   or	   granuloma,	   instead	   using	   of	   the	   non-­‐specific	   term	  
‘focus’,	  and	   stating	   that	   the	   ‘softening’	   of	   the	   focus	   is	   the	   most	   important	   event	   in	   active	   TB	  
(71).	   Rich	   claimed	   instead	   that	   granuloma	   necrosis	   is	   the	   source	   of	   cavities	   (69),	   a	   hypothesis	  
carried	   forwards	   by	   Lurie	   and	   Dannenberg	   after	   observing	   disease	   progression	   in	   rabbits	   (74,	  
75).	   The	   linking	   of	   granuloma	   formation	   and	   cavity	   formation	   has	   persisted,	   despite	   clear	  
evidence	   that	   these	   events	  may	   occur	   independently	   (73).	   There	   has	   been	   persistent	   focus	   on	  
the	   granulomatous	   pathology;	   with	   many	   high-­‐impact	   reviews	   neglecting	   non-­‐granulomatous	  
pathology	   entirely	   (53,	   76-­‐82).	   The	  terms	   used	   in	   tissue	   destruction	   during	   TB	   are	   numerous,	   but	  
whether	   it	   is	   called	   softening,	   cavity	   formation,	   liquefaction,	   this	   occurrence,	   is	   the	   most	  
fundamental	  defining	  feature	  of	  active	  TB	  in	  the	  immunocompetent	  host.	  
	  
1.4.3. The	   cavity	   is	   an	  environment	   that	   facilitates	  bacterial	  proliferation	  and	   immune	  
evasion	  
Regions	  	  of	  	  tissue	  	  destruction	  	  represent	  	  immune	  	  failure	  	  and	  	  favour	  	  bacterial	  	  proliferation	  	  (83).	  
Erosion	  of	  destroyed	  tissue	  leads	  to	  cavity	  formation,	  and	  the	  erosion	  of	  this	  tissue	  into	  airways	  i.e.	  
the	   process	   of	   cavity	   formation,	   allows	   for	   expectoration	   of	   high	   numbers	   of	   bacteria,	   a	   process	  
assumed	  to	  result	   in	  transmission	  (84,	  85).	  The	  cavity	  has	   long	  been	  described	  as	  the	  most	  difficult	  
lesion	   in	   TB	   to	   sterilise	   with	   antibiotics	   (71,	   86)	   and	   extensive	   cavitary	   disease	   predisposes	   to	  
antibiotic	  failure	  (87).	  It	  is	  also	  a	  key	  site	  from	  which	  drug	  resistant	  bacteria	  can	  be	  isolated	  (71).	  The	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immune-­‐privileged	   nature	   of	   this	   site	   is	   confirmed	   by	   the	   fact	   that	   even	   after	   effective	   antibiotic	  
therapy,	   the	  cavity	  may	  be	  a	   site	  of	   fungal	   infections	  only	  otherwise	   seen	   in	   immunocompromised	  
individuals	  (39,	  60).	  	  
	  
Understanding	  the	  process	  of	  cavity	  formation	  is	  fundamental	  to	  understanding	  what	  defines	  active	  
disease,	   and	   also	   why	   prolonged	   treatment	   is	   necessary.	   Fundamentally,	   there	   are	   two	   key	  
processes	  that	  occur	  during	  tissue	  destruction:	  Necrosis	  and	  extracellular	  matrix	  (ECM)	  degradation.	  
In	  TB,	  matrix	  degradation	  and	  cavity	  formation	  is	  the	  predominant	  characteristic,	  a	  phenotype	  rarely	  
seen	  in	  other	  conditions	  (88).	  
	  
1.4.4. Tissue	  destruction	  requires	  ECM	  degradation	  
The	   lung	   ECM	   is	   a	   complex	   and	   extraordinarily	   resilient	   structure.	   It	   undergoes	   continuous	  
mechanical	   stress	   during	   repeated	   expansion	   and	   contraction,	   whilst	   maintaining	   the	   delicate	  
structure	   required	  for	  gaseous	  exchange.	  Although	  supported	  and	  maintained	  by	   the	  resident	  cells	  
(primarily	   epithelial	   cells	   and	   fibroblasts),	   the	   lung	   ECM	   does	   not	   depend	   on	   these	   cells	   for	   its	  
physical	  properties	  and	  can	  maintain	  its	  mechanical	  properties	  in	  the	  absence	  of	  cells	  (89,	  90).	  
	  
The	   principal	   mechanical	   components	   of	   the	   lung	   ECM	   are	   fibrillar	   collagens	   (types	   I	   and	   III)	   and	  
elastin.	  The	  basement	  membrane	  of	  the	  alveoli	  is	  largely	  type	  IV	  collagen.	  The	  remaining	  lung	  matrix	  
is	   composed	   of	   other	   collagens	   and	   glycoproteins	   that	   have	   some	   structural	   roles,	   but	   are	   also	  
central	   to	   cell	   adhesion,	  maturation,	   survival	  and	   signalling	   (91-­‐93).	   The	  matrix	   also	  plays	   a	  crucial	  
role	  at	   the	   interface	  with	   the	  vascular	  surfaces,	   regulating	  permeability	  and	   immune	  cell	  migration	  
(39).	  Given	  its	  biological	  importance,	  and	  the	  importance	  of	  its	  microstructure,	  lung	  ECM	  turnover	  is	  
closely	   regulated.	   Of	   particular	   importance	   in	   the	   regulation	   of	   ECM	   are	   the	   Matrix	  
Metalloproteinases	   (MMPs)	  and	   their	   inhibitors,	   tissue	   inhibitors	  of	  metalloproteinases	   (TIMPs).	  As	  
their	   name	   suggests,	  MMPs	   collectively	   have	   the	   ability	   to	   degrade	   all	   known	   components	   of	   the	  
ECM	  (94).	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1.4.5. MMPs	  can	  collectively	  degrade	  all	  components	  of	  the	  ECM	  
MMPs	  are	   a	   family	  of	  24	  enzymes	  with	   Zn2+	  catalytic	   domain.	   They	   share	   a	   conserved	  pro-­‐domain	  
and	   are	   commonly	   classified	   according	   to	   ECM	   substrate	   (collagenases,	   gelatinases,	   stromelysins	  
etc.).	  MMPs	  also	  have	  many	  non-­‐ECM	  substrates	  (92,	  95).	  
	  
MMP	  activity	   is	  regulated	  at	  transcriptional	  and	  translational	   levels,	  as	  well	  as	  by	  post-­‐translational	  
modification	  and	   finally	  by	  enzymatic	   activation	   (96).	  Their	  expression	   is	   tightly	  controlled,	  and	  the	  
majority	  of	  MMPs	  are	  not	  expressed	  in	  healthy	  tissue	  (97).	  The	  proteolytic	  activity	  can	  be	   inhibited	  
by	  TIMPs	  (98,	  99).	  
	  
Unregulated	  MMP	   expression	   and	  MMP	   activity	   have	   been	   associated	   with	   a	   number	   of	   disease	  
processes	   (100-­‐102),	   and	   although	   originally	   this	   association	   was	   linked	   to	   disease	   in	   which	   ECM	  
turnover	   had	   a	   clearly	   identifiable	   role,	   such	   as	   rheumatoid	   arthritis,	   they	   have	   since	   been	  
discovered	   in	   numerous	   inflammatory	   conditions,	   and	   have	   roles	   in	   these	   conditions	   that	   extend	  
beyond	  ECM	  degradation	  (103).	  
	  
Most	  importantly	  in	  terms	  of	  pulmonary	  ECM	  regulation,	  the	  MMP	  family	  includes	  the	  only	  enzymes	  
known	  to	  degrade	  fibrillar	  collagen	  at	  neutral	  pH,	  the	  collagenases	  (MMPs	  -­‐1,	  -­‐8,	  -­‐13,	  and	  -­‐14)	  (104).	  
The	   only	   other	   enzyme	   known	   to	   degrade	   structural	   collagen	   is	   cathepsin	   K	   (CTSK),	   a	   lysosomal	  
cysteine	  protease	  with	  peak	  activity	  at	  a	  pH	  5.0-­‐6.0	  (104).	  
	  
1.4.6. MMPs	  and	  TB	  
It	   is	   clear	   that	   alterations	   in	   the	   lung	   ECM	  occur	   during	   active	   TB.	   This	   led	   to	   the	   hypothesis	   that	  
MMPs	  may	  play	  an	  important	  role	  in	  disease.	  The	  first	  article	  in	  this	  area	  was	  published	  in	  1996	  (99),	  
and	  since	  then,	  a	  series	  of	  studies	  have	  identified	  an	  association	  between	  MMP	  activity	  and	  TB	  (85,	  
105-­‐117).	  
	  
Many	   pulmonary	   cell	   types	   are	   found	   to	   secrete	   disproportionately	   elevated	   levels	   of	   MMPs,	  
especially	  MMP-­‐1,	  in	  response	  to	  TB	  infection	  (109,	  110,	  114,	  116,	  117).	  This	  explains	  why	  increased	  
MMP-­‐1	  expression	  and	  activity	  is	  present	  in	  humans	  with	  active	  TB	  (105,	  107,	  109).	  The	  data	  strongly	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indicate	   that	  MMP-­‐1	  has	  a	  central	   role	   in	   the	  cavity	  process	   in	   TB.	  Elkington	  et	  al.	  have	   suggested	  
that	  MMP-­‐1	  expression	   is	   the	  most	   important	  mediator	  of	   tissue	  destruction,	  and	  that	   therapeutic	  
targeting,	  with	  the	  collagenase	  specific	   inhibitor	  Cipemastat	  (which	  has	  passed	  phase	  II	  safety	  trials	  
in	  man),	  may	  be	  beneficial	   to	   TB	  patients	   (84,	  107,	  109,	  118).	  One	  caveat	  of	   this	   suggestion	   is	   the	  
unpredictably	   of	   outcomes	   when	   inhibiting	   MMPs	   (119).	   MMP	   inhibitory	   therapy	   is	   fraught	   with	  
complicated	  risks	  arising	   from	  disruption	  of	  proteolytic	  networks	   (120),	  or	  unexpected	  functions	  of	  
MMPs	   in	   modulating	   host	   immune	   responses,	   either	   through	   direct	   function,	   or	   through	  
modification	  of	   immune	   signalling,	   or	   effector	  molecules	   (119).	   Early	  MMP	   inhibitors	   also	   had	  off-­‐	  
target	  effects,	  which	  accounted	  for	  some	  unwanted	  side-­‐effects	  (121-­‐124).	  Interestingly,	  there	  is	  no	  
identified	  risk	  associated	  with	  specifically	  targeting	  MMP-­‐1	  (119).	  
	  
Currently	   there	   is	   only	   an	   association	   between	   collagenase	   activity	   and	   cavity	   formation,	   and	   a	  
causative	  link	  between	  MMP-­‐1	  and	  cavity	  formation	  has	  not	  been	  established.	  Such	  a	  causative	  link	  
would	   require	   trial	   of	   collagenase	   inhibitors	   in	  humans.	  Given	   the	  potential	   risk	  of	   such	   therapies,	  
preclinical	   efficacy	   and	   safety	   trials	   are	   required.	   Such	   trials	   require	   relevant	   animal	  models	  of	   TB.	  
However,	  human-­‐like	  TB	  models,	   especially	  models	  of	   cavity	   formation,	  are	  challenging	   to	  use	  and	  
poorly	  understood.	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1.5. Animal	  models	  of	  destructive	  pulmonary	  TB	  
	  
	  
‘All	  models	  are	  wrong,	  but	  some	  are	  useful’	   G.E.P.	  Box	  (125)	  
	  
	  
The	  only	  requirements	  for	  a	  model	  is	  that;	  	  
(i)	   The	   outcomes	   of	   experiments	   in	   the	   model	   can	   be	   used	   to	   accurately	   predict	   outcomes	   in	   the	  
system	   they	   model,	   (ii)	   it	   can	   be	   manipulated	   and	   monitored	   in	   a	   manner	   with	   measureable	  
outcomes,	  and	  (iii)	  it	  is	  accessible	  to	  a	  diverse	  research	  community.	  
	  
What	  must	  be	  remembered	  in	  clinical	  medicine	   is	  that	  each	  attempt	  at	  treatment	   is	  an	  experiment;	  
the	  variables	  in	  the	  biological	  system	  (i.e.	  the	  unique	  biology	  of	  the	  patient,	  stage	  of	  disease,	  the	  skill	  
of	  the	  caregiver)	  are	  impossible	  to	  control.	  Each	  experiment	  results	  in	  either	  net	  benefit,	  or	  net	  harm	  
or	  equivalence.	  If	  an	  intervention	  leads	  to	  reproducibly	  beneficial	  outcomes,	  the	  intervention	  may	  be	  
broadly	   applicable	   –	   however,	   the	   broader	   the	   variation	   in	   subject,	   the	   less	   likely	   outcomes	   will	  
correlate	  between	  patients.	  This	  concept	  fundamentally	  underpins	  all	  clinical	  trials.	  
	  
Animal	   models	   can	   allow	   us	   to	   perform	   experiments	   which	   may	   be	   of	   unacceptable	   risk	   on	   an	  
individual	  scale,	  and	  if	  interpreted	  correctly,	  with	  an	  understanding	  of	  their	  limitations,	  can	  allow	  for	  
the	  first	  experiment	  on	  a	  person	  to	  be	  a	  low	  risk	  to	  benefit	  event.	  Animal	  models	  can	  also	  allow	  for	  
investigations	  that	  are	  not	  achievable	  in	  humans,	  for	  example	  observations	  in	  closely	  matched	  post-­‐	  
mortem	   tissues.	   It	   must	   be	   remembered	   that	   without	   direct	   correlation	   to	   human	   disease,	   these	  
observations	  are	  limited	  to	  being	  characterisations	  of	  the	  model,	  until	  such	  point	  as	  the	  observations	  
are	  shown	  to	  relate	  directly	  to	  human	  disease.	  
	  
1.5.1. Animal	  models	  of	  TB	  
Animal	  models	   of	   TB	   have	   a	   long	   and	   controversial	   history.	   Current	   animal	  models	   of	   TB	   show	   a	  
variety	   of	   relationships	   to	  human	  disease,	   the	   full	   discussion	  of	  which	   is	   beyond	   the	   scope	  of	   this	  
thesis.	   The	   following	  paragraphs	   focus	  on	  how	  well	   animal	  models	  of	   TB	   represent	   destructive	   TB	  
pathology	  and	  ECM	  degradation.	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1.5.2. Mice;	  bacterial	  growth	  in	  the	  absence	  of	  human-­‐like	  pathology	  
Mice	  are	  the	  most	  commonly	  used	  animal	  for	  investigating	  M.	  tb	  infection.	  They	  are	  mainly	  used	  for	  
investigating	   the	   potential	   efficacy	   of	   novel	   antibiotic	   regimens,	   as	   they	   can	   provide	   preliminary	  
information	  on	  bioavailability,	   toxicity	  and	  bacterial	  growth	  (126-­‐129),	  but	  do	  not	  show	  destructive	  
pulmonary	   pathology.	   The	   mouse	   orthologs	   to	   MMP-­‐1	   (McolA	   and	   McolB)	   have	   very	   poor	  
collagenolytic	  capacity	   (130).	  A	  mouse	  which	  expresses	  human	  MMP-­‐1	   in	  macrophages	   is	  available	  
(131),	   but	   since	   in	   vitro	   studies	   suggest	   that	   fibroblasts	   and	   epithelial	   cells	   may	   be	   the	   most	  
abundant	   source	   of	   MMP-­‐1	   (110,	   117),	   this	   mouse	   may	   not	   fully	   replicate	   the	   potential	   role	   for	  
MMP-­‐1	   in	   TB	   pathology.	   When	   infected	   with	   M.	   tb,	   these	   mice	   do	   show	   increased	   collagen	  
destruction,	  but	  not	  cavity	  formation	  (109).	  Recently,	  the	  C3HeB/FeJ	  or	  ‘Kramnik’	  mouse	  model	  has	  
been	  used	  because	  it	  develops	  granuloma-­‐like	  lesions	  with	  necrosis	  (127,	  132-­‐138),	  it	  is	  claimed	  that	  
cavity	   formation	   has	   been	   observed	   (138),	   but	   this	   is	   exceedingly	   rare.	   Since	   neither	   human-­‐like	  
tissue	   destruction,	   nor	   MMP-­‐1	   expression,	   is	   observed	   mice,	   they	   are	   a	   poor	   candidate	   for	  
investigations	  into	  the	  tissue	  destructive	  role	  of	  MMP-­‐1.	  
	  
1.5.3. Zebrafish;	  powerful	  tools	  in	  the	  absence	  of	  pulmonary	  tissue	  
The	   zebrafish	   infected	  with	  M.	  marinum	  has	  been	  used	  as	   a	  model	  of	   granuloma	   formation.	  After	  
infection,	   macrophage	   aggregation	   is	   followed	   by	   formation	   of	   a	   lymphocytic	   cuff.	   Eventually	  
caseation	  of	  the	  granuloma	  may	  occur	  (111,	  139,	  140).	  This	  model	  is	  particularly	  useful	  because	  the	  
embryos	   are	   transparent	   and	   can	   be	   subjected	   to	   genetic	   knockdown	   (morpholinos).	   This	   means	  
that	  the	  model	  can	  be	  used	  to	  simultaneously	  monitor	  bacterial	   infection	  and	  cellular	  responses	  at	  
the	   initiation	  of	   infection,	  on	  an	  array	  of	  genetic	  backgrounds	   (111,	  141-­‐143).	   It	   is	  yet	  to	  be	  proven	  
whether	  the	  dynamics	  of	  the	  granuloma	   in	  this	  model	  accurately	   replicate	  the	  events	   that	  occur	   in	  
human	   TB.	   Mortality	   in	   this	   model	   is	   rapid	   (less	   than	   100	   days),	   and	   there	   is	   failure	   to	   contain	  
infection	  (140,	  144,	  145).	  Extensive	  tissue	  destruction	  is	  not	  seen	  in	  this	  model	  (140).	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1.5.4. Guinea	  pigs;	  granuloma-­‐like	  lesions	  but	  high	  susceptibility	  to	  infection	  
The	  next	  most	  commonly	  used	  model	   is	  the	  guinea	  pig.	  Guinea	  pigs	  are	  highly	  susceptible	  to	  M.	  tb	  
infection	   and	   develop	   progressive	   disease	   after	   infection	   with	   as	   few	   as	   10	   colony-­‐ forming	   units	  
(CFU)	   (146).	  Guinea	  pigs	  develop	  a	  granulomatous	   response	   to	  TB	   that	   is	   continuously	  progressive	  
and	  eventually	  forms	  central	  necrosis.	  Cavities	  and	  human-­‐like	  tissue	  destruction	  are	  not	  observed	  in	  
guinea	  pigs	  (146).	  
	  
1.5.5. Non-­‐human	  primates;	  human-­‐like	  disease	  but	  in	  a	  challenging	  system	  
The	  cynomologous	  macaque	  model	  of	  TB	  is	  perhaps	  most	  representative	  of	  human	  disease.	  Multiple	  
different	  lesion	  types	  are	  produced	  and	  a	  spectrum	  of	  outcomes,	  from	  primary	  progressive	  disease	  to	  
disease	  resolution,	  are	  seen	  (147).	  This	  model	  is	  extremely	  useful	  for	  studying	  the	  varying	  outcomes	  
of	   infection	   (148-­‐150),	   but	   this	   variability	  makes	   the	  model	   challenging	   to	   use	  when	   assessing	   the	  
benefits	  of	   therapeutic	   interventions	   (151).	  The	  animals	  are	  expensive	  to	  purchase	  and	  house,	  and	  
difficult	   to	   handle.	   Rhesus	   macaques	   are	   more	   susceptible	   to	   infection	   and	   develop	   progressive	  
disease	  after	  aerosol	  infection	  (152).	  
	  
1.5.6. Rabbits;	  human-­‐like	  disease	  in	  a	  ‘small	  animal’	  
Rabbits	  also	  demonstrate	  a	  full	  spectrum	  of	  human-­‐like	  responses	  to	  M.	  tb	  infection	  (75).	  Depending	  
on	  the	  virulence	  and	  dose	  of	  the	  infecting	  organism,	  granulomas,	  necrosis	  and	  tissue	  destruction	  are	  
observed	  (153-­‐155).	  Commonly	  used	  out-­‐bread	  New	  Zealand	  White	  rabbits	  are	  considered	  relatively	  
resistant	  to	  active	  disease	  (75).	  When	  infected	  with	  less	  than	  500	  CFU	  of	  M.	  tb	  H37Rv	  and	  CDC1551	  
these	  animals	  usually	  contain	  infection,	  and	  can	  be	  expected	  to	  have	  no	  countable	  bacteria	  after	  3	  
months	  (155,	  156).	  
	  
1.5.6.1. Rabbits	  and	  cavitary	  pulmonary	  disease	  
The	  rabbit	  has	  been	  utilised	  specifically	  for	  studying	  cavity	  formation	  on	  a	  number	  of	  occasions.	  The	  
first	   documented	  experiments	   took	  place	   in	   the	  1950s,	  when	  Yamamura	  et	  al.	  described	   that	   pre-­‐	  
sensitisation	   of	   the	   rabbit	   by	   repeated	   subcutaneous	   administration	   of	   a	  mycobacterial	   extract	   in	  
mineral	  oil	  and	  lung	  tissue,	  followed	  by	  inoculation	  of	  M.	  tb	  transthoracically	  (also	  in	  mineral	  oil	  and	  
lung	   tissue)	   led	   to	   the	   reliable	   development	   of	   cavities	   (157-­‐161).	   For	   a	   considerable	   period	   after	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these	   studies,	   cavity	   formation	   was	   not	   specifically	   studied.	   Cavity	   formation	   was	   observed	   in	   a	  
number	  of	   studies	  by	  Lurie	  and	  Dannenberg	  where	   lengthy	  and	  sustained	  Mycobacterial	   infections	  
were	   achieved	   by	   inoculating	   either	  M.	   tb	   resistant	   rabbits	   with	  M.	   bovis	   or	   an	   inbred	   strain	   of	  
susceptible	  rabbits	  with	  M.	  tb	  (74,	  75).	  Subsequently,	  it	  was	  documented	  by	  Converse	  et	  al.	  that	  M.	  
tb	  H37Rv	   (a	   virulent	  human	   isolate)	   infection	   can	   lead	   to	   cavity	   formation	   in	   resistant	   rabbits,	   but	  
only	  after	  very	  high	  infectious	  doses	  (162).	  More	  recently,	  Subbian	  et	  al.	  and	  Via	  et	  al.	  described	  that	  
high-­‐dose	  aerosol	  delivery	  of	  M.	  tb	  HN878,	  (a	  virulent	  human	  isolate	  of	  the	  Beijing	  lineage),	  leads	  to	  
progressive	  disease	  with	  occasional	  cavity	  development	   (155,	  163-­‐166).	  Some	  gene	  expression	  data	  
from	  HN878	   infected	  rabbits	  was	  published	  by	  Subbian	  et	  al.	  and	  suggests	   that	  TB	  pathogenesis	   in	  
this	  model	  was	  associated	  with	  MMP-­‐1	  expression,	  but	  associations	  with	  cavity	  formation	  were	  not	  
investigated	  (167).	  
	  
1.5.6.2. Pre-­‐sensitisation	  in	  rabbits,	  a	  reliable	  method	  to	  develop	  cavitary	  disease?	  
The	  most	   reproducible	   description	  of	   tissue	   destruction	   in	   TB	   comes	   from	  Nedeltchev	   et	   al.	   (168,	  
	  
169)	   who	   modified	   the	   method	   of	   Yamamura	   et	   al.	   (157-­‐161)	   to	   develop	   a	   reliable	   cavity	  
model.	  Nedeltchev	  et	   al.	   performed	  bronchoscopic	  instillation	  of	  virulent	  M.	  tb	  H37Rv	  and	  CDC1551	  
and	  M.	  bovis	  AF2122/97	  and	  ravenel	  after	  a	  pre-­‐sensitising	  regimen	  consisting	  of	  repeated	  injection	  
of	   heat-­‐killed	  M.	   bovis	   in	   incomplete	   Freund’s	   adjuvant	   (168,	   169).	   Unlike	   Yamamura,	   Nedeltchev	  
did	   not	   inoculate	   bacteria	   in	   mineral	   oil	   and	   lung	   homogenate,	   and	   did	   not	   use	   transthoracic	  
injection.	   Nedeltchev	   et	   al.	   observed	   cavity	  formation	  in	  all	  animals	  when	  sacrificed	  between	  50	  to	  
105	   days	   (7	   to	   15	   weeks)	   post-­‐infection.	   The	   apparent	   reproducibility	   of	   cavities	  marked	   a	  major	  
breakthrough	  in	   investigating	  this	  process,	  however,	  the	  model	  still	  resulted	   in	  diverse	  pathologies,	  
and	   the	   process	   of	   cavity	   formation	   was	   not	   characterised.	   Because	   of	   the	   inconsistency	   in	  
outcomes	  in	  this	  model,	  it	  could	  not	  readily	  be	  used	  for	  the	  preclinical	  assessment	  of	  therapeutics.	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1.5.6.3. The	  challenge	  of	  working	  in	  rabbit	  models	  
Immunological	  investigations	  in	  rabbits	  are	  extremely	  challenging.	  Antibodies	  against	  even	  the	  most	  
basic	   immune	   components	   are	   rare,	   and	   so	   the	   classic	   tools	   for	   the	   immunologist	   such	   as	   Flow	  
Cytometry	   and	   ELISAs	   (enzyme-­‐linked	   immunosorbent	   assays)	   are	   not	   readily	   available	   to	   rabbit	  
researchers.	  Since	  rabbits	  are	  only	  distantly	   related	  to	  humans	  and	  mice,	   for	  which	  the	  majority	  of	  
reagents	   are	   available,	   the	   level	   of	   cross-­‐reactivity	   of	   antibodies	   is	   limited,	   and	   rarely,	   if	   ever,	  
validated.	  This	  problem	  is	  confounded	  by	  the	  fact	  that	  rabbits	  are	  the	  primary	  source	  of	  commercial	  
antibodies,	   which	   almost	   guarantees	   a	   lack	   of	   cross-­‐reactivity	   with	   rabbit	   proteins.	   In	   addition	   to	  
this,	  very	  few	  members	  of	  the	  scientific	  community	  are	  experienced	  in	  handling	  such	  animals	  and	  so	  
individuals	  must	  be	  trained	  and	  gain	  experience	  with	  the	  animals	  prior	  to	  conducting,	  often	  lengthy,	  
studies.	  
	  
1.5.6.4. Rabbit	  models	  have	  a	  promising	  future	  in	  the	  ‘–omics	  era’	  
Despite	  these	  problems,	  the	  rabbit	  is	  an	  excellent	  TB	  model	  in	  a	  number	  of	  ways;	  primarily	  because	  
it	   accurately	   recapitulates	   many	   human	   pathologies	   (74,	   75,	   155).	   It	   is	   clear	   that	   much	   could	   be	  
learned	   from	   this	   model,	   and	   with	   the	   growing	   availability	   of	   antibody-­‐free	   technologies	   for	  
evaluating	   protein,	   lipid	   and	   carbohydrate	   components	   (in	   particular	   mass-­‐spectrometry	   based	  
platforms),	   and	   the	   availability	   of	   genomic	   databases	   against	  which	  RNA	  profiles	   can	  be	  matched,	  
the	  paucity	  of	  immunologic	  reagents	  is	  becoming	  less	  of	  a	  hindrance.	  The	  development	  of	  methods	  
for	  assessing	  tissues	  in	  these	  animals	  is	  essential.	  Since	  rabbits	  are	  large,	  comparisons	  can	  easily	  be	  
made	  between	  matched	  tissues	  from	  the	  same	  animal.	  The	  relative	  ease	  with	  which	  biological	  fluids	  
can	   be	   sampled,	   and	   high	   quality	   in	   vivo	   imaging	   can	   be	   performed,	   means	   that	   longitudinal	  
assessment	   of	   disease	   progression	   can	   be	   correlated	   with	   peripheral	   biomarkers	   in	   individual	  
animals	   (165,	  170).	  
	  
1.5.6.5. Summary:	  A	  reliable,	  well-­‐characterised	  model	  of	  cavitary	  disease	  is	  within	  sight	  
There	  is	  no	  reliable,	  well-­‐characterised	  model	  of	  pulmonary	  tissue	  destruction	  in	  response	  to	  M.	  tb	  
	  
infection.	  The	  Nedeltchev	  model	  is	  the	  most	  reliable	  model	  of	  tissue	  destruction,	  but	  correlates	  with	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human	   disease	   have	   not	   been	   investigated,	   and	   the	   process	   of	   cavity	   development	   is	   poorly	  
characterised.	   The	   aim	   of	   the	  work	   presented	   in	   this	   thesis	   was	   to	   improve	   both	   the	  model,	   and	  
analytical	  methods,	   to	   a	  point	  where	   rabbits	   can	  be	  used	   for	   relevant	  preclinical	   trials	  of	  novel	   TB	  
therapeutics.	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1.6. Summary	  
TB	   kills	   more	   people	   now	   than	   at	   any	   point	   in	   history,	   despite	   the	   relatively	   wide	   availability	   of	  
simple	   diagnostics	   and	   antibiotic	   therapy	   (1).	   We	   desperately	   need	   improved	   preventative,	  
diagnostic	  and	  treatment	  measures.	  The	  uniquely	  destructive	  pathology	  of	  active	  TB	  contributes	  to	  
disease	  progression,	  transmission	  and	  treatment	  failure	  (71,	  84,	  85,	  87,	  118,	  171),	  and	  may	  therefore	  
be	   therapeutically	   targetable.	  Tissue	  destruction	   is	   characterised	  by	  necrosis	  and	  ECM	  destruction.	  
Of	  these	  two	  components,	  ECM	  destruction	  is	  the	  least	  well	  characterised	  and	  is	  more	  extensive	  and	  
consistent	  in	  TB	  than	  other	  pulmonary	  diseases	  (88).	  The	  collagenase,	  MMP-­‐1,	  is	  highly	  implicated	  in	  
this	  process	  (99,	  105,	  107,	  109,	  110,	  112-­‐114,	  116,	  117).	  Our	  limited	  knowledge	  of	  tissue	  destruction	  
is	  hindered	  by	   the	  absence	  of	  animal	  models	  of	   this	  process,	  although	   a	   recently	  developed	   rabbit	  
model	  of	  cavitary	  disease	  may	  be	  useful	  in	  understanding	  the	  importance	  of	  tissue	  destruction	  in	  TB,	  
as	  well	  as	  its	  molecular	  pathogenesis	  (168,	  169).	  
	  
This	   thesis	   describes	   how,	   using	   Nedeltchev’s	   model	   as	   a	   basis,	   a	   novel	   rabbit	   model	   of	   tissue	  
destruction	   was	   developed.	   It	   describes	   how	   novel	   technologies,	   especially	   quantification	   of	  
computed	   tomography	   (CT),	   can	   be	   used	   to	   monitor	   disease	   in	   rabbits.	   There	   is	   an	   emphasis	   on	  
simple	  and	  safe	  technologies,	  with	  translation	  to	  any	  facility	  in	  which	  animals	  can	  be	  bio-­‐safety	  level	  
3	  (BSL-­‐3)	   contained.	  Finally,	  having	   	  generated	  	  a	   reliable,	  accessible	   model	   of	   human-­‐like	   tissue	  
destruction,	   the	  thesis	   focuses	  on	  characterising	  correlates	   to	  human	  disease,	  with	  a	  specific	   focus	  
on	  molecular	  mechanisms	  of	  tissue	  destruction.	  The	  implications	  for	  these	  discoveries,	  and	  utility	  of	  
this	  model,	  are	  discussed	  at	  the	  end	  of	  the	  thesis.	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1.7. Hypothesis	  




1. Develop	  and	   characterise	  a	   rabbit	  model	   of	   destructive	   pulmonary	   TB.	   Establish	  protocols	  
for	  investigating	  therapeutic	  regimens	  in	  this	  model.	  
2. Investigate	  the	  role	  of	  MMPs	  in	  tissue	  destruction	  in	  the	  rabbit	  model.	  
	  
3. Investigate	  whether	  MMP-­‐1	  inhibition	  alters	  pathology	  in	  TB.	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All	   reagents	   were	   purchased	   from	   Sigma-­‐Aldrich	   (www.sigmaaldrich.com)	   unless	   specified.	   Cell	  
culture	  materials	   were	   purchased	   from	   Invitrogen	   (www.invitrogen.com).	   Ro32-­‐3555	   (Cipemastat)	  
was	  purchased	  from	  Tocris.	  Reagents	  were	  made	  up	  according	  to	  solubility	  information	  provided	  by	  
manufacturers.	  Where	  possible	  water	  was	  used,	  however,	  DMSO	  was	  used	  when	  substances	  were	  
not	  soluble	  in	  water.	  
	  
2.2. In	  vitro	  experimental	  methods	  
	  
2.2.1. Mycobacterial	  culture	  
Mycobacterium	  tuberculosis	  H37Rv	  and	  CDC1551	  (purchased	  from	  ATCC,	  VA,	  USA)	  was	  preserved	  as	  
50%	   glycerol	   frozen	   stocks,	   it	   was	   cultured	   for	   use	   in	  Middlebrook	   7H9	  medium	   (BD,	   Sparks,	  MD,	  
USA),	   supplemented	  with	   10%	   OADC	   (oleic	  acid,	   albumin,	  dextrose,	   catalase)	   enrichment	  medium,	  
0.5%	  glycerol,	  0.02%	  Tween	  80	  and	   rotated	  at	  200RPM	   (revolutions	  per	  minute)	   at	   37°C.	   This	  was	  
subcultured	   at	   least	   once	   with	   an	   optical	   density	  (OD)	   of	   less	   than	   1	   (measured	  	  at	   600nm,	   by	  
BioWave	  density	  meter,	  WPA,	  Cambridge).	  Midlog	  growth	  phase	  density	  cultures	  were	  used	  with	  the	  
estimation	  that	  an	  OD	  of	  1	  was	  equivalent	  to	  1x108	   CFU.	  CFU	  was	  measured	  by	  plating	  on	  selective	  
7H11	  plates	  (BD,	  Sparks,	  MD,	  USA).	  
	  
Mycobacterium	   bovis	   ravenel	   (purchased	   from	   ATCC,	   VA,	   USA)	   was	   cultured	   in	   Middlebrook	   7H9	  
medium	   supplemented	   as	   above	   with	   the	   exception	   that	   4.16g/l	   sodium	   pyruvate	   was	   utilised	   in	  
addition	  to	  glycerol.	  No	  other	  strain	  of	  M.	  bovis	  was	  used.	  
	  
2.2.2. TB	  Sup	  production	  
M.	   tb	   culture	   at	  OD	   0.6	  was	   spun	   down	   at	   13000RPM	   for	   5	  minutes	   and	   the	   supernatant	   filtered	  
through	  a	  0.22μM	  Durapore	  (Millipore)	  filter.	  Aliquots	  were	  made	  and	  stored	  at	  -­‐20°C.	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2.2.3. UV	  killed	  M.	  tuberculosis	  
1ml	   of	   logarithmically	   growing	  M.	   tb	  was	   placed	   into	   a	   sterile	   60mm	   petri	   dish,	   which	   was	   then	  
sealed	   using	   parafilm.	   The	  dish	   is	   then	   rotated	   to	   ensure	   even	   coverage	  of	   bacteria	   on	   plate.	   The	  
petri	   dish	   is	   then	   placed	   in	   a	   ziplock	   bag	   and	   irradiated	   for	   90	  minutes	   on	   a	   UV	   transilluminator	  
(wavelength	  365nm,	  UVP,	  Upland,	  CA,	  USA).	  This	  is	  then	  stored	  at	  -­‐20°C.	  Effectiveness	  of	  UV	  killing	  is	  
confirmed	  by	  culture	  on	  Middlebrook	  7H11	  agar	  supplemented	  with	  OADC	  enrichment	  medium	  and	  
0.5%	  glycerol.	  100μl	  of	  original	  culture	  was	  plated	  as	  a	  positive	  control.	  
	  
In	  figure	  85,	  UVTB	  and	  wUVTB	  are	  used.	  These	  were	  made	  by	  centrifuging	  UV	  killed	  TB,	  as	  described	  
above,	  and	  removing	  the	  supernatant.	  The	  cells	  were	  then	  washed	  3x	  in	  PBS	  prior	  to	  resuspension	  in	  
either	  the	  original	  supernatant	  (UVTB)	  or	  in	  the	  Middlebrook	  7H9	  (wUVTB).	  
	  
2.2.4. Macrophage	  culture	  
Monocytes	   were	   isolated	   from	   donor	   leukocyte	   cones	   (National	   Blood	   Transfusion	   Service).	   The	  
entire	   content	   of	   the	   leukocyte	   cone	  was	  mixed	  50:50	  with	  HBSS.	   35mls	   of	   this	  mixture	  was	   then	  
pipetted	  into	  a	  50ml	  conical	  falcon	  tube	  containing	  15mls	  Ficoll	  Paque	  (Amersham	  Biosciences,	  UK).	  
Centrifugation	   at	   480	   RCF	   (relative	   centrifugal	   force)	   for	   30	   minutes	   followed.	   The	   serum	   was	  
discarded	  and	  the	  monocyte	  layer	  removed	  into	  a	  new	  falcons.	  The	  cells	  were	  then	  washed	  5	  times	  
by	  resuspension	   in	  50mls	  HBSS	  then	  centrifugation	  for	  5	  minutes	  at	  308	  RCF.	  This	   technique	  yields	  
monocyte	   purity	   over	   95%,	   with	   less	   than	   5%	   cells	   CD3	   positive	   (our	   group,	   unpublished	  
observations).	  Total	  monocyte	  concentration	  was	  calculated	  by	  incubation	  for	  5	  minutes	  at	  37°C	  on	  
a	  haemocytometer,	   then	   visual	   counting	  of	   adherent	   cells.	  Monocytes	  were	  plated	  at	   2.5x105	  cells	  
per	  cm²	  in	  24	  well	  plates.	  Adherence	  took	  place	  during	  a	  1	  hour	  incubation	  in	  supplement	  free	  RPMI.	  
Non-­‐adherent	  cells	  were	   removed	  after	   this	  time	  by	  washing	  with	  HBSS.	  Monocytes	  were	  matured	  
into	  macrophages	  over	  4	  days	  in	  RPMI	  containing	  20ng/ml	  macrophage	  colony	  stimulating	  factor	  (M-­‐	  
CSF,	  R&D,	  Abbingdon,	  UK)	  and	  10%	  FCS	   (foetal	   calf	   serum).	  Cells	  were	   then	   rested	   for	  24	  hours	   in	  
RPMI	  +	  10%	  FCS,	  without	  M-­‐CSF	  prior	  to	  starting	  experiments.	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2.2.5. In	  vitro	  macrophage	  experimental	  protocol	  
After	  maturation,	  macrophages	   were	   either	   stimulated	  with	   TB	   Sup,	   UVTB,	   or	  wUVTB.	   They	   were	  
then	  left	  for	  72	  hours	  prior	  to	  harvesting	  of	  supernatants,	  which	  were	  stored	  at	  -­‐20°C.	  
	  
When	   live	   infection	   took	  place,	  M.	   tb	  H37Rv	  OD	  was	   utilised	   to	   assess	   CFU/ml	   and	   ensure	   that	   a	  
multiplicity	   of	   infection	   (MOI)	   of	   1	   was	   achieved.	   After	   2	   hours,	   the	   cell	   culture	   supernatant	  was	  
changed	   to	   remove	   non-­‐infecting	   bacteria.	   Supernatants	   were	   harvested	   at	   72hours	   and	   filter	  
sterilised	   through	   Durapore	   0.22μm	   spin	   filters	   (EMD	   Millipore	   Corporation,	  MA,	   	   USA)	   prior	   	   to	  
evaluation	  of	  MMP	  secretion.	  
	  
Cells	   were	   observed	   by	   light	   microscopy	   during	   and	   at	   the	   close	   of	   each	   experiment	   to	   assess	  
viability.	  Experiments	  were	  not	  analysed	  if	  alterations	  in	  cell	  viability	  were	  observed.	  
	  
2.2.6. Sandwich	  ELISAs	  
All	   ELISAs	   were	   completed	   according	   to	   manufactures	   protocols:	   MMP-­‐1,	   MMP-­‐3	   and	   tumour	  
necrosis	   factor	   alpha	   (TNFα)	   levels	   in	   the	   cell	   culture	   supernatants	   were	   analysed	   by	   ELISA	   (R&D	  
Systems	  Duoset	  ELISA)	  according	   to	   the	  manufacturer’s	   instructions.	   All	  breakdown	  product	  assays	  
(CICP;	   type	   I	   C-­‐terminal	   collagen	   propeptide,	   HP;	   Helical	   Peptide,	   PYD;	   	   pyridinoline,	   DPD;	  
deoxypyridinoline)	  were	  purchased	  from	  Quidel	  Corp	  (San	  Diego,	  CA,	  USA).	  Rabbit	  MMP-­‐1	  ELISA	  was	  
purchased	   from	   USCN	   (Wuhan,	   China).	   Prior	   to	   analysis	   all	   samples	   were	   spun	   for	   5	   minutes	   at	  
>10000	   RCF,	   prior	   to	   filtration	   through	   0.22μM	  Durapore	   spin	   filters	   (EMD	  Millipore	   Corporation,	  
	  
MA,	  USA).	  96	  well	  plates	  were	  coated	  with	  100μl	  of	  0.8μg/ml	  capture	  antibody	  and	  left	  over	  night.	  3	  
washes,	   using	   300μl	   of	   0.05%	   tween	   in	   PBS	   (phosphate	   buffered	   saline)	   took	   place	   between	  
additions	  of	  a	  new	  reagent.	  The	  plate	  was	  then	  blocked	   for	  1	  hour	  with	  1%	  bovine	   serum	  albumin	  
(BSA).	  100μl	  per	  well	  of	  sample	  and	  standards	  were	  then	  added,	   followed	  by	  addition	  of	  100μl	  per	  
well	   of	   biotinylated	  detection	  antibody.	   Streptavidin	   horseradish	  peroxidise	   (HRP)	  was	   then	  added	  
prior	   to	   the	   final	   wash.	   100μl	   of	   substrate	   solution	  was	   then	   added	   and	   the	   plate	  monitored	   for	  
colour	  change	  over	  a	  period	  of	  5-­‐30minutes.	  50μl	  per	  well	  of	  2M	  H2SO4	  was	  added	  prior	  to	  analysis	  
in	  a	  450nm	  microplate	  reader.	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2.2.7. Luminex	  (multiplex	  immunoassay)	  
MMP-­‐1,	   -­‐3	   and	   -­‐7	  were	   analysed	  utilising	  multiplex	   immunoassay	   according	   to	   the	  manufacturer’s	  
instructions	  (R&D	  systems).	  Cell	  culture	  supernatants	  were	  diluted	  1:5	  prior	  to	   incubation	  on	  a	  pre-­‐	  
moistened,	   96-­‐well	   filter	   plate.	   The	   samples	   were	   incubated	   in	   a	   1:1	   ratio	   with	   primary	   antibody	  
coated	  microparticles,	  then	  incubated	  for	  2	  hours,	  whilst	  shaking	  at	  500rpm.	  The	  microparticles	  are	  
then	  washed	  by	   repeated	  vacuum	  driven	   removal	   of	   fluid	   and	  addition	  of	  wash	  buffer.	   Secondary	  
biotinylated	   antibody	   is	   added,	   and	   the	   plate	   is	   incubated	   for	   a	   further	   1	   hour	   with	   shaking.	  
Incubation	   for	   30	   minutes	   with	   streptavidin	   phycoerythrin	   then	   took	   place,	   then	   washing	   and	  
resuspension	  in	  wash	  buffer.	  Analysis	  was	  performed	  on	  the	  Luminex	  platform	  (BioPlex	  200,	  BioRad).	  
	  
2.2.8. Primer	   design	   for	   quantitative	   real	   time	   polymerase	   chain	   reaction	   (qRT-­‐PCR)	  
analysis	  
Primers	  	  were	  	  designed	  	  using	  	  Vector	  	  NTI	  	  (Life	  	  Technologies,	  	  Carlsbad,	  	  CA,	  	  USA).	  	  Primers	  	  were	  
	  
required	  to	  be	  18	  and	  25	  bases	  long,	  with	  a	  melting	  temperature	  between	  55	  and	  65°C,	  GC	  content	  
from	  40-­‐60%	  and	  a	  product	  length	  from	  80-­‐200bp	  (base	  pairs)	  long.	  
	  
2.2.9. qRT-­‐PCR	  analysis	  of	  rabbit	  lung	  tissue	  
Rabbit	  lung	  samples	  were	  cut	  into	  0.3mm	  (maximum)	  cubes	  and	  placed	  into	  RNAlater	  (Qiagen)	  using	  
a	  no	  touch,	  RNAse	  free	  technique.	  This	  was	  stored	  at	  4°C	  for	  up	  to	  1-­‐2	  days	  to	  allow	  for	  penetration,	  
prior	  to	  removal	  and	  storage	  at	  -­‐80°C.	  RNA	  (ribonucleic	  acids)	  were	  extracted	  under	  BSL-­‐3	  conditions	  
using	  the	  following	  method.	  The	  RNeasy	  Fibrous	  Tissue	  Mini	  Kit	   (Qiagen)	  was	  utilised,	  although	  the	  
protocol	   required	  adaptation	   in	  order	   to	  produce	  DNA	   (deoxyribonucleic	  acid)	   free	  RNA.	   Less	   than	  
30mg	   of	   tissue	   was	  homogenised	   in	   Buffer	   RLT	   and	   1%	   β-­‐mercaptoethanol,	   by	   3	   cycles	   of	   the	  
following:	   bead-­‐beating	   with	   2mm	   beads	   at	   250rpm	   followed	   by	   30	   seconds	   centrifugation	   at	  
13000g.	   This	   is	   followed	   1:59	   proteinase	   K:water	   treatment	   at	   55°C	   for	   10	  minutes.	   The	   samples	  
were	   then	   subjected	   to	   centrifugation	   at	   10000g	   for	   3	  minutes.	   The	   supernatant	   is	   removed	   and	  
added	   to	  equal	   volumes	  of	  100%	  ethanol.	   The	  samples	  were	   then	  passed	   through	  an	  RNEasy	  mini	  
spin	   column	  and	   cleaned	  with	  wash	   buffer	   prior	   to	   on	   column	  DNAse	   treatment.	   After	   30minutes	  
exposure	  to	  DNAse	  a	  2x	  ethanol	  wash	  is	  performed	  prior	  to	  elution	  from	  the	  column	  with	  water.	  The	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sample	   is	   then	   resuspended	   on	   a	   new	   column	   and	   retreated	   with	   DNAse,	   and	   eluted	   in	   water	   a	  
second	  time.	  This	  re-­‐treatment	  process	  successfully	  yields	  DNA	  free	  RNA	  of	  high	  quality	  as	  tested	  by	  
analysis	  of	  the	  28s:18s	  ratio	  on	  the	  Agilent	  BioAnalyser	  (Agilent,	  CA).	  
	  
RNA	   concentration	   in	   the	   eluted	   sample	   is	  measured	   by	  Nanodrop	   Spectrophotometry	   (Nanodrop	  
2000C	   ThermoScientific,	   DE,	   USA),	   and	   the	   concentration	   adjusted	   to	   0.5μg/μl.	   The	   RNA	   is	   then	  
subjected	   to	   cDNA	   conversion	   utilising	   the	   Agilent	   Superscript	   cDNA	   synthesis	   kit	   (Agilent,	   CA)	  
according	   to	   the	  manufacturer’s	   instructions.	   10:3:1:6	   Superscript	   II	  Mastermix:	   Random	   Primers:	  
Reverse	  Transcriptase:	  0.5μg/μl	  RNA	  mixture	  were	  subjected	  to	  25°C	  for	  5	  minutes,	  then	  42°C	  for	  15	  
minutes,	   and	   finally	   95°C	   for	   5	  minutes	   prior	   to	   storage	   at	   -­‐20°C.	   (-­‐80°C	   if	   prolonged	   storage	   is	   to	  
follow).	  A	  no	  reverse	  transcriptase	  control	  is	  also	  synthesised	  and	  subjected	  to	  qRT-­‐PCR	  analysis	  with	  
primers	  capable	  of	  amplifying	  genomic	  DNA	  sequences,	  to	  ensure	  the	  absence	  of	  genomic	  DNA	  from	  
reaction	  mixtures.	  
	  
qRT-­‐PCR	   was	   carried	   out	   using	   SYBR	   II	   (BioRad,	   CA)	   and	   the	   iQ5	   platform	   according	   to	   the	  
manufacturer’s	  instructions.	  40	  cycles	  were	  performed	  and	  the	  raw	  data	  exported	  to	  excel.	  This	  data	  
was	   then	   analysed	   using	   LinReg	   	   software	   (172)	   to	   	   calculate	   efficiency,	   and	   ct	   (cycle	   threshold)	  
values.	  Excel	  was	  utilised	  to	  calculate	  ΔΔct	  and	  fold	  changes.	  
	  
2.2.10. Gelatin	  zymography	  
Rabbit	  lung	  samples	  in	  PBS	  were	  homogenised	  by	  bead-­‐beating	  in	  a	  sealed	  2ml	  O-­‐ring	  tube,	  with	  15	  
2mm	  glass	  beads.	  Samples	  were	  then	  spun	  at	  10000g	  for	  30	  seconds,	  and	  then	  re-­‐suspended.	  Bead	  
beating	  was	  repeated	  until	  a	  clump-­‐free	  homogenate	  was	  produced	  (approximately	  5-­‐10x).	  Samples	  
were	  then	  filtered	  through	  Durapore	  spin	   filters	  (Millipore,	  MA).	  Samples	  were	  then	  mixed	  with	  5x	  
loading	  buffer	   (0.25M	  Tris	   pH	  6.8,	   50%	   glycerol,	   5%	   sodium	  dodecyl	   sulphate	   -­‐	   SDS,	   bromophenol	  
blue)	  and	  run	  on	  an	  11%	  acrylamide	  gel	  impregnated	  with	  0.1%	  gelatin	  at	  180V	  for	  approximately	  3	  
½	   hours	   (buffer	   25mM	   Tris,	   190mM	   glycine,	   0.1%	   SDS).	   A	   standard	   of	   2ng	   recombinant	   MMP-­‐9	  
(Oncogene,	  Nottingham,	  UK)	  were	  loaded	  on	  each	  gel.	  	  Once	  the	  marker	  had	  reached	  the	  end	  of	  the	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gel,	  the	  gel	  was	  washed	  in	  2.5%	  Triton-­‐X	  for	  1	  hour,	  then	  rinsed	  twice	  in	  low	  salt	  collagenase	  buffer	  
(55mM	   Tris	   base,	   200mM	   sodium	   chloride,	   5mM	   calcium	   chloride,	   0.02%	   Brij,	   pH	   7.6)	   prior	   to	  
incubation	  at	  37o	   for	  16	  hours	  in	  collagenase	  buffer.	  	  Areas	  of	  gelatinolytic	  activity	  were	  revealed	  by	  
a	  single	  step	  stain-­‐destain	  method	  using	  0.02%	  Coomassie	  Blue	  (Pharmacia,	  Sweden)	  in	  1:3:6	  acetic	  
acid	  :	  methanol	  :	  water.	  
	  
2.2.11. Casein	  Zymography	  
The	   samples	   were	   processed	   as	   above.	   The	   same	   running	   and	   loading	   buffer	   are	   used.	   The	   gel	  
utilised	   is	   the	   commercially	   available	   12%	   casein	   gel	   (Invitrogen).	   Samples	   were	   run	   at	   180V	   for	  
approximately	  90	  minutes	   (or	  until	   the	  marker	   reached	  the	  end	  of	   the	  gel),	   in	   the	   Invitrogen	  XCell	  
SureLock	   MiniCell.	   All	   samples	   were	   run	   alongside	   a	   recombinant	   human	   10ng	   MMP-­‐1	   standard	  
(CalBiochem	  #444208).	  
	  
2.2.12. Whole	  trancriptome	  sequencing	  of	  rabbit	  pulmonary	  tissue	  
Tissue	  was	  dissected	  under	  gross	  observation	  from	  cavity	  wall,	  contralateral	  upper	   lobe	  of	   infected	  
lung,	  and	  uninfected	  lungs	  and	  stored	  in	  RNAlater	  (Ambion)	  at	  4°C	  for	  24	  hours	  prior	  to	  transfer	  to	  -­‐	  
80°C.	   Tissue	   fragments	   <30mg	  were	   homogenized	   by	   bead	   beating	   in	   TRIzol,	   RNA	   extraction	   was	  
achieved	   by	   the	   addition	   of	   chloroform,	   centrifugation	   and	   then	   isolation	   in	   ethanol.	   The	  
ethanol/chloroform	  mix	  was	   then	  bound	   to	   a	  column	   (Qiagen)	   for	   cleanup.	  Washing	  preceded	  on-­‐	  
column	  DNAse	  treatment	  (Ambion)	  at	  37°C	  for	  15minutes.	  This	  was	  followed	  by	  further	  washing	  and	  
elution	  in	  RNAse	  free	  water.	  200-­‐500ng	  of	  samples	  were	  then	  submitted	  to	  the	  Johns	  Hopkins	  Core	  
sequencing	  facility.	  The	  sequencing	  facility	  completed	  the	  following	  steps;	  RNA	  integrity	  was	  tested	  
using	  the	  Agilent	  2100	  Bioanalyzer	   (Agilent	  Technologies,	  Santa	  Clara,	  CA),	  mRNA	   (messenger	  RNA)	  
was	   enriched	   using	   the	   RIBOminus	   kit	   according	   to	   the	   manufacturer's	   instructions	   (Life	  
technologies,	  Grand	  Island,	  NY).	  Successful	  removal	  of	  rRNA	  (ribosomal	  ribonucleic	  acid)	  was	  verified	  
by	  another	  Bioanalyzer	  assay.	  Fragmentation	  of	  the	  RNA	  was	  performed	  by	  chemically	  as	  described	  
in	   Applied	   Biosystems	   SOLiD™	   Total	   RNA-­‐Seq	   Kit	   protocol	   (Applied	   Biosystems,	   Carlsbad,	   CA).	  
Fragmented	  	   RNA	  	   was	  	   purified	  	   using	  	   the	  	   Invitrogen	  	   RiboMinus	  	   Concentration	  	   Module	  	   (Life	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technologies,	   Grand	   Island,	   NY)	   and	   the	   size	   distribution	   and	   yield	   were	   assessed	   by	   Bioanalyzer	  
using	  the	  RNA	  6000	  pico	  Chip	  Kit	  (Agilent	  technologies,	  Santa	  Clara,	  CA)	  and	  Qubit	  Fluorometer	  (Life	  
technologies,	   Grand	   Island,	   NY).	   Once	   the	   concentration	   was	   confirmed,	   construction	   of	   the	  
amplified	  whole	  transcriptome	  library	  was	  performed	  as	  specified	  in	  the	  Applied	  Biosystems	  SOLiD™	  
Total	   RNA-­‐Seq	   Kit	   protocol,	   which	   is	   intrinsically	   strand-­‐specific.	   After	   reverse	   transcription	   was	  
complete,	  each	  sample	  was	  barcoded	  with	  a	  unique	  3’	  primer	  during	  the	   library	  amplification	  step.	  
Libraries	   were	   run	   on	   DNA1000	   chip	   using	   the	   Agilent	   Bioanalyzer	   to	   assess	   size	   distribution	   and	  
quality	  of	  the	  amplified	  library.	  Quantification	  of	  each	  library	  was	  performed	  by	  qPCR	  and	  equimolar	  
concentrations	   of	   each	   library	   were	   pooled	   together	   prior	   to	   completion	   	   of	   emulsion	   PCR	   and	  
sequencing	   on	   the	   AB	   5500xl	   SOLiD	   sequencer	  (Applied	   Biosystems,	   Carlsbad,	   CA).	   Reads	   were	  
aligned	   to	   OryCun	   2.0	   (http://www.ncbi.nlm.nih.gov/genome/316?project_id=42933)	   using	   the	  
Bioscope	   1.3	   Whole	   Transcriptome	   Analysis	   Pipeline	  using	  	  default	  settings	  (Applied	  	  Biosystems,	  
Carlsbad,	   CA).	   The	   number	   of	   reads	  mapped	   to	   each	   transcript	  was	   calculated	   using	   HTSeq-­‐count	  
v0.5.3.	  The	  overlap	  resolution	  mode	  was	  set	  to	  “intersection-­‐nonempty”	  and	  feature	  type	  was	  set	  to	  
“exon”.	  (http://www.huber.embl.de/users/anders/HTSeq/doc/install.html#download)	  
	  
Differential	   expression	   between	   the	   sample	   groups	   was	   determined	   using	   DESeq	   v1.4.1	  
(http://genomebiology.com/2010/11/10/R106),	   using	   a	   test	   based	   on	   the	   negative	   binomial	  
distribution,	   modeling	   both	   biological	   and	   technical	   variation.	   p-­‐values	   are	   adjusted	   for	   multiple	  
comparisons	  using	   the	  Benjamini	   -­‐	  Hochberg	  method.	  Transcripts	  with	  adjusted	  p-­‐values	   less	   than	  




Tissues	   were	   fixed	   by	   immersion	   in	   10%	   neutral	   buffered	   formalin.	   Processing	   was	   completed	   by	  
Histoserv	  or	  the	  Comparative	  Pathology	  Core	  at	  Johns	  Hopkins	  University.	  For	  the	  final	  rabbit	  study	  
analysis	   was	   performed	   by	   Marlene	   Orandle	   at	   the	   NIH/NIAID	   comparative	   pathology	   laboratory	  
(figures	   31	   and	   32).	   Briefly,	   tissue	  was	   embedded	   in	   paraffin,	   sectioned	   at	   4μm	   and	   stained	  with	  
hematoxylin	   and	   eosin	   (H&E)	   for	   routine	   histopathology	   or	   with	   an	   acid	   fast	   stain	   for	   bacteria.	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Sections	   were	   examined	   by	   light	   microscopy	   using	   an	   Olympus	   BX51	   microscope	   and	  
photomicrographs	  were	  taken	  using	  an	  Olympus	  DP70	  camera.	  
	  
2.2.14. Immunohistochemistry	  
This	   was	   performed	   by	   Jin	   Park	   and	   Marc	   Halushka	   and	   images	   of	   stained	   slides	   were	   taken	   to	  
identify	   specific	   pathologies	   (173).	   Formalin-­‐fixed	   and	   paraffin-­‐embedded	   tissues	   were	   de-­‐	  
paraffinized	  with	  xylenes	  and	  rehydrated.	  Antigen	  retrieval	  was	  performed	  at	  95°C	   in	  citrate	  buffer	  
(DAKO,	  Carpinteria,	  CA)	  and	  endogenous	  peroxidase	  was	  blocked	  with	  hydrogen	  peroxide	  (DAKO)	  for	  
10	  min.	  After	  blocking,	  tissues	  were	  incubated	  with	  mouse	  monoclonal	  antibodies	  directed	  at	  human	  
cathepsin	  K	   (clone	  3F9;	  Abcam,	  Cambridge,	  MA,	  USA)	  overnight	  at	  4°C.	  After	  washing	   in	  PBS,	  HRP-­‐	  
conjugated	   secondary	   antibodies	   were	   applied	   for	   1	   hour	   at	   37°C	   and	   the	   staining	  was	   visualized	  
with	   3,3-­‐diaminobenzidine	   (DAKO)	   for	   2	   min.	   Nuclei	   were	   counterstained	   with	   Mayer’s	  
haematoxylin.	  
2.2.15. PBMC	  stimulation	  and	  TNFα	  analysis	  
PBMCs	   were	   collected	   as	   described	   below	   and	   cells	   were	   counted	   by	   Countess	   Automated	   Cell	  
Counter	  (Invitrogen).	  Live/dead	  cells	  were	  stained	  using	  0.4%	  trypan	  blue	  (Invitrogen	  T10282).	  PBMC	  
stimulation	  was	  carried	  out	  in	  96-­‐well	  flat	  bottom	  plates	  (BD).	  105	  live	  cells	  were	  added	  to	  each	  well.	  
Cells	  were	  stimulated	  with	  PMA	  (30	  ng/mL)	  (Sigma	  P8139),	  PPD	  (5	  TU)	  (Tubersol	  NDC	  49281-­‐752-­‐22,	  
Lot	   C3949AA),	   ESAT-­‐6	   /CFP-­‐10	   (30	   µg/mL)	   (BEI	   resources,	  NR-­‐14868,	  NR-­‐14869),	   and	   a	  media	   only	  
control	  group	  was	  also	  included.	  Cells	  were	  incubated	  with	  antigen	  for	  24	  hours	  and	  then	  supernatant	  
was	   collected	   and	   filtered	   with	   a	   0.22µm	   filter.	   Single	   cytokine	   ELISA	   were	   done	   according	   to	  
manufacturer	  protocol	  (USCN	  Life	  Science	  Inc.	  E90133Rb	  for	  TNFα).	  
2.3. Animal	  procedures:	  
	  
2.3.1. Animals	  
Female	  New	  Zealand	  white	  rabbits	  were	  used	  for	  all	  animal	  experiments.	  Animals	  were	  maintained	  
in	  BSL-­‐3	  conditions	  in	  accordance	  with	  the	  protocols	  approved	  by	  the	  Institutional	  Animal	  Care	  and	  
Use	  Committee	  (IACUC)	  at	  Johns	  Hopkins	  University,	  USA.	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2.3.2. Sensitisation	  
3-­‐3.5kg	   rabbits	   (Covance	   research	   products/Myrtles	   rabbitry/Robinsons)	   were	   sensitised	   with	  
5x0.2ml	  subcutaneous	  injections	  containing	  varying	  amounts	  (as	  dictated	  by	  experiment)	  of	  M.	  bovis	  
ravenel	  at	   mid-­‐log	  growth,	   that	   	  had	   	  been	   	  heat-­‐killed	   	   (3	  hours	  at	   72°C),	  and	   	  mixed	   	  50:50	  with	  
incomplete	  Freund’s	  adjuvant,	   to	   form	  a	  water	   in	  oil	  emulsion.	  18-­‐25	  days	  after	   the	   final	   injection,	  
skin	   test	   reactivity	   was	   determined	   by	   injection	   of	   0.1ml	   of	   old	   tuberculin	   (OT)	   (Synbiotics	  
Corporation,	  Exdale,	  CA,	  USA)	  or	  5IU	  (international	  units)	  purified	  protein	  derivative	  (PPD)(Tubersol)	  
(Sanofi-­‐Aventis,	   Bridgewater,	   NJ,	   USA)	   and	   read	   48	   hours	   later	   to	   assess	   reactivity.	  Measurement	  
was	   performed	  using	   callipers	   to	  measure	   two	   perpendicular	   dimensions	  of	   the	   raised	   area	   in	   the	  
plane	   of	   the	   skin	   and	   a	   thickness	   measurement	   by	   subtracting	   skin	   fold	   thickness	   in	   a	   matched	  
untreated	   area	   of	   skin	   to	   the	   region	   the	   TST.	   Halving	   these	   diameters	   give	   the	   radii	   a,	   b	   and	   c	  
respectively.	  Skin	  test	  volume	  was	  calculated	  using	  the	  volume	  of	  an	  ellipsoid	  (174):	  43 𝜋𝑎𝑏𝑐	  
	  
2.3.3. Rabbit	  infection	  
Rabbits	   were	   anaesthetised	   with	   intramuscular	   ketamine	   (5-­‐10mg/kg)	   and	   xylazine	   (15-­‐25mg/kg),	  
prior	   to	   placement	   of	   a	   4.5mm	   diameter	   endotracheal	   tube.	   A	   3.0mm	   flexible	   Pentax	   FB-­‐8V	  
paediatric	   bronchoscope	   (Pentax	  Medical	  Company,	  Montvale,	   NJ,	   USA)	  was	   guided	   into	   the	   right	  
lower	   lobe	   of	   the	   lung	   and	   a	   catheter	   inserted	   through	   the	   instrument	   port.	   The	   inoculums	   was	  
administered	   through	   a	   catheter	   composed	   of	   a	   1ml	   luer-­‐lock	   syringe,	   a	   22	   gauge	   luer	   stub,	   and	  
90cm	   of	   TE-­‐50	   tubing	   (which	   allows	   the	   catheter	   tip	   to	   be	   visualised	   at	   the	   end	   of	   the	  
bronchoscope’s	   instrument	   port).	   Inoculum	   delivery	   was	   directly	   visualised	   through	   the	  
bronchoscope	  to	  confirm	  correct	  placement.	  
	  
2.3.4. In	  vivo	  sampling	  
	  
2.3.4.1. Blood	  collection	  
Blood	  was	  collected	  from	  the	  middle	  ear	  artery,	  when	  animals	  were	  anaesthetised	  for	  other	  studies.	  
Acepromazine	  (0.2mg)	  was	  utilised	  to	  cause	  vasodilatation.	  A	  22	  gauge	  canula	  (Smiths	  Medical)	  was	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placed	  into	  the	  artery,	  and	  blood	  collected	  into	  10ml	  syringes	  (BD,	  Sparks,	  MD,	  USA).	  Using	  a	  blunt	  
18G	   filling	   needle	   (BD,	   Sparks,	   MD,	   USA)	   blood	   was	   transferred	   either	   to	   tubes	   containing	   	   no	  
additive	  (for	  serum),	  or	  lithium	  heparin	  (for	  plasma),	  (BD,	  Sparks,	  MD,	  USA),	  or	  Ficoll/Citrate	  for	  the	  
collection	  of	  peripheral	  blood	  mononuclear	  cells	   (PBMCs).	  Tubes	  were	   centrifuged	  at	  1600g	   for	  15	  
minutes	   (a	   delay	   of	   2	   hours	   precedes	   this	   step	   if	   serum	   is	   being	   collected),	   prior	   to	   collection	   of	  
supernatant.	   The	   brake	   is	   in	   the	   on	   position	   except	   for	   the	   processing	   of	   PBMCs,	   which	   was	  
performed	  according	  to	  the	  manufacturer’s	  instructions.	  	  
2.3.4.2. Urine	  collection	  
Urine	  was	   collected	   from	   the	   bladders	   of	   anaesthetised	   rabbits	   by	   placing	   firm	   pressure	   from	   the	  
apex	  of	   the	  bladder	   in	   the	  direction	  of	   the	   sacrum.	  The	  bladder	   apex	  was	  palpated	  approximately	  
10cm	  above	  the	  pubic	  symphysis.	  Urine	  was	  collected	  in	  a	  receptacle	  (figure	  38).	  
	  
Lung	   samples	  were	  obtained	   at	   necropsy	   via	   rapid	  dissection.	   This	   took	  place	  after	   anaesthesia	   as	  
above	   by	   IV	   (intravenous)	   administration	   of	   an	   overdose	   with	   Euthasol	   (Virbac	   Corporation,	   Fort	  
Worth,	  TX).	  Samples	  of	  tissue	  were	  dissected	  by	  macroscopic	  appearance.	  Tissue	  for	  protein	  analysis	  
was	   immediately	   snap-­‐frozen	   in	   liquid	   nitrogen,	   RNA	   later	   (Ambion)	   was	   used	   for	   RNA	   analysis	  
within	  15minutes	  of	  overdose.	  Subsequently	  tissues	  were	  taken	  for	  histological	  analysis	  by	  fixation	  in	  
10%	  formalin,	  and	  placed	  in	  PBS	  for	  CFU	  enumeration.	  The	  weight	  of	  each	  sample	  was	  caculated	  by	  
addition	  pre	  and	  post	  weighing	  sample	  collection	  vials.	  
	  
2.3.5. Rabbit	  Imaging	  
Imaging	  took	  place	  under	  gas	  anaesthesia.	  Anaesthesia	  was	  induced	  using	  ketamine	  and	  xylazine	  as	  
above,	   prior	   to	   transfer	   onto	   1%	   isofluorane	   in	   3lmin-­‐1	   oxygen	   delivered	   to	   a	   sealed	   chamber	   in	  
which	   the	   anaesthetised	   animal	   was	   contained.	   IV	   injection	   of	   0.2mCi	   of	   18F-­‐FDG	   (2-­‐deoxyy-­‐2-­‐	  
(18F)fluoro-­‐D-­‐glucose)	   via	   the	   marginal	   ear	   vein	   preceded	   transfer	   to	   the	   chamber	   if	   positron	  
emission	   tomography	   (PET)	   imaging	  was	   utilised.	   The	   input	   and	   output	   of	   the	   chamber	   are	  HEPA	  
(high-­‐efficiency	  particulate	  air)	  filtered	  in	  order	  to	  contain	  BSL-­‐3	  conditions	  within	  the	  chamber.	  The	  
chamber	   is	   then	   transferred	   to	   BSL-­‐2	   conditions	   where	   a	   clinical	   8	   slice	   scanner	   (Neruologica	  
CereTom)	  is	  used	  to	  generate	  CT	  image	  data.	  PET	  scanning	  is	  performed	  using	  the	  Philips	  Mosaic	  HP	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Small	  Animal	  PET	  Imager.	  
CT	   and	   PET	   scans	   were	   manually	   co	   registered	   using	   AMIRA	   (Visualization	   Sciences	   Group,	  
Burlington,	   MA,	   USA).	   Specific	   regions	   of	   interest	   (ROIs)	   where	   used	   were	   selected	   using	   a	   3	  
dimensional	   selection	   tool	  of	  equal	   size.	  Whole	   lung	  segmentation	  was	   completed	  using	  AMIRA	  as	  
described	   in	   figure	   47.	   Briefly	   a	   contiguous	   selection	   of	   region	   in	   density	   -­‐1024	   to	   -­‐200	   HU	   was	  
isolated	  using	  space	  filling	  tool	  originating	  in	  the	   lung	  field.	  This	  was	  enlarged	  3	  pixels	   in	  all	  planes.	  
Holes	  within	  the	  segmented	  region	  were	  filled.	  Next,	  regions	  which	  link	  non-­‐lung	  regions	  to	  the	  lung	  
were	  manually	  removed	  –	  and	  then	  a	  space-­‐filling	  tool	  was	  used	  to	  remove	  the	  contiguous	  non-­‐lung	  
regions.	  Next,	  a	  smoothing	  algorithm	  was	  applied	  to	  the	  entire	  shape.	  If	  dilated,	  the	  oesophagus	  was	  
removed	  with	  a	  space-­‐filling	  tool	  in	  the	  range	  of	  -­‐1024	  to	  -­‐800	  HU.	  Finally,	  the	  segmented	  region	  was	  
eroded	  by	  3	  pixels	  in	  all	  directions.	  
	  
Breath	   hold	   scanning	   is	   described	   fully	   in	   the	   text	   (figure	   42).	   Scanning	   required	   the	   use	   of	   a	  
custom-­‐built	  BSL-­‐3	  chamber	  (figure	  41).	  Briefly,	  rabbits	  were	  intubated	  and	  connected	  via	  a	  T-­‐tube	  to	  
a	   HEPA	   filtered	   circuit	   through	   which	   3lmin-­‐1	   of	   oxygen	   containing	   1%	   isoflurane	   was	   delivered.	  
Lung	   inflation	   was	   initiated	   by	   closing	   a	   valve	   in	   the	   expiratory	   limb.	   Pressure	   was	   set	   by	  
immersing	   a	  division	  of	  the	  inspiratory	   limb	  to	  the	  required	  depth	   in	  a	  column	  of	  water.	  When	  the	  
predetermined	  pressure	  was	   reached,	   a	   valve	   distal	   to	   the	   pressure	   trap	  was	   closed.	   The	   CT	   scan	  
was	   acquired	   at	  this	  point.	  After	  acquisition	  both	  valves	  were	  opened	  to	  allow	  normal	  breathing	  in	  
the	  rabbit.	  
	  
2.3.6. Immunosuppression	  with	  dexamethasone	  
Immunosuppression	   was	   performed	   by	   giving	   a	   subcutaneous	   10mg/kg	   loading-­‐dose	   of	  
dexamethasone	  followed	  by	  daily	  maintenance	  doses	  of	  0.1mg/kg	  subcutaneously	  for	  28	  days	  (154,	  
175).	  
	  
2.3.7. Culture	  of	  bacteria	  from	  rabbit	  tissue	  
Two	   methods	   were	   used	   to	  assess	   bacterial	   burden	   in	   tissue;	   biopsy	   sampling	   and	   whole	   lobe	  
homogenisation.	  When	   lung	  was	   sampled	   a	   small	   piece	  of	   representative	   tissue	  was	   placed	   into	   a	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pre-­‐weighed	  o-­‐ring	   tube	  containing	  approximately	  2mm	  of	  glass	  beads	  and	  800μl	  of	  PBS.	  This	  was	  
stored	  for	  24	  hours	  at	  4°C	  prior	  to	  homogenisation	  using	  a	  bead	  beater	  at	  250RPM	  for	  30	  seconds,	  
then	   centrifugation	   for	   30	   seconds	   at	   13000g.	   This	  was	   repeated	   3	   times.	   500μl	   of	   homogenised	  
sample	  was	  plated	  on	  selective	  7H11	  (BD,	  Sparks,	  MD,	  USA).	  1	  to	  10	  serial	  dilutions	  were	  also	  plated	  
up	   to	  1:100	   000	   dilutions.	   CFU	   were	   enumerated	   28	   days	   after	   plating.	  The	   range	   of	   accurate	  
detection	  was	   considered	   to	   be	   a	   CFU	   from	   10	   to	   300.	  Where	   2	   dilutions	   fell	   into	   this	   range	   the	  
count	  in	  the	  range	  from	  10	  to	  100	  was	  utilised	  for	  calculating	  CFU.	  
	  
To	  calculate	  entire	  lobe	  CFUs	  each	  lobe	  was	  first	  weighed,	  then,	  the	  of	  specimens	  for	  histological	  and	  
molecular	   analysis	  were	   removed	  and	   the	   remaining	   lung	  weighed	   and	   placed	   into	   a	  50ml	   conical	  
falcon	  tube	  containing	  20ml	  of	  PBS.	  This	  was	  left	  for	  24	  hours	  at	  4°C	  prior	  to	  homogenisation	  using	  a	  
Polytron	  homogeniser	  (Kinematica,	  Luzern,	  Switzerland),	  in	  a	  sealed	  glovebox.	  The	  homogenate	  was	  
then	  diluted	   to	  40ml	  and	  plating	  proceeded	  as	  described	  above,	   except	  dilutions	   included	  1:1	  000	  
000	  dilutions	  for	  highly	  affected	  lobes.	  
	  
2.4. Statistical	  Analysis:	  
All	   statistical	   analysis,	   with	   the	   exception	   of	   that	   specifically	   listed	   as	   being	   performed	   by	   the	  
sequencing	   facility	   (section	   2.2.12.),	   was	   conducted	   using	   GraphPad	   Prism	   5.	   Specific	   tests	   are	  
including	  within	  the	  figure	  legends.	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3. Investigating	   Factors	   That	  Contribute	   to	   Cavity	   Formation	   in	   the	  Rabbit	  Model	  of	  Tuberculosis	  
	  
Cavity	   formation	   is	  a	  distinguishing	   feature	  of	  active	  TB	  (9,	  10,	  39,	  60,	  69,	  71).	   It	   is	  associated	  with	  
morbidity	  (176-­‐179),	  mortality	   (180-­‐183),	  transmission	  (184,	  185)	  and	  treatment	  failure	  (71,	  86,	  87,	  
186).	  It	  is	  the	  site	  where	  the	  highest	  numbers	  of	  bacteria	  are	  found	  in	  post-­‐mortem	  specimens	  (71).	  
Targeting	   the	   processes	   involved	   in	   cavity	   formation	   may	   be	   beneficial	   in	   preventing	   morbidity,	  
death	  and	  transmission	  (84,	  85,	  118,	  171).	  Further	  examination	  of	  this	  process	  and	  the	  environment	  
it	   generates	   may	   also	   allow	   us	   to	   improve	   the	   effectiveness	   of	   antibiotics,	   resulting	   in	   shorter	  
regimens	  and	  preventing	  the	  emergence	  of	  resistance.	  
	  
Currently	   the	   processes	   involved	   in	   cavity	   formation	   are	   poorly	   understood,	   partly	   because	   it	   is	  
challenging	   to	   study	   experimentally.	   The	   overall	   aim	   of	   the	   following	   studies	   was	   to	   better	  
understand	  pre-­‐sensitised	  rabbit	  models	  and	  develop	  a	  model	  suitable	  for	  trialing	  novel	  therapeutics	  
in	  the	  context	  of	  cavitary	  disease.	  The	  requirements	  of	  the	  model	  were:	  
	  
i) That	  it	  recapitulates	  human	  cavity	  formation	  
	  
ii) It	  is	  consistent	  in	  phenotype	  
	  
iii) It	  can	  be	  easily	  and	  accurately	  monitored,	  and	  hence	  be	  economically	  viable	  for	  use	   in	  
preclinical	  trials	  
	  
The	   following	   chapter	  describes	   investigations	   of	   cavity	   development,	   using	   the	  Nedeltchev	  model	  
(168,	  169)	  as	  a	  starting	  point*.	  
	  
*Readers	  may	  wish	  to	  read	  chapter	  4	  (in	  particular	  section	  4.7),	  prior	  to	  reading	  this	  chapter,	  especially	  if	  they	  wish	  to	  understand,	  in	  detail,	  
how	   the	  quantitative	   imaging	  analysis	  was	  performed.	  The	   relevant	  sections	  of	   chapter	  4	  are	   referenced	   in	   the	   text	   of	   this	   chapter,	  and	  
could	  be	  reviewed,	  if	  necessary	  at	  the	  relevant	  points	  in	  this	  chapter.	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3.1. M.	  tuberculosis	  CDC1551	  infection	  in	  the	  pre-­‐sensitised	  rabbit	  
Nedeltchev	   et	   al.	   noted	   that	   infection	   of	   pre-­‐sensitised	   with	  M.	   tb	   CDC1551,	   H37Rv	   or	  M.	   bovis	  
ravenel	   or	   AF2122/97	   resulted	   in	   cavities	   7	   to	   15	   weeks	   later	   (168).	   In	   an	   attempt	   to	   reproduce	  
Nedeltchev’s	   findings,	   rabbits	   were	   sensitised	  with	   5	   injections	   of	   107	  heat-­‐killed	  M.	   bovis	   ravenel	  
over	  14	  days.	  After	  23	  days,	  animals	  were	  subjected	  to	  tuberculin	  skin	  testing	  (TST),	  with	  0.1ml	  of	  old	  
tuberculin	   (OT).	  The	   test	  was	   read	  48	  hours	   later.	  After	   this,	   the	   rabbits	  were	   transferred	   to	  BSL-­‐3	  
conditions	  where	  they	  were	  infected	  with	  103	   CFUs	  of	  M.	  tb	  CDC1551	  via	  a	  catheter	  passed	  through	  
the	  instrument	  port	  of	  a	  bronchoscope.	  This	  strain	  was	  used	  because	  a	  transposon	  mutant	  library	  is	  
available	   on	   this	   background	   (187),	   and	   it	   was	   hypothesised	   that	   this	   could	   be	   used	   to	   identify	  
virulence	  factors	  required	  prior	  to	  and	  after	  cavity	  formation	  (188).	  The	  bronchoscope	  was	  wedged	  
into	   a	   third	   generation	   airway,	   and	   the	   catheter	   tip	   visually	   introduced	   into	   a	   distal	   airway.	   This	  
technique	  allows	   for	  direct	  visualisation	  of	   the	  delivered	   inoculum	   into	  a	   fourth	  generation	  airway.	  
Animals	  were	  sacrificed	  at	  6	  and	  10	  weeks	  post	  infection,	  and	  gross	  pathology	  observations	  made.	  
	  
Very	  few	  animals	  formed	  cavities,	  and	  often	  there	  was	  a	  complete	  absence	  of	  any	  observable	  gross	  
pathology	   (table	   1).	   Any	   pathology	   (lesion)	   was	   documented.	   When	   present,	   these	   lesions	   were	  
small,	   firm	  nodules.	  These	   findings	  did	  not	   fit	  with	   the	  observations	  of	  Nedeltchev	  et	  al.	   (168,	  169)	  
and	   suggested	   that	   OT-­‐TST	   positivity	   does	   not	   universally	   predispose	   to	   cavity	   formation	   as	  
Nedeltchev	  described.	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It	  was	  reasoned	  that	  the	  period	  of	  infection	  may	  have	  been	  too	  brief	  and	  so	  a	  10-­‐week	  experiment	  
was	  conducted,	  and	  only	  OT-­‐TST	  positive	  animals	  were	  infected	  (table	  2).	  
	  
These	  studies	  demonstrated	  that	  even	  strongly	  positive	  OT-­‐TST	  reactions	  did	  not	  reliably	  predispose	  
to	   cavities	   at	   6	   or	   10	   weeks	   (table	   1	   and	   2).	   As	   a	   result	   of	   these	   studies	   it	   was	   concluded	   that	  
sensitisation	  with	   five	   injections	   1x107	   heat-­‐killed	   bacilli	   in	   incomplete	   Freund’s	   adjuvant	   does	  not	  
universally	  lead	  to	   OT-­‐TST	   reactivity	   and	   that	  M.	   tb	   CDC1551	   does	   not	   reliably	   establish	   infection	  
in	   pre-­‐sensitised	   rabbits.	   Not	   all	   OT-­‐TST	   positive	   animals	   developed	   observable	   cavities.	   It	   is	  
possible	   that	   cavitary	   disease	   had	   occurred	   and	   that	   gross	   pathological	   observation	   was	   not	  
sufficient	   to	   detect	   it.	   To	   address	   this	   concern	   in	   vivo	   computed	   tomography	   (CT)	   imaging	   was	  
employed	  in	  subsequent	  experiments.	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3.2. Investigating	   M.	   bovis	   ravenel	   infection	   in	   OT-­‐TST	   positive	   and	  
negative	  animals	  
To	   further	   investigate	   the	   relationship	   between	   OT-­‐TST	   sensitivity	   and	   cavity	   development,	   three	  
OT-­‐TST	  positive	  and	  three	  OT-­‐TST	  negative	  animals	  were	  infected	  with	  M.	  bovis	  ravenel	   (all	  animals	  
received	   sensitisation	   as	   in	   3.1.),	  which	   is	   known	   to	   have	  high	   virulence	   in	   rabbits	   (162,	   168,	   169,	  
174,	  189).	   It	   was	   expected	   that	   this	   higher	   virulence	   would	   correlate	   with	   cavity	   development.	  
Lung	  disease	   in	   the	   animals	  was	   assessed	   using	   CT/18F-­‐FDG	   PET	   scanning	   and	   gross	   pathology.	   All	  
animals	   failed	   to	   develop	   cavities	   at	   7	   weeks.	   Surprisingly,	   all	   animals	   showed	   disease	   resolution	  
by	   in	  vivo	  imaging	  (figure	  1)	  and	  negligible	  pathology	  at	  necropsy	  (figure	  2).	  












The	   failure	   to	   develop	   progressive	   disease	   and	   extensive	   lesions	   was	   unexpected,	   and	   could	   be	  
explained	  by	  three	  hypotheses:	   (i)	  The	  strain	  being	  utilised	  was	  exhibiting	  reduced	  virulence	   in	  the	  
model,	   (ii)	   the	   sensitisation	   process	   was	   protecting	   against	   disease	   development	   or	   (iii)	   the	  
experimental	  infection	  technique	  was	  not	  reproducible.	  
	  
To	  address	  the	  third	  hypothesis,	  a	  short	  study	  investigating	  both	  the	  strain	  and	  method	  of	  infection	  
was	   performed	   (figure	   34).	   This	   demonstrated	   that	   the	   infection	   method	   was	   reproducible.	   To	  
investigate	   the	  first	  hypothesis,	  an	  experiment	  to	  see	  whether	   the	  sensitising	  strain	  was	  protective	  
against	  a	  different	  laboratory	  isolate	  of	  M.	  bovis	  ravenel	  was	  conducted.	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3.3. Investigating	   the	   strain-­‐specific	   effect	   on	  protection	   from	  	  extensive	  
M.	  bovis	  disease	  
A	  different	  laboratory	  M.	  bovis	  ravenel	  isolate	  was	  cultured	  from	  a	  rabbit	  with	  extensive	  pathology.	  
It	  was	   used	   to	   infect	   6	   rabbits	   sensitised	  with	   the	  M.	   bovis	   ravenel	   strain	   that	   had	   failed	   to	   show	  
virulence	  in	  the	  previous	  experiment	  (section	  3.2).	  If	  the	  strain	  used	  for	  sensitisation	  was	  protective	  
from	  disease,	   containment	   and	   resolution	  of	   infection	  would	  be	  expected.	  6	  weeks	   after	   infection	  
gross	  pathology	  (figures	  3	  and	  4)	  and	  bacterial	  burden	  (figure	  5)	  were	  analysed.	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All	  6	  infected	  animals	  developed	  extensive	  pulmonary	  disease,	  far	  beyond	  that	  seen	  in	  the	  previous	  
experiment,	   despite	   similar	   infectious	   doses	   (figure	   3	   and	   4).	   This	   was	   in-­‐keeping	   with	   the	  
observations	  that	  M.	  bovis	  is	  highly	  virulent	  in	  rabbits	  (74,	  75,	  168,	  169,	  189).	  Bacteria	  were	  found	  in	  
all	   regions	  of	   the	   lung	   sampled,	  with	  a	   strong	   concordance	  between	   regions	  of	   grossly	  observable	  
pathology	  and	  bacterial	  burden	  (figure	  5D).	   Interestingly,	  animal-­‐to-­‐animal	  bacterial	  burdens	  varied	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Figure 6A. Histopathology of sensitised, M. bovis infected rabbits, demonstrating a range of responses to 
infection: Extensive necrosis is observed at the site of infection in all animals (necrotic focus). This is 
characterised by total destruction of the tissue architecture with infiltration of mononuclear cells accompanied 
by varying degrees of lymphocytic infiltration. Adjacent to this, varying degrees of necrosis with occasional 
granuloma forma- tion (Q,N,R and L) are observed. In minimally affected areas, granulomas are still observed in 
animals with more extensive gross pathology (R,L). 
	  
	  
Figure 6B. Uninfected lung tissue from the right lower lobe showing normal lung architecture: (4x 
magnification, H+E stain). 
 
Figure 6B 
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The	  presence	  of	  extensive	  pathology	  and	  high	  bacterial	  burden	   indicated	  that	  the	  sensitising	  strain	  
was	  not	  protective	  against	   infection,	  and	   it	  was	  concluded	  that	   the	  original	   isolate	  used	   in	   section	  
3.2	  was	  avirulent	  in	  rabbits.	  
	  
	  
Interestingly,	   the	  M.	  bovis	   ravenel	   isolate	   from	   infected	   rabbits,	   did	   not	   cause	   cavities	   to	   from	   (as	  
identifiable	   at	   necropsy).	   This	  was	   despite	  OT-­‐TST	  positivity,	   extensive	   local	   necrosis	   and	  apparent	  
tissue	  destruction.	  This	  added	   to	   the	  already	   substantial	  evidence	   that	  OT-­‐TST	  positivity	  alone	  was	  
not	  sufficient	  to	  cause	  cavitary	  disease.	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3.4. M.	  tuberculosis	  infection	  leads	  to	  cavity	  formation	  more	  rapidly	  than	  
M.	  bovis	  infection	  
Having	  established	  that	  OT-­‐TST	  positivity	  was	  not	  sufficient	  to	  develop	  rapid	  cavities,	  we	  proceeded	  
to	   investigate	   if	  the	  virulent	  M.	  bovis	   isolate,	  when	  utilised	  for	  sensitisation,	  predisposed	  rabbits	  to	  
cavity	  formation.	  In	  addition	  to	  this,	  infection	  with	  M.	  bovis	  ravenel	  was	  compared	  to	  infection	  with	  
M.	   tb	   H37Rv.	   Skin	   tests	   were	   not	   conducted,	   as	   OT	   had	   been	   removed	   from	   the	   market.	   All	   10	  
rabbits	   received	   5	   injections	   of	   1x107	   of	   heat-­‐killed	   M.	   bovis	   ravenel,	   in	   incomplete	   Freund’s	  
adjuvant.	  After	  25	  days,	  5	  rabbits	  were	   infected	  with	  M.	  bovis	  and	  4	  with	  M.	  tuberculosis	  (1	  animal	  
due	  to	  be	  infected	  with	  M.	  tuberculosis	  died	  during	  anaesthesia	  prior	  to	  infection).	  The	  animals	  were	  
monitored	  by	  CT/18F-­‐FDG	  PET	  imaging.	  
	  
Cavities	   formed	   in	  75%	  of	  animals	   infected	  with	  M.	  tb	  within	  5	  weeks	   (figure	  8A).	  No	  cavities	  were	  
observed	   in	  any	  animals	   infected	  with	  M.	  bovis	  during	   this	   time	  period;	   cavities	  were	   seen	   in	  2	  of	  
these	   5	   animals	   by	   10	  weeks.	   Each	   group	  was	   infected	  with	   equal	   bacterial	   numbers	   (103.95	  M.	   tb	  
H37Rv	  and	  103.96	  M.	  bovis	   ravenel	  CFU).	  The	  time	  to	  cavity	   formation	   in	   the	  M.	  tb	   infected	  animals	  
was	   significantly	   faster	   than	   in	   M.	   bovis	   infected	   rabbits	   (p=0.025	   log-­‐rank	   Mantel-­‐Cox	   test).	  
Interestingly,	  intrapulmonary	  spread	  of	  M.	  bovis	  led	  to	  equal	  distribution	  of	  bacteria	  throughout	  the	  
lung	  by	  10	  weeks,	  even	  though	  cavities	  did	  not	  form	  (figure	  8B).	  





Rudimentary	  quantification	  of	  CT	  changes	   in	  matched	  regions	  of	   interest	   (ROIs)	  demonstrated	  that	  
in	  M.	  tb	  infected	  animals	  the	  consolidated	  regions	  (-­‐50	  to	  +50	  Hounsfield	  units;	  HU)	  did	  not	  change	  
significantly	   during	   infection	   with	  M.	   tb	   (figure	   9A	   and	   C).	   This	   suggested	   that	   there	  was	   relative	  
containment	   of	   disease	   in	   the	   primary	   region	   of	   infection.	   This	   was	   associated	   with	   limited	  
dissemination	  of	  bacteria	  to	  the	  contralateral	   lower	   lobe	  (figure	  8B).	   In	  contrast,	  M.	  bovis	   infection	  
resulted	   in	   continued	   growth	   of	   CT	   observable	   regions	   of	   consolidation.	   This	   increase	   resulted	   in	  
significantly	  greater	  involvement	  of	  the	  lung	  by	  week	  5	  (figure	  9C).	  The	  degree	  of	  18F-­‐FDG	  PET	  uptake	  
increased	   dramatically	   in	   M.	   bovis	   infected	   animals,	   suggesting	   a	   continued,	   and	   substantial,	  
inflammatory	  response,	  whereas	  no	  increase	  was	  seen	  in	  the	  M.	  tb	  infected	  animals.	  
	  
Together,	  these	  observations	  suggest	  that	  the	  degree	  of	  inflammation	  and	  pulmonary	  infiltrate	  does	  
not	  correlate	  with	  cavity	  formation.	  They	  also	  indicate	  that	  M.	  tb	  H37Rv	  does	  not	  drive	  as	  extensive	  
an	  inflammatory	  response	  to	  M.	  bovis	  ravenel,	  even	  thought	  the	  response	  to	  M.	  tb	  infection	  results	  
in	   cavity	   formation.	   Interestingly,	   the	   bacillary	   burden	   at	   the	   site	  of	   the	   infection	  was	   very	   similar	  
between	   species,	   suggesting	   that	   the	   local	   number	   of	   bacteria	   does	   not	   dictate	   the	   degree	   of	  
inflammation	  (as	  measured	  by	  18F-­‐FDG	  PET)	  or	  cavity	  formation.	  Two	  plausible	  explanations	  are:	  (i)	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There	   is	  either	   a	   dampening	  of	   responses	   to	  M.	   tb	   through	   immune	   evasion	  or	   suppression	  or	   (ii)	  
overall,	   but	   not	   local,	   bacterial	   burden	   contribute	   to	   local	   18F-­‐FDG	   uptake.	   Importantly,	   this	   study	  
demonstrated	   that	   cavity	   formation	   	   in	   	   this	   pre-­‐sensitised	  model	   is	   	   not	   simply	   the	   result	   of	   an	  
overwhelming	  inflammatory	  reaction,	  but	  a	  Mycobacterial	  species-­‐specific	  process.	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To	   further	  understand	   the	  cavity	   formation	  and	   identify	  potential	  predictors	  of	  cavity	   formation;	  a	  
long-­‐term	   experiment	   using	   peripheral	   biomarkers,	   TST	   responses	   and	   in	   vivo	   imaging	   was	  
conducted.	   As	   	   OT	  was	   no	   longer	   commercially	   available	  we	   utilised	   	   tuberculin	   	   purified	   protein	  
derivative	  (PPD),	  which	  is	  precipitate	  of	  OT	  (190).	  
84	  |	  Page	  
3.5. PPD-­‐TST	   positivity	   is	   the	   best	   predictor,	   if	   not	   a	   requirement,	   for	  
cavity	  development	  in	  the	  rabbit	  model	  
This	  	  study	  	  was	  	  designed	  	  to	  	  utilise	  	  the	  	  variable	  	  outcomes	  	  experienced	  	  in	  	  this	  	  model	  	  to	  	  better	  
	  
understand	   cavity	   formation	  with	   a	   view	   to	  maximising	   reproducibility	   in	   future	   experiments.	   The	  
primary	   aim	  of	   this	   study	  was	   to	   identify	   peripheral	  markers	   of	   disease	   progression	  by	   intensively	  
monitoring	   the	  early	   stage	  of	   infection	   (figure	  70,	   section	  5.6).	  A	   secondary	   aim	  was	   to	  determine	  
the	   long	   term	   outcome	   of	   disease	   in	   context	   of	   immune	   responsiveness	   to	   the	   mycobacterial	  
antigens	  in	  PPD.	  
	  
10	   animals	   were	   sensitised	   utilising	   the	   same	   regimen	   described	   previously	   (5	   equally	   spaced	  
injections	  of	  107	  	  heat-­‐killed	  CFU	  of	  M.	  bovis	  ravenel),	  and	  were	  tested	  18	  days	   later	  using	  the	  PPD-­‐	  
TST	   (figure	   10).	   5	   out	   of	   the	   remaining	   9	   animals	   developed	   positive	   PPD-­‐TSTs	   (figure	   13A).	   This	  
suggested	   that	   there	   is	   either	   an	   inherent	   variability	   in	   response	   to	   sensitising	   regimens	   or	   in	  
responsiveness	   to	   PPD	   antigens.	   Animals	   were	   infected	   via	   bronchoscope	   with	   103	   CFU	   of	  M.	   tb	  
H37Rv	  (figure	  10).	  The	  infection	  procedure	  failed	  in	  one	  animal	  –	  and	  it	  was	  subsequently	  excluded	  
from	  the	  study	  (the	  skin	  test	  of	  this	  animal	  had	  been	  negative).	  





CT/18F-­‐FDG	  PET	  scanning	  demonstrated	  that	  all	  animals	  had	  more	  extensive	  disease	  at	  day	  14	  than	  
at	   day	   3	   (figure	   11),	   suggesting	   active	   disease	   progression.	   The	   primary	   outcomes	   at	   day	   35	  were	  
divided	  into	  two	  types	  based	  on	  imaging	  findings;	  cavity	  forming	  (5	  animals)	  and	  non-­‐cavity	  forming	  
(4	   animals).	   Two	   cavity	   subtypes	   were	   defined,	   terminal	   cavities	   and	   non-­‐terminal	   cavities	   (figure	  
11).	  A	  terminal	  cavity	  was	  characterised	  by	  being	  large	  enough	  that	  it	  posed	  an	  immediate	  threat	  to	  
the	  well-­‐being	   of	   the	   rabbit,	   in	   	   this	   case	   euthanasia	   	  was	   performed	   	   (3	   animals)	   so	   that	   	   tissue	  
samples	   could	  be	   collected	   for	   further	  analysis	   (figure	   12).	   If	   cavities	  were	   small,	   and	  deemed	  not	  
immediately	  life-­‐threatening	  (2	  animals),	  animal	  health	  was	  monitored	  closely,	  and	  animals	  were	  not	  
euthanised	   (non-­‐terminal	   cavities).	   There	   was	   no	   significant	   difference	   in	   the	   degree	   of	   18F-­‐FDG	  
uptake	  between	  terminal	  and	  non-­‐terminal	  cavities,	  or	  between	  cavity	  and	  non-­‐cavity	  animals	  prior	  
to	  cavity	  formation	  (figure	  13B).	  























PPD-­‐TST	   was	   positive	   prior	   to	   infection	   in	   all	   animals	   which	   later	   formed	   cavities.	   PPD-­‐TST	   was	  
negative	   in	   those	   that	  did	  not	   form	  cavities	   (figure	  13A).	  Cavity	   formation	  was	  not	  associated	  with	  
increased	   inflammation	   as	  measured	   by	   18F-­‐FDG	   PET	   activity	   (figure	   13B).	   This	   suggests	   a	   specific	  
relationship	  between	  PPD	  sensitivity	  and	  cavity	  formation.	  In	  an	  attempt	  to	  understand	  the	  specific	  
immune	   mechanisms	   involved,	   cytokine	   levels	   in	   supernatants	   from	   stimulated	   peripheral	   blood	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mononuclear	   cells	   (PBMCs)	  were	  examined	   (figure	  13C).	   The	  PBMCs	  were	   stimulated	  with	  phorbol	  
12-­‐myristate	   13-­‐acetate	   (PMA)	   or	   a	   combination	   of	   culture	   filtrate	   protein	   10	   (CFP10)	   and	   early	  
secretory	  antigenic	  target	  6	  (ESAT6)	  (both	  antigens	  used	  in	  IGRAs).	  PBMCs	  isolated	  at	  3	  time	  points	  
were	  examined.	  A	   comparison	  was	  made	  at	   each	   time	  point,	   between	  3	   animals	  which	  developed	  
terminal	   cavities,	   and	   3	   which	   had	   negative	   PPD-­‐TSTs	   prior	   to	   infection,	   (and	   did	   not	   develop	  
cavities).	   Interferon	   gamma	   (IFNɣ)	   could	   not	   be	   detected	  using	   available	   reagents,	   however,	   TNFα	  
was	   detected.	   Although	   TNFα	   responses	   were	   not	   significantly	   different	   at	   any	   time	   point	   or	  
between	  outcomes,	   it	  was	  noted	  that	  at	  day	  14	   the	   relative	   response	  of	   the	  cells	   to	  M.	  tb	  specific	  
antigens	  when	  compared	  to	  their	  respective	  PMA	  control	  was	  significantly	  greater	  in	  animals	  which	  
did	   not	   develop	   cavities	   (figure	   13C).	   This	   indicates	   that	   antigen-­‐specific	   TNFα	   responses	   were	  
greater	   in	   rabbits	   which	   did	   not	   form	   cavities.	   Clearly,	   further	   investigation	  would	   be	   required	   to	  
confirm	   the	   precise	   mechanisms	   involved,	   however,	   this	   preliminary	   evidence	   allows	   for	   the	  
speculation	  that	  TNFα	  responsiveness	  may	  unexpectedly	  reduce	  tissue	  destruction.	  
	  
To	  assess	  the	  long	  term	  outcome	  of	  these	  initial	  responses	  to	  M.	  tb	   infection,	  the	  surviving	  animals	  
were	  followed	  for	  a	   further	  105	  days	  and	  subjected	  to	  CT/18F-­‐FDG	  PET	  scanning	  on	  day	  140	  (figure	  
14).	  






PPD-­‐TSTs	  were	   conducted	   at	   day	   133,	   by	  which	   time	   all	   animals	   had	   some	   reaction,	   although	   the	  
response	   in	   rabbit	   H	  was	  minimal,	  with	   some	   reddening	   and	   no	   oedema	   (figure	   14D).	   All	   animals	  
appeared	  to	  be	  resolving	  disease	  by	  subjective	  CT	  and	  PET	  observations	  (figures	  15	  and	  16)	  and	  also	  
by	  quantitative	  18F-­‐FDG	  PET	  uptake	  measurements	  (figure	  14A).	  Overall	  health	  appeared	  to	  improve	  
as	  indicated	  by	  continued	  increases	  in	  weight	  (figure	  14B).	  Animals	  without	  cavities	  appeared	  to	  be	  
devoid	  of	  any	   identifiable	  sign	  of	  disease	  (Figure	  16).	  However,	  animals	  which	  had	  formed	  cavities	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still	   had	   disease	   as	   classified	   by	   both	   subjective	  CT/18F-­‐FDG	   PET	  observations	   (figure	   15).	   SUVmax	  
measurements	  confirmed	  these	  subjective	  observations	  (figure	  14C).	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In	  those	  animals	  with	  chronic	  infection,	  lesions	  remained	  at	  the	  original	  site	  of	  infection	  (figure	  15).	  
Interestingly,	   in	  animal	  E,	  where	   two	  distinct	   lesions	  developed,	  both	  continued	  to	  have	  significant	  
18F-­‐FDG	  uptake,	  even	   though	  only	  one	   lesion	  was	  at	   the	  site	  of	   the	  previous	  cavity.	  This	  allows	   for	  
the	   speculation	   that	   the	   cavity	   itself	   is	   not	   the	   predisposing	   factor	   to	   chronic	   disease.	   Instead	   it	  
suggests	  that	  the	  factors	  that	  predispose	  to	  cavity	  formation	  also	  predispose	  to	  disease	  reactivation.	  
This	   observation	   lends	   credence	   to	   the	   idea	   that	   not	   only	   did	   PPD-­‐TST	   positivity	   indicate	   a	  
predisposition	   to	   cavity	   formation,	   but	   that	   PPD	   responsiveness	   itself	   increases	   the	   risk	  of	   chronic	  
disease	  in	  rabbits.	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Having	   identified	   that	   4	   out	   of	   the	   6	   animals	   appeared	   to	   have	   resolved	   disease	   (figure	   16),	   the	  
question	  remained	  as	   to	  whether	   these	  animals	  had	  cleared	   infection.	   To	  answer	   this,	   the	  animals	  
were	   then	   immunosuppressed	   with	   high-­‐dose	   dexamethasone.	   It	   has	   been	   demonstrated	   by	  
Subbian	   et	   al.	   that	   the	   pulmonary	   bacterial	   burden	   can	   fall	   to	   levels	   that	   are	   not	   detectable	   by	  
culture	  of	  rabbit	  lung,	  and	  that	  subsequent	  immune	  suppression	  for	  can	  increase	  bacterial	  burden	  to	  
an	   extent	   where	   bacillary	   burden	   is	   detectable	   (156).	   After	   4	   weeks	   of	   immune	   suppression	   the	  
animals	   were	   allowed	   4	   weeks	   to	   reconstitute	   their	   immune	   systems.	   After	   this	   recovery	   period	  
disease	  was	  again	  assessed	  by	  CT/18F-­‐FDG	  PET	  (figure	  17)	  and	  the	  whole	  lung	  cultured	  to	  determine	  
bacterial	   burden,	   with	   the	   exception	   of	   a	   small	   region	   (<5%	   of	   total	  mass)	   which	  was	   excised	   for	  
histological	   analysis.	   In	   4	   out	   of	   6	   animals	   substantial	   bacterial	   burdens	   (~104	  CFU	   per	   lobe)	  were	  
found	   (figure	  18A).	  Bacilli	  were	  cultured	   from	  the	  site	  where	  primary	   infection	  took	  place,	  but	  not	  
any	  other	  site	  (except	  in	  rabbit	  H	  which	  had	  approximately	  1x103.4	  CFU	  in	  the	  right	  middle	  lobe	  –	  the	  
lobe	   adjacent	   to	   where	   the	   infection	   took	   place).	   The	   total	   number	   of	   CFU	   was	   similar	   in	   these	  
animals.	   No	  bacilli	   were	   cultured	  	  from	   the	   lungs	   of	  rabbits	   F	  	  and	   K.	  Histopathological	   changes	  
associated	   with	   TB	   were	   identified	   only	   in	   those	   rabbits	   from	   which	   bacteria	   could	   be	   cultured	  
(figure	  19).	   The	   lesions	   in	   rabbits’	   I	   and	  E	  appeared	  more	  necrotic	   than	   those	   seen	   in	  L	   and	  H;	   in-­‐	  
keeping	   with	   the	   hypothesis	   that	   necrosis	   is	   a	   component	   of	   active	   disease;	   whereas	   granuloma	  
formation	   may	   be	   associated	   with	   disease	   containment	   (but	   not	   necessarily	   eradication).	   The	  
threshold	  of	  detection	  for	  bacteria	  was	  estimated	  to	  be	  20	  CFU	  per	  lobe.	  Interestingly,	  only	  2	  of	  the	  
4	  animals	  with	  detectable	  bacterial	  burden	  demonstrated	  disease	  by	  CT/18F-­‐FDG	  PET	  (figure	  18).	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This	  study	  proved	  highly	   informative.	  First,	   it	  demonstrated	  a	  clear	   link	  between	  PPD-­‐TST	  positivity	  
and	   cavity	   formation.	   It	   indicated	   that	   there	   was	   a	   predisposition	   in	   certain	   rabbits	   to	   PPD-­‐TST	  
positivity,	   and	   hence	   a	   predisposition	   to	   developing	   the	   immune	   response	   associated	   with	   cavity	  
formation.	  Second,	  it	  showed	  that	  tissue	  destruction	  in	  the	  form	  of	  cavity	  formation	  was	  associated	  
with	   significantly	   slower	   resolution	   of	   disease,	   and	   relatively	   limited	   TNFα	   responses	   to	   M.	   tb	  
antigens	  early	  during	  infection.	  Whether	  slowed	  resolution	  is	  the	  result	  of	  cavities	  themselves,	  or	  is	  
the	  result	  of	  a	  dysfunctional	  immune	  response	  that	  concurrently	  drives	  cavity	  formation	  is	  presently	  
unknown.	   Finally,	   the	   different	   clinical	   states	  of	   the	   animals	   (i.e.	   increased	   18F-­‐FDG	  uptake	   and	  CT	  
changes	   consistent	   with	   infection),	   despite	   equal	   bacterial	   burden,	   supports	   the	   idea	   that	   active	  
disease	   in	   rabbits,	   like	   humans,	   is	   dependent	   not	   only	   on	   bacterial	   burden	   but	   also	   host-­‐	  
responsiveness.	   Although	   this	   study	   is	   very	   small,	   the	   data	   indicates	   that	   altered	   host-­‐responses,	  
resulting	   from	   previous	   exposure	   to	   mycobacterial	   antigens	   may	   predispose	   M.	   tb	   infected	  
individuals	  to	  active	  disease.	  
	  
Because	  PPD-­‐TST	   reactivity	  predisposed	  strongly	   to	   cavity	   formation	   the	   sensitisation	   regimen	  was	  
altered	  to	  enhance	  PPD-­‐TST	  responses.	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3.6. PPD-­‐TST	  positivity	  is	  induced	  in	  rabbits	  with	  high-­‐dose	  sensitization	  
and	   reliably	   leads	   to	   cavity	   formation:	   A	   70	   day	  model	   of	  M.	   tuberculosis	  
cavity	  development	  
To	  further	  examine	  the	  relationship	  between	  PPD-­‐TST	  positivity	  and	  cavity	  formation	  in	  rabbits,	  an	  
	  
attempt	  was	  made	  to	   induce	  very	  high	   levels	  of	   sensitivity	   to	  mycobacterial	  antigens	   by	   increasing	  






Unsurprisingly,	   all	   rabbits	   in	   this	   cohort	   became	   PPD-­‐TST	   positive.	   The	   degree	   of	   response	   was	  
variable,	   but	   universally	   some	   degree	   of	   oedema	   developed	   by	   48	   hours	   post	   PPD-­‐TST	  
administration	  (table	  3,	  figure	  21).	  103	  CFU	  of	  M.	  tb	  H37Rv	  were	  delivered	  via	  bronchoscope	  into	  the	  
right	   or	   left	   lower	   lobe	   of	   the	   lung	   (figure	   23)	   and	   the	   animals	   randomly	   assigned	   to	   necropsy	   at	  
either	  5	  or	  7	  weeks	  post-­‐infection	  (figure	  20).	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All	   animals	   developed	   extensive	   cavities	   within	   28	   days;	   as	   identified	   by	   breath-­‐hold	   CT	   imaging	  
(figure	  22),	  which	  remained	   identifiable	  at	  necropsy	   (figure	  23).	   This	   technology	   is	  described	   in	  the	  
methods	  (section	  2.1.2.5.)	  and	  in	  section	  4.6.	  
	  
This	  study	  showed	  that	  cavities	  occurred	  in	  all	  rabbits	  with	  PPD-­‐TST	  positive	  reactions	  and	  supports	  
the	   hypothesis	   that	   PPD-­‐TST	   positivity	   is	   essential	   in	   rabbits	   for	   the	   generation	   of	   cavities.	   It	   also	  
demonstrates	  for	  the	  first	  time	  a	  model	  of	  cavity	  development	  in	  which	  trials	  of	  therapeutics	  could	  
be	   assessed	   for	   their	   effectiveness	   in	   cavitary	   disease.	   The	   tissue	   destructive	   phenotype,	  which	   is	  
the	   most	   common	   gross	   pathology	   observable	   in	   active	   TB,	   has	   never	   been	   directly	   included	   in	  
preclinical	  trials	  of	  drugs	  or	  vaccines,	  despite	  being	  the	  site	  where	  the	  highest	  bacterial	  burdens	  are	  
located	  during	  active	  TB.	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3.7. Characterisation	   of	   a	   70	   day	   model	   of	   M.	   tuberculosis	   cavity	  
development	   by	   in	   vivo	   imaging,	   gross	   pathological,	   histological	   and	  
bacteriologic	  methods	  
As	  a	   result	  of	   the	   study	  above	  a	   significant	  number	  of	   closely	   related	  matched	  samples	   (12)	  were	  
	  
generated.	   It	  was	  therefore	  possible	   to	   investigate	   the	  pathogenesis	  of	  M.	  tb	   infection	   in	  the	  PPD-­‐	  
TST	  positive	  animal.	   For	   the	   first	   time,	  with	  a	  high	  degree	  of	  accuracy,	   the	   structural	   changes	   that	  
occur	  during	  cavity	  formation	  in	  this	  model	  were	  monitored.	  This	  was	  achieved	  using	  a	  custom-­‐built	  
ventilator,	   which	   allowed	   for	   BSL-­‐3	   containment	   combined	   with	   pulmonary	   pressure	   control	   (see	  
section	  4.6	  for	  further	  details).	  
	  
3.7.1. In	  vivo	  breath-­‐hold	  CT	  findings	  
Cavity	  formation	  is	  an	  extremely	  rapid	  process.	  In	  this	  model,	  infection	  is	  followed	  by	  an	  infiltrative	  
process.	   There	   is	   a	   reduction	   in	   infiltrates	   over	   the	   first	   14	   days	   (as	   assessed	   by	   non	   breath-­‐hold	  
images),	  but	  increased	  localised	  density	  as	  a	  more	  clearly	  defined	  lesion	  becomes	  apparent.	  The	  next	  
observation	   is	   a	  progressive	   increase	   in	   this	  density,	  which	  occasionally	   increases	   in	  volume.	  Next,	  
this	   tissue	   erodes;	   often	   nearly	   the	   entire	   apparently	   consolidated	   region	   is	   lost,	   leaving	   a	   dense	  
surrounding	  ring.	  Finally	  the	  cavity	  appears	  to	  reduce	  in	  size,	  accompanied	  in	  surrounding	  regions	  by	  
increases	  in	  consolidation	  and	  infiltrate	  (figure	  24).	  




Figure 24. Example of cavity formation and progression: (A-G) False coloured 30 reconstructed CT scans at 
1OcmH O (except* taken without anaesthesia) demonstrate the dynamic cavity forming process (dorsal views are 
shown). Initially the infiltrated region is small. Between day 7 and day 14 infiltrates become more localised. At day 21, a 
large highly dense infiltrate is seen. Between day 21 and 28 the entirety of this region is replaced by a cavity, which is 
surrounded by a highly dense region. The cavity is enlarged at day 35. By day 49 the size of the lesion has drastically 
been reduced and infiltrates are seen in the adjacent region. (H) Posterior view of resected lungs from this animal. (I) 
Cut section through cavity region (dotted line in H) demonstrating cavity and surrounding necrosis. Healthy tissue is 
relatively under-represented in such images,as it collapses after the lung is removed. 
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Because	  scans	  from	  day	  21	  through	  49	  were	  conducted	  utilising	  the	  breath-­‐hold	  technique	  (section	  
4.6),	   more	   subtle	   observations	   of	   the	   pathology	   surrounding	   cavity	   formation	   during	   this	   period	  
were	  recorded.	  20cmH2O	  of	  pressure	  allow	  for	  the	  identification	  of	  regions	  of	  density	  as	  small	  as	  1-­‐	  
2mm	   in	   diameter.	   This	   was	   of	   particular	   interest,	   as	   increased	   infiltrates	   appear	   after	   cavity	  
formation	   in	   distal	   regions	   of	   the	   lung	   (Figure	   25).	   This	   suggested	   that	   cavity	   formation	   was	  
associated	  with	  intra-­‐pulmonary	  dissemination.	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The	   changes	   in	   lung	   parenchyma	   were	   quantified	   over	   time	   (figure	   27).	   The	   amount	   of	   tissue	  
recruited	   was	   calculated	   by	   comparing	   the	   density	   measurements	   at	   two	   separate	   pressures	   at	  
which	  breath-­‐hold	  manouvers	  were	  performed	  (191).	  By	  monitoring	  tissue	  density	  (as	  measured	  by	  
hounsfield	  units;	  HU)	  and	  evaluating	   tissue	  mass,	  as	  opposed	   to	  volume,	  an	  estimate	  of	   functional	  
tissue	  could	  be	  established	  (section	  4.8).	  This	  analysis	  demonstrated	  a	  decrease	  in	  functional	  tissue	  
following	  infection,	  but	  also	  that	  functional	  tissue	  was	  lost	  between	  day	  21	  and	  day	  35,	  indicating	  a	  
measurable	  progression	  of	  disease.	  Cavities	  can	  be	  considered	  a	  space	  occupying	   lesion	  where	  gas	  
exchange	   is	   not	   occuring,	   changes	   in	   the	   size	   of	   the	   cavity	   most	   likely	   reflect	   the	   health	   of	  
surrounding	  tissue,	  and	  the	  ability	  to	  preferentially	  inflate	  these	  regions	  in	  comparison	  to	  the	  cavity	  
(figure	  27).	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As	   expected,	   progressive	   infection	   is	   associated	   with	   progressive	   change	   in	   quantifiable	   CT	  
observations.	   Importantly,	   these	   measurements	   may	   be	   useful	   for	   investigating	   changes	   after	  
administration	  of	  therapeutic	  interventions.	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3.7.2. Gross	  pathology	  correlates	  with	  in	  vivo	  imaging	  and	  is	  associated	  with	  bacterial	  
burden	  
Breath-­‐hold	  CT	  observations	  correlate	  very	  closely	  with	  gross	  pathology	  observations,	  and	  also	  with	  
	  
bacterial	  burden	  (figure	  29).	   Infiltrative	  pathologies	  are	  seen	   in	  both	  the	  scans	  and	  photographs	  at	  
the	   experimental	   endpoints.	   More	   than	   99%	   of	   the	   bacterial	   burden	   is	   located	   within	   the	   lobe	  
containing	   the	   cavity	   (figure	   28	   and	   29).	   Interestingly,	   bacterial	   dissemination	   to	   the	   spleen	  were	  
observed	  in	  5/6	  animals	  at	  day	  35	  and	  only	  1	  animal	  sacrificed	  at	  day	  42.	  This	  fits	  with	  the	  proposed	  
concept	   of	   early	   bacterial	   dissemination	   put	   forward	   by	   Volkmann	   et	   al.	   (111).	   The	   reason	   for	  
clearance	  for	  these	  early	  disseminated	  organisms	  by	  week	  7	  is	  unclear.	  This	  may	  indicate	  a	  change	  in	  
immune	   status	   from	   a	   situation	   in	   which	   bacterial	   dissemination	   to	   the	   spleen	   can	   occur,	   to	   a	  
situation	  where	  this	  dissemination	  is	  prevented.	  There	  was	  no	  concordance	  between	  pulmonary	  and	  
splenic	  bacterial	  burden.	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Biopsies	   from	   the	   affected	   lung	   lobes	   were	   taken.	   These	   were	   used	   to	   assess	   the	   bacterial	  
distribution	   within	   the	   affected	   lobe.	   This	   demonstrated	   that	   the	   vast	   majority	   of	   the	   bacterial	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burden	  	   in	  	   the	  	   affected	  	   lobe	  	  was	  	   present	  	   at	  	   the	  	   cavity	  	   surface	  	   and	  	   not	  	   in	  	   the	  	   surrounding	  
inflammatory	  tissue	  (figure	  30).	  
	  
3.7.4. Histopathological	  	  	  analysis	  	  	  demonstrated	  	  	  human-­‐like	  	  	  disease,	  	  	  including	  	  	  high	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Specimens	   taken	   from	   the	   regions	   of	   interest	   demonstrated	   a	   full	   complement	   of	   human-­‐like	  
pathologies	  (figure	  31	  and	  32).	  
	  
3.7.5. Summary	  
The	  disease	  processes	  surrounding	  cavity	  formation	  in	  this	  model	  are	  similar	  in	  a	  number	  of	  ways	  to	  
human	   TB.	   First,	   there	   is	   cavity	   development	   –	   a	   phenotype	   not	   reliably	   produced	   in	   any	   other	  
model	   but	   present	   in	   the	   majority	   of	   active	   TB	   cases.	   The	   pathology	   seems	   to	   be	   similar	   to	   the	  
descriptions	   of	   cavity	   development	   by	   RL	   Hunter	   (73);	   there	   are	   changes	   in	   the	   proximal	   airway	  
(figure	   25	   and	   26)	   and	   the	   cavity	   arises	   from	   an	   infiltrative	   lesion,	   with	   subsequent	   granuloma	  
formation	  in	  adjacent	  tissues.	  There	  are	  also	  infiltrative	  changes	  subsequent	  to	  cavity	  development	  –	  
indicating	   a	   dissemination	   event,	   or	   continuous	   dissemination,	   corresponding	   to	   cavity	   formation	  
(figure	  25	  and	  26).	  As	  in	  humans,	  there	  are	  extremely	  high	  bacterial	  burdens	  within	  the	  cavity	  itself,	  
and	  apparent	   containment	  of	  disease	   in	   the	   rest	  of	   the	  animal	   (figure	  29,	  30	  and	  32).	  None	  of	  the	  
animals	  lost	  weight	  during	  the	  49	  day	  period,	  and	  the	  animals	  appeared	  grossly	  healthy;	  suggesting	  
that	  this	  extensive	  pathology	  is	  not	  highly	  symptomatic	  (in	  this	  early	  stage)	  –	  however,	  longer	  term	  
studies	  would	  be	   required	   to	   see	   if	   disease	   progressed	  or	   resolved	   in	   these	   animals.	  Whether	   the	  
model	   could	   be	   extended	   to	   explore	   chronic	   disease	  depends	   on	  whether	   these	   large	   cavities	   can	  
sustain	  infection	  in	  a	  host	  which	  is	  globally	  resistant	  to	  infection.	  
	  
Although	  the	  model	  is	  highly	  artificial,	  it	   is	  as	  a	  result	  highly	  reproducible.	  The	  immense	  power	  that	  
in	   vivo	   imaging	   adds	   in	   the	   form	  of	   virtual	   necropsy	   is	   only	   briefly	   touched	  on	   here,	   although	   the	  
correlations	  are	  remarkable.	  It	  is	  clear	  from	  these	  studies	  that	  this	  technology	  means	  that	  relatively	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small	  numbers	  of	   animals	   could	  be	  used	   to	   examine	  how	   therapies	   can	  affect	   cavity	  development	  
and	   associated	   disease	   progression,	   and	   also	   how	   current	   and	   novel	   therapies	   act	   in	   this	  
environment	  and	  how	  this	  action	  is	  involved	  in	  the	  development	  of	  resistance.	  
	  
This	  model	  uniquely	  recapitulates	  the	  most	  common	  form	  of	  active	  tuberculosis	  which	  is	  disease	  in	  
the	  immunocompetent	  individual	  with	  global	  immunity	  to	  M.	  tb	  but	  local	  immune	  failure.	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4. Novel	   Technologies	   for	   Assessing	  Pathology	  in	  Rabbits	  
	  
There	  are	  a	  number	  of	  challenges	  involved	  in	  working	  with	  rabbits	  (170).	  Not	  least	  amongst	  which	  is	  
the	  expense	  and	   technical	  expertise	   required	  to	  work	   in	   this	  model.	  Whilst	   the	  methods	  described	  
below	  are	  largely	  based	  on	  methods	  that	  previously	  existed,	  each	  required	  special	  adaptation	  for	  use	  
under	  BSL-­‐3	  conditions	  and	  some	  are	  entirely	  conceptually	  novel	  within	  the	  field.	  This	  chapter	  aims	  
to	  provide	   the	   reader	  with	   insight	   into	  how	  the	  methods	  used	   in	  section	  3	  and	  5	  were	  developed,	  






The	  rabbit	  has	   fallen	  from	  favour	   in	  tuberculosis	   research	  (figure	  33),	  despite	   its	  obvious	  relevance	  
to	  human	  disease	   (74,	  75,	  155).	  The	   reasons	   for	   this	  become	  clear	  when	  you	  consider	   the	  scale	  of	  
performing	  a	  drug	  study	  in	  these	  animals:	  Prior	  to	  beginning	  this	  thesis,	  a	  study	  proposed	  at	  looking	  
at	   an	   anti-­‐cavity	   therapy	   would	   require	   a	   model	   in	   which	   100	   days	   of	   infection,	   39	   days	   of	  
sensitisation	  and	  highly	  variable	  outcomes	  must	  be	  accommodated	  for.	   If	  3	  time-­‐points	  were	  used,	  
and	  6	  animals	  per	  treatment	  are	  required,	  36	  animals	  would	  be	  needed.	  Each	  animal	  weighs	  3.5	  to	  
5kg	  and	  this	  means	  that	  a	  study	  requiring	  10mg/kg	  of	  drug	  would	  require	  at	  a	  minimum	  of	  72g	  of	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drug	   for	   just	   these	  18	  data	  points.	  An	  equivalent	   sized	   study	   in	  mice	  would	  require	  only	  360mg	  of	  
drug	   –	   i.e.	   the	   same	   volume	  of	   drug	  would	   allow	   for	   200	   times	  more	   data	   points.	   This	   is	  without	  
including	   the	   tribulations	   of	   animal	   housing,	   reagent	   and	   tissue	   storage	   and	   the	   scheduling	   	   of	  
studies.	   Rabbit	   studies	   are	   both	   logistically	   difficult	   to	   manage,	   but	   also	   costly	   and	   technically	  
challenging.	  With	   no	   promise	   of	   positive	   results,	   they	   are	   also	   a	   daunting	   investment	   of	   time	   and	  
money	  for	  academics.	  
	  
This	   chapter	   outlines	   how	   the	   use	   of	   simple	   technologies,	   applied	   to	   the	  model	   described	   in	   the	  
previous	  chapter,	  can	  be	  used	  to	   simplify	  rabbit	   research,	  putting	   it	   in	  reach	  of	  more	   investigators.	  
This	   is	   achieved	   by	   describing	   methods	   which	   can	   be	   used	   with	   limited	   technical	   expertise	   and	  
commonly	   available	   resources.	   The	   biosafety	   element	   of	   working	   with	   pathogenic	   Mycobacteria	  
species	   is	   foremost	   in	   the	   design	   of	   the	   strategies	   developed.	   Some	   investigations	   into	   the	  
infectiousness	   of	   rabbits	   were	   performed,	   and	   the	   data	   presented	   here	   is	   indicative	   that	   these	  
animals	   are	  minimally	   infective,	   however,	   it	  must	   be	   noted	   that	   the	   studies	   were	   performed	   in	   a	  
manner	  aiming	  to	  quantify	  whether	  culturable	  bacilli	  were	  exhaled	  under	  normal	  conditions,	  and	  do	  
not	  exclude	  the	  potential	  risk	  of	  infection.	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4.1. Delivering	  a	  reproducible	  infectious	  inoculum:	  
Although	  simple,	  aerosol	   infection	  techniques	  are	  not	  reproducible.	  For	  each	  aerosolised	   infectious	  
delivery	   in	  mice,	  5	  mice	  are	  required	  to	  evaluate	  what	   the	   infectious	  bacterial	  burden	   in	  any	  given	  
experiment	  is.	  This	  is	  because	  machines	  such	  as	  the	  commonly	  used	  glas-­‐col	  nebuliser,	  are	  variable	  
in	  their	  ability	  to	  aerosolise	  and	  distribute	  bacteria.	  
	  
Following	  from	  Nedeltchev	  et	  al.	  (168)	  we	  utilised	  a	  bronchoscopic	  infection	  technique	  (also	  used	  by	  
Lewinsohn	   et	   al.	   for	   infection	   of	   cynomologus	   macaques(192)).	   A	   known	   volume	   of	   bacteria	   are	  
delivered	  under	   direct	   bronchoscopic	   guidance	   to	   the	   lower	   lobe	  of	   the	   lung.	   To	   confirm	   that	   this	  
method	  is	  a	  reliable,	  a	  study	  was	  conducted	  to	  evaluate	  both	  the	  volume	  of	   liquid	  delivered	  in	  this	  
manner	  as	  well	  as	  the	  bacterial	  number	  (figure	  34).	  This	  study	  established	  that	  bacterial	  delivery	  via	  
simple	  catheters	  made	  from	  luer-­‐stubs	  and	  TE-­‐50	  tubing	  could	  be	  used	  to	  deliver	  measured	  amounts	  
of	  bacteria.	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4.2. Arterial	  line	  for	  blood	  sampling	  
Blood	   is	   the	  most	   readily	   available	   fluid	   in	   clinical	   settings,	   it	   is	   routinely	   taken	   for	   diagnosis	   and	  
monitoring	   of	   a	   huge	   number	   of	   conditions	   and	   changes	   in	   composition	   	   indicate	   the	   immune,	  
chemical	  and	  physiological	  status	  of	  the	  subject.	   In	  rabbits,	  blood	  is	  taken	  from	  either	  the	  marginal	  
ear	   vein	   or	   central	   ear	   artery.	   Many	   researchers	   utilise	   blood	   withdrawal	   techniques	   with	   no	  
anaesthesia.	   In	   our	   experience,	   this	   is	   highly	   stressful	   and	   painful	   to	  	  the	   animal	   and	   results	   in	  
unknown	   effects	   on	   the	   animals’	   physiology.	   Complete	   anaesthesia	   easily	   	   facilitates	   blood	  
withdrawal	  and	  volumes	  of	  up	  to	  20-­‐30mls.	  This	  volume	  is	  appropriate	  for	  complex	  analysis	  such	  as	  
flow	  cytometry.	  Anaesthesia	  is	  an	  appropriate	  solution	  if	  the	  animal	  is	  sedated	  for	  other	  reasons	  (for	  
example	   imaging	   procedures);	   however,	   wherever	   possible	   it	   is	   preferable	   to	   avoid	   the	   potential	  
complications	   of	   anaesthesia	   or	   the	   confounding	   effects	   of	   anaesthetic	   drugs.	   Additionally,	   during	  
pharmacokinetic	  studies	  repeated	  samples	  must	  be	  taken,	  and	  so	  a	  method	  for	  repeated	  withdrawl	  
without	   repeated	   needle	   sticks	  was	   developed.	   This	  method	   allows	   for	   an	   indwelling	   ear	   catheter	  
which	  we	  have	  maintained	  for	  72	  hours	  with	  no	  significant	  signs	  of	  ear	  damage	  or	  inflammation.	  
	  
The	  animal	   is	  anesthetised	  using	  ketamine,	  xylazine	  and	  acepromazine	  (as	  per	  methods).	  The	  ear	   is	  
shaved	   and	   sterilised.	   Using	   a	   standard	   22	   gauge	   IV	   catheter,	   the	   central	   auricular	   artery	   is	  
canulated.	  At	  this	  time	  blood	  can	  be	  retrieved.	  The	  hub	  of	  the	  catheter	  can	  then	  be	  capped	  using	  a	  
Clade	  device.	  Blood	  can	  be	  drawn	  through	  the	  device,	  and	  if	  warranted	  a	  heparin	  lock	  can	  be	  placed.	  
For	   prolonged	   placement,	   heparinisation	   is	   suggested	   –	   this	   is	   challenging	   as	   rabbits	   metabolise	  
heparin	   rapidly	   (193).	  The	  catheter	   can	  be	   secured	   in	  place	   and	  kept	   from	  the	  conscious	   rabbit	  by	  
securing	  the	  ears	  to	  each	  other.	  When	  blood	  withdrawal	  is	  required	  the	  first	  1ml	  can	  be	  drawn	  and	  
discarded	  to	  remove	  any	  residual	  heparin,	  and	  a	  second	  draw	  is	  then	  made	  of	  the	  required	  volume	  
whilst	  the	  animal	   is	   lightly	  restrained.	  Covering	  the	  eyes	  of	  the	  animal	  can	  facilitate	  placement	   in	  a	  
non-­‐anaesthetised	  animal.	  
130	  |	  Page	  
	  
 
131	  |	  Page	  
4.3. Accurate	  drug	  delivery	  in	  rabbits	  
Delivering	  accurate	  amounts	  of	  drug	  to	  large	  animals	  is	  not	  always	  a	  straight-­‐forward	  task.	  A	  number	  
of	  studies	  have	  used	  oral	  gavage.	  However,	   the	  physical	  strength	  of	   rabbits	  means	   they	  may	   injure	  
themselves	  or	   the	   investigator	  during	   such	  procedures	   (194).	   Stress	  may	  have	   confounding	  effects	  
during	   investigations	  of	   inflammation	  as	   rabbits	  have	  strong	  adrenocorticoid	   responses	   (195,	   196).	  
This	  can	  be	  controlled	  for	  by	  sham	  treating	  control	  animals,	  but	  may	  add	  a	  complicated	  variable	  to	  
experiments.	  Syringe	  feeding	  has	  been	  also	  been	  used	  to	  treat	  animals,	  but	  is	  only	  appropriate	  when	  
unpleasant	  tasting	  drugs	  can	  be	  masked	  by	  fruit	  flavourings	  or	  sweeteners.	  Accurate	  delivery	  of	  drug	  
is	   challenging	  when	   syringe	   feeding,	   as	   there	   is	   no	   guarantee	   that	   the	   entire	   amount	   of	   drug	  will	  
enter	   the	   oral	   cavity,	   or	   that	   the	   animal	   will	   swallow	   it.	   A	   further	   problem	   with	   oral	   drug	  
administration	   is	   that	   antibiotics	   are	   reported	   to	   have	   dramatic	   effects	   on	   the	   gut	   flora,	   and	   as	   a	  
result,	  bacterial	  overgrowth	  syndromes	  are	  common	  in	  lagomorphs	  (197).	  
	  
The	  following	  strategies	  were	  developed:	  
	  
	  
i) Nasogastric	  tube	  placement;	  for	  accurate	  delivery	  of	  oral	  drug	  doses	  (figure	  36)	  
	  
ii) Peripherally	  Inserted	  Central	  Catheters	  (PICC);	  for	  long-­‐term	  IV	  drug	  delivery	  (figure	  37)	  





Two	   animals	   underwent	   nasogastric	   (NG)	   tube	   placement,	   as	   described	   in	   (198),	   except	   that	  
placement	  was	  performed	  under	  anaesthesia.	  The	  animals	  were	  monitored	  for	  48-­‐72	  hours.	  NG	  tube	  
placement	   appeared	   highly	   distressing	   for	   the	   animals;	   they	   became	   lethargic,	   hunched	   and	  
ungroomed.	  Faecal	  output	  was	  reduced,	  as	  was	  dietary	  intake.	  1	  tube	  blocked	  after	  48	  hours	  despite	  
regular	   flushing	  with	  water.	  The	  use	  of	   smaller	   tubes	  may	   reduce	   the	  stress	  of	  placement,	  but	  are	  
more	   liable	   to	   blockage.	   This	  method	  may	   be	   suitable	   for	   accurate	   oral	   drug	   delivery	   in	   the	   short	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term	   (24-­‐48hours),	   but	   longer	   term	   placement	   is	   inappropriate.	   This	   method	   may	   allow	   for	  
accurately	   timed	   and	   volumetrically	   reproducible	   oral	   dosing	   for	  PK	   studies.	   Some	   articles	   suggest	  
repeated	   gavage	   using	   this	   technique	   is	   feasible,	   however,	   our	   experience	   calls	   into	   question	   the	  
broad	  application	  of	  this	  technique	  (194,	  198).	  
	  
Since	  IV	  delivery	  is	  the	  most	  reliable	  manner	  in	  which	  to	  deliver	  accurate	  levels	  of	  drug,	  studies	  were	  
conducted	  to	  assess	  the	  ease	  of	  placement	  of	  peripherally	  inserted	  central	  lines	  –	  a	  technique	  which	  
has	  been	  shown	  to	  be	  feasible	  but	  costly	  (199).	  Utilising	  commercially	  available	  fine	  tubing,	  a	  simple	  
catheter	   stud,	   and	   a	   through	   needle	   delivery	   system	   we	   generated	   a	   simple,	   safe	   and	   clean	  
technique	  for	  placement	  of	  central	  line	  catheters	  in	  rabbits	  (figure	  37).	  





2	   rabbits	   underwent	   PICC	   line	   placement	   as	   described	   above,	   alongside	   simultaneous	   arterial	  
catheterisation.	   The	   PICC	   lines	   remained	   patent	   for	   72	   hours	   and	   allowed	   for	   hazard	   free	  
administration	  of	  heparinised	  saline.	  We	  also	  demonstrated	  that	   if	  necessary	  blood	  could	  be	  drawn	  
from	  the	  PICC	  line	  –	  however	  the	  fine	  gauge	  of	  the	  line	  is	  liable	  to	  cause	  haemolysis,	  and	  so	  this	  may	  
not	  be	  a	  suitable	  method	  for	  blood	  sampling	  in	  some	  conditions.	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4.4. Urine	  withdrawal	  techniques	  
Urine	  is	  perhaps	  the	  most	  easily	  available	  sample	  in	  the	  clinical	  setting,	  and	  so	  has	  great	  potential	  as	  
a	  matrix	  from	  which	  to	  extract	  biomarkers.	  It	  is	  also	  a	  convenient	  sample	  to	  handle,	  although	  its	  high	  
salt	  content	  often	  means	  sample	  processing	  is	  required	  prior	  to	  assessment.	  
	  
Using	   a	   technique	   adopted	   from	   (170)	   manual	   urine	   can	   be	   reliably	   achieved.	   An	   anaesthetised	  
rabbit	   is	   placed	   in	   dorsal	   recumbence,	   the	   bladder	   is	   manually	   palpated	   by	   identifying	   the	   pubic	  
synthesis	   and	  moving	   in	   a	   superior	   direction	   (usually	   about	   5-­‐10cm).	   By	   applying	   a	   firm	   constant	  
pressure	   from	  the	  superior	  aspect	  of	   the	  bladder	   in	  the	  direction	  of	  sacrum,	  urine	  can	  be	  expelled	  
and	   collected	   in	   a	   50ml	   conical	   tube	   (figure	   38).	   On	   average	   between	   1-­‐5mls	   can	   be	   consistently	  
collected,	  and	  often	  as	  much	  as	  20mls	  is	  easily	  available.	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Alternatively	   catheterisation	   allows	   for	   cleaner	   sample	   collection,	   and	   more	   reliable	   delivery,	   but	  
requires	   more	   equipment	   and	   time,	   and	   runs	   the	   risk	   of	   traumatic	   injury	   to	   the	   urethra	   (170).	  
Metabolic	  cage	  collection	  protocols	  are	  also	  available	  (170),	  but	  were	  not	  necessary	  during	  the	  trials	  
conducted.	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4.5. Computed	  tomography	  (CT)	  of	  rabbits	  
CT	   scanning	   can	   provide	   high	   resolution	   structural	   imaging	   of	   rabbit	   anatomy.	   The	   information	  
collected	  during	  CT	  scans	  of	  rabbits	  has	  primarily	  been	  used	  to	  correlate	  PET	  readings	  with	  structural	  
information	   (such	   as	   organ	  position	   and	  bone	   structure)	   (165).	   In	   this	   context,	   reproducibility	   and	  
detailed	  structural	  information	  are	  not	  important.	  
	  
Since	   the	   pathologies	   of	   interest	   in	   TB	   are	   often	   identifiable	   on	   CT	   scans	   –	   use	   of	   CT	   to	   assess	  
pathology	   in	   a	   longitudinal	  manner	  was	   assessed.	   A	  number	   of	   challenges	   had	   to	   be	   overcome	   in	  
order	  to	  achieve	  accurate,	  reproducible	  and	  comparable	  scans:	  
	  
i) Breathing	  artefact:	  CT	  scans	  utilising	  the	  clinical	  scanners	  commonly	  available	  in	  hospital	  
settings	  take	  anywhere	  from	  4-­‐20	  seconds	  to	  cover	  a	  20cm	  window	  (approximately	  the	  
size	  of	  the	  inflated	  rabbit	  lung);	  during	  this	  time	  both	  cardiac	  and	  respiratory	  motion	  can	  
cause	  movement	   artefacts	  within	   the	   images.	   Rabbits	   average	   between	  30-­‐60	   breaths	  
per	  minute,	  and	  so	  there	  is	  nearly	  always	  motion	  present	  within	  scans.	  
ii) Lack	   of	   normalisation:	   Even	   if	   the	   motion	   artefact	   were	   prevented,	   a	   problem	   in	  
comparing	   the	   scan	   from	  one	   time	   point	   to	   the	   next	   arises	   because	   the	   period	   of	   the	  
breathing	  cycle	  during	  which	  the	  scan	  is	  taken	  may	  be	  different.	  
iii) Scanning	  of	  BSL-­‐3	   pathogen	   infected	   animals:	   The	  majority	  of	   researchers	  do	  not	  have	  
access	   to	   expensive	   scanning	   machinery	   in	   dedicated	   BSL-­‐3	   facilities;	   however,	   it	   is	  
becoming	  increasingly	  common	  to	  have	  scanning	  facilities	  in	  adjoining	  BSL-­‐2	  facilities	  or	  
machines	   that	   are	   accessible	   in	   clinical	   settings.	   In	   order	   to	   be	   financially	   viable,	   the	  
Center	  for	  Inflammation	  and	  Infection	  Imaging	  Research	  (CI3R)	  at	  Johns	  Hopkins	  is	  a	  fine	  
example	   of	   how	   temporary	   biosafety	   enclosures	   can	   be	   utilised	   to	   contain	   BSL-­‐3	  
pathogen	  infected	  animals	  safely	  in	  a	  BSL-­‐2	  laboratory	  (134,	  135).	  However,	  this	  requires	  
that	  all	  systems	  are	  fully	  sealed	  with	  the	  exception	  of	  HEPA	  filtered	  gas	  exchange.	  
iv) Pulmonary	   collapse	   during	   anaesthesia.	   Respiratory	   support	   is	   not	   commonly	   used	   in	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BSL-­‐3	   laboratory	   rabbit	   anaesthesia,	   due	   to	   the	   challenges	   of	   intubating	   and	   operating	  
ventilator	   support	   safely	   in	   the	   BSL-­‐3	   environment.	   As	   a	   result,	   raised	   peak	   end	  
expiratory	   pressures	   (PEEP)	   are	   not	   used.	   Since	   muscular	   tone	   is	   decreased	   during	  
anaesthesia	   lung	   collapse	   occurs	   and	   can	   appear	   as	   consolidation	   (as	   observed	   during	  
this	  study).	  
	  
There	   are	   a	  number	  of	  options	   for	  dealing	  with	   respiratory	  motion	  during	  CT	  acquisition.	  Dynamic	  
scanning	  can	  be	  used	  to	  acquire	  a	  series	  of	  low	  dose	  CT	  images	  over	  time,	  and	  facilitate	  observations	  
of	  motion,	  or	  construct	  visual	  averages	  of	  moving	  objects.	  However,	  this	  requires	  newer	  generations	  
of	   scanners	   –	  which	  were	  not	   available	  at	   the	   facility	   in	  which	   this	   research	   took	  place	   (or	   indeed	  
widely	   available).	   Another	   option	   is	   a	   respiratory	   gating	   strategy,	   whereby	   scans	   are	   designed	   to	  
synchronise	  with	  breathing	  cycles.	  Respiratory	  monitoring	  equipment	  and	  an	  interface	  between	  the	  
scanner	  and	  monitoring	  equipment	  is	  required	  for	  this	  to	  occur	  (200).	  Again,	  such	  facilities	  were	  not	  
available.	  Another	  option	  would	  be	  to	  use	  a	  ventilator	  system	  that	  minimised	  lung	  movement	  during	  
scan	   acquisition,	   such	   as	   high-­‐frequency	   ventilation,	   however,	   these	   systems	   would	   require	  
development	  of	  novel	  protocols	  as	  well	  as	  purchase	  and	  service	  expenses.	  The	  use	  of	  paralytics	  and	  
full	  ventilation	  could	  also	  be	  used,	  but	  is	  extremely	  difficult	  to	  justify	  in	  animal	  research,	  as	  paralytics	  
may	  prevent	   the	   animal	   from	   responding	   if	   anaesthesia	   is	   insufficient	   –	   a	   situation	   tantamount	   to	  
performing	   an	   intervention	   in	   fully	   conscious	   animal.	   Instead,	   the	   natural	   tolerance	   of	   rabbits	   for	  
high	   carbon	   dioxide	   (201)	   was	   used	   to	   justify	   developing	   modified	   technique,	   previously	   used	   in	  
infants	  (202)	  to	  breath-­‐hold	  animals	  during	  scanning	  (section	  4.5.1.).	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4.5.1. Development	  of	  a	  breath-­‐hold	  scanning	  technique	  for	  use	  in	  BSL-­‐3	  pathogen	  
infected	  rabbits	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A	  number	  of	   ventilators	  which	  utilise	   either	  pressure	  or	   volume	  based	  breath-­‐hold	   techniques	   are	  
available.	   Two	   main	   systems,	   the	   Harvard	   Apparatus	   ‘Inspira	   Advanced	   Safety	   Single	   Animal	  
Pressure/Volume	   Controlled	   Ventilator	   (ASPV-­‐IH)’	   and	   the	   SciReq	   ‘Flexivent’,	   are	   both	   suitable	   for	  
the	   task	   of	   breath-­‐hold	   ventilation,	   but	   cost	   $10,000	   and	   $50,000	   respectively.	   Additionally	   both	  
systems	  require	  professional	  maintenance,	  and	  are	  not	  easily	  decontaminated	  using	  common	  anti-­‐	  
tuberculocidal	  products.	  A	  trial	  of	  the	  ASPV-­‐IH	  demonstrated	  that	  breath-­‐holding	  could	  dramatically	  
improve	  image	  quality:	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On	  the	  basis	  of	  the	  quality	  of	  image	  provided	  it	  was	  apparent	  that	  breath-­‐hold	  imaging	  could	  vastly	  
improve	   identification	   of	   structures	   and	   had	   great	   potential.	   Unfortunately,	   the	   commercially	  
available	   system	   could	   not	   be	   modified	   in	   a	   manner	   which	   allowed	   safe	   ventilation	   of	   BSL-­‐3	  
pathogen	  infected	  animals.	  A	  custom	  built	  bio-­‐container	  which	  allowed	  for	  manual	  breath-­‐holding	  at	  
set	  pressures	  was	  designed	  and	  manufactured	  (figures	  41	  and	  42).	  




































































This	   system	   allowed	   for	   breath-­‐hold	   scanning	   of	   rabbits	   at	  matched	   pressures.	   The	   total	   cost	   for	  
manufacture	  was	  $132.50	  for	  the	  acrylic	  tubing,	  $102.50	  for	  the	  endcaps,	  $30	  for	  the	  valve,	  $2	  per	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filter	  and	  $0.50	  per	   feet	   for	   the	  tubing.	  To	  modify	  the	  existing	  chamber	  to	  allow	  combined	  breath-­‐	  
hold	   and	   PET	   imaging	   a	   cap	   was	   built	   for	   less	   than	   $100.	   The	   system	   is	   easily	   utilised,	   and	  
customisable	  by	  the	  insertion	  of	  further	  ports	  for	  either	  monitoring	  equipment,	  or	  sampling	  devices	  
(figure	  41	  and	  42).	  





Initial	   trials	   demonstrated	   that	   breath-­‐holds	   at	   10-­‐25cmH2O	   of	   pressure	   were	   well-­‐tolerated	   and	  
provided	   different	   information	   (figure	   43).	   At	   the	   writing	   of	   this	   thesis	   more	   than	   100	   scans	   of	  
infected	  animals	  have	  been	  performed,	  with	  no	  adverse	  events	  recorded.	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4.5.2. Non-­‐anaesthetised	  imaging	  of	  rabbits	  
On	  the	  CT	  acquisition	  system	  used	  scanning	  of	  the	  rabbit	  takes	  approximately	  a	  minute	  for	  the	  entire	  
body	  length,	  and	  reconstruction	  takes	  5-­‐10	  minutes.	  The	  majority	  of	  time	  during	  scan	  days	  is	  taken	  
by	  anaesthesia	  and	  recovery	  of	   the	  animal.	  Because	  anaesthesia	  poses	  a	   risk	   to	  animal	  health	  and	  
experimental	   outcomes,	  methods	   for	   scanning	   of	   non-­‐anaesthetised	   animals	   were	   investigated.	   A	  
low-­‐stress,	   and	   safe	   procedure	   that	   allowed	   for	   capture	   of	   informative,	   high-­‐quality	   CT	   scans	   of	  
rabbits	  was	  developed	  (figure	  44).	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The	   reproducibility	   of	   these	   scans	   was	   compared	   to	   breath-­‐hold	   images	   by	   segmenting	   the	   lung	  
volume	   (figure	   47)	   and	   assessing	   the	   distribution	   of	   densities	   within	   the	   scan	   (figure	   45).	   This	  
demonstrated	   that	   the	   variations	   between	   scans	   were	   very	   small,	   suggesting	   that	   such	   scanning	  




Image	   quality	   was	   also	   subjectively	   compared,	   non-­‐anaesthetised	   images	   could	   be	   used	   to	  
accurately	  	  quantify	   changes,	  	  but	   this	   method	   outperformed	   anaesthetised	   scans	  	  where	  	  breath-­‐	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holding	  was	   not	   used.	  Non-­‐anaesthetised	   scans	   do	   not	  match	   the	   clarity	   of	   images	  when	   breath-­‐	  
holding	  was	  applied	  (figure	  46).	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4.6. Segmentation	  of	  CT	  images	  
In	   order	   to	   quantify	   images,	   two	   general	   methods	   are	   used;	   scoring	   systems	   and	   quantification.	  
Scoring	  systems	  are	  inherently	  subjective;	  this	  can	  be	  compensated	  for	  by	  utilising	  multiple	  readers,	  
blinded	  to	  the	  information	  in	  the	  study.	  When	  one	  considers	  the	  cost	  of	  a	  trained	  radiologist’s	  time,	  
and	  that	  many	  imaging	  studies	  may	  have	  4-­‐5	  timepoints	  and	  as	  many	  as	  30	  animals,	  the	  cost	  of	  such	  
analysis	   is	  beyond	  the	  capabilities	  of	  most	  research	  laboratories.	  Additionally,	  there	  are	  also	  only	  a	  
few	  experts	  in	  laboratory	  animal	  anatomy,	  and	  almost	  none	  with	  familiarity	  of	  specific	  pathologies	  in	  
diverse	   models.	   Quantification	   can	   be	   unbiased	   –	   but	   is	   extremely	   challenging,	   especially	   when	  
considering	  the	  identification	  of	  pathologies	  that	  are	  complex	  in	  nature.	  
	  
The	  most	  common	  quantitative	  methods	  are	  those	  applied	   to	  Positron	  Emission	  Tomography	   (PET)	  
scanning.	  The	  emission	  of	  positrons	  from	  a	  trapped	  radiotracer	   is	  counted	  –	  and	  the	  location	  of	  the	  
origin	   of	   these	   counts	   is	   used	   to	   generate	   a	   3-­‐dimensional	   ‘uptake’	   scan.	   Because	   the	   amount	   of	  
tracer	  injected	  into	  the	  animal	  can	  be	  measured	  accurately,	  the	  uptake	  value	  can	  be	  standardised	  by	  
its	  distribution	   to	   generate	   standardised	  uptake	   values	   (SUVs).	   These	  values	   take	   into	   account	   the	  
amount	  of	  tracer	   injected	  and	  the	  volume	  of	   the	  animal.	  Such	  scans	  require	   co-­‐registration	  onto	  a	  
structural	  scan,	  such	  as	  a	  CT,	   in	  order	  to	   localise	  uptake.	  PET	  scans	  take	  significant	  periods	  of	   time	  
(anywhere	  from	  20	  minutes	  to	  several	  hours	  depending	  on	  the	  isotope	  being	  used).	  Co-­‐registration	  
is	   relatively	   straightforward	   in	   stationary	   organs;	   however,	   within	   the	   lung,	   motion	   is	   inevitable.	  
Although	   strategies	   were	   developed	   to	   reduce	   motion	   artefact,	   a	   strategy	   for	   taking	   scans	  
representative	   of	   the	   average	   breathing	   cycle	   has	   not	   been	   developed.	   As	   a	   result,	   in	   the	   images	  
presented	   in	   this	   thesis	   (as	   in	   all	  work	  where	  CT	   scans	   are	   not	   dynamically	   acquired	  with	   the	   PET	  
scan),	  the	  area	  of	  uptake	  is	  only	  approximately	  relative	  to	  the	  CT	  image.	  
	  
Quantification	  of	  CT	  images	  themselves	  is	  often	  on	  a	  case-­‐by-­‐case	  basis,	  for	  example,	  monitoring	  the	  
change	   in	   the	   size	   or	   number	   of	   lesions.	   This	   process	   is	   normally	   carried	   out	   using	   trained	  
radiologists.	   An	   alternative	   to	   this	   is	   to	   use	   ‘computer	   vision’	   to	   detect	   and	   segment	   images	  
completely	   	   automatically	   	   (203).	   	   Technologies	   are	   being	   developed,	   and	   a	   cavity	   and	   airway
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segmentation	  strategy	  was	  developed	  as	  part	  of	   this	  project	   (204).	  For	   the	  work	  presented	  here,	  a	  
semi-­‐automated	  segmentation	  technique,	  which	  allowed	  for	  isolation	  and	  measurement	  of	  the	  lung-­‐	  
field	   was	   developed	   (figure	   47).	   This	   method	   which	   used	   commercially	   available	   tools	   (Amira),	  
allowed	   for	   objective	   quantification	   of	   density	   changes	   within	   the	   lung	   field,	   as	   well	   as	   the	  
generation	  of	   reconstructions	   of	   this	   isolated	   field.	   These	   reconstructions	   also	   allow	   for	   improved	  
subjective	  assessment.	  The	  process	  takes	  approximately	  15	  minutes	  per	  scan	  (figure	  47	  and	  48).	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4.7. Identification	  of	  regions	  of	  interest	  in	  CT	  scans:	  
Having	  developed	  a	  method	  for	  set	  pressure	  breath-­‐holding	  of	  animals	  during	  scans	  (figures	  41,	  42	  
and	  43),	  and	  a	  way	  to	  reliably	  segment	  the	  lungs	  (figure	  47	  and	  48),	   the	   identification	  of	  regions	  of	  
interest	  was	  attempted	  by	  comparing	  scans	  at	  different	  pressures,	  before	  and	  after	  infection.	  These	  
data	  were	  also	  used	  to	  make	  basic	  estimate	  of	  lung	  compliance.	  More	  complex	  studies	  were	  beyond	  
the	  realm	  of	  this	  thesis	  –	  but	  the	  proof	  of	  principal	  that	  relatively	  simple	  technologies	  can	  be	  used	  to	  
generate	   quantitative	   information	   in	   a	   non-­‐biased	   manner,	   demonstrates	   that	   such	   types	   of	  
evaluation	  could	  be	  used	  to	  assess	  the	  effect	  of	  therapeutics	  in	  this	  model.	  
	  
4.7.1. Lung	   density	   changed	   in	   a	   reproducible	   manner	   when	   inflated	   to	   controlled	  
pressures	  
First,	   the	   reproducibility	  of	  breath-­‐hold	   scans	  was	  assessed.	  This	  was	  achieved	  by	   segmenting	   the	  
	  
lung	   window	   and	   counting	   the	   number	   of	   voxels	  	  (3-­‐dimensional	   pixels)	   that	   fall	   within	   a	   given	  
density	  range	  (figure	  49).	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4.7.2. The	  reproducibility	  of	  CT	  scan	  changes	  corresponded	  to	  specific	  pathologies	  
Figure	  49	  shows	  that	  the	  biggest	  change	  in	  volume	  of	  a	  given	  density	  occurred	  in	  the	  range	  -­‐1022	  to	  
	  
-­‐754	   (the	   peak	   at	   -­‐853)	   when	   lungs	   were	   inflated	   from	   10	   to	   20cmH2O	   of	   this	   region	   at	   these	  
pressures.	   There	  was	   a	   reduction	   in	   the	   volume	   of	   a	   large	   range	   of	   denser	   tissues	   (-­‐754	   to	   -­‐321)	  
suggesting	  that	  the	  expansion	  in	  the	  low	  density	  peaks	  occurred	  as	  a	  result	  of	  recruitment	  from	  this	  
region.	  The	  absence	  of	  any	  change	  below	  -­‐450	  suggest	  strongly	  that	  there	  is	  no	  recruitment	  of	  this	  at	  
these	  pressures.	  These	  data	  indicate	  that	  compliant,	  functional	  lung	  tissue	  lies	  in	  the	  range	  of	  -­‐500	  to	  
-­‐925	   HU	   in	   a	   rabbit	   CT	   scan.	   This	   is	   in-­‐keeping	   with	   human	   CT	   findings	   where	   the	   arbitrary	  
designations	  for	  lung	  tissue	  are	  (i)	  -­‐1000	  to	  -­‐900;	  hyperexpanded,	  (ii)	  -­‐900	  to	  -­‐500;	  normally	  aerated	  
(iii)	  -­‐500	  to	  -­‐100;	  poorly	  aerated	  and	  (iv)	  -­‐100	  to	  100;	  not	  aerated	  (191).	  
	  
	  
Next	  the	  data	  was	  analysed	  to	  assess	  whether	  specific	  changes	  occurred	  after	   infection.	  To	  do	  this,	  
lung	  density	  from	  preinfection	  scans	  was	  compared	  to	  each	  time	  point	  after	  infection	  (figure	  50).	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4.7.3. Identifying	  changes	  which	  correspond	  to	  pathology	  
 
	  
A	  distinct	  pattern	  of	  change	  was	  observed	  after	   infection	  (figure	  50).	  There	  was	  an	   increase	   in	  the	  
proportion	  of	  tissue	  at	  high	  density	  and	  very	  low	  density	  tissue.	  There	  was	  a	  concurrent	  decrease	  in	  
163	  |	  P	  a	  g	  e	  	  
the	   ‘normally	   aerated’	   tissue	   (-­‐900	   to	   -­‐500	   HU).	   These	   changes	   indicated	   that	   normal	   tissue	   was	  
replaced	  by	  both	  low	  and	  high	  density	  changes	  post	  infection;	  the	  densities	  of	  which	  correspond	  to	  
cavity	  formation	  (very	   low	  density),	  hyper-­‐expansion	  (low	  density)	  and	  consolidation	  (high	  density).	  
As	  shown	  in	  figure	  50,	  the	  change	  in	  the	  low	  density	  peak	  in	  20cmH2O	  scan	  is	  bimodal.	  The	  10cmH2O	  
scan	   shows	  only	   a	   singular	   peak	  which	   corresponds	  with	   the	   lowest	  density	   peak	  of	   the	  20cmH2O	  
scan.	  It	  was	  hypothesised	  that	  the	  very	  low	  density	  peak	  was	  the	  result	  of	  cavity	  formation	  and	  that	  
the	   slightly	   less	   dense	   peak	   was	   the	   result	   of	   hyperexpansion.	   To	   test	   this,	   cavity	   and	   non-­‐cavity	  
animals	  from	  a	  single	  time	  point	  were	  assessed	  (figure	  51).	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By	   comparing	   the	   10cmH2O	   scans	   of	   cavity	   to	   non-­‐cavity	   animals	   at	   a	   single	   time	   point,	   a	   cavity	  
signature	   (-­‐1022	   to	   -­‐918HU)	  was	   distinguished	   from	  a	   hyperexpansive	   (-­‐829	   to	   -­‐796HU)	   signature	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(figure	   51).	   There	  was	   no	   increase	   in	   the	   cavity	   region	  when	   observing	   non-­‐cavity	   animals.	   In	   the	  
20cmH2O	   scan,	   hyperexpansion	   occurred	   in	   those	   animals	   with	   cavities.	   Non-­‐cavitary	   animals	  
showed	   a	   reduction	   (from	   preinfection)	   in	   hyperexpanded	   zones.	   These	   data	   suggested	   that	   the	  
20cmH2O	   scan	   could	   be	   used	   to	   demonstrate	   newly	   hyperexpanded	   regions,	   and	   that	   these	   are	  
identifiable	  by	  a	  threshold	  values	  within	  the	  scan.	  
	  
This	   was	   tested	   by	   segmenting	   the	   lung	   tissue	   from	   surrounding	   tissue	   in	   the	   scans,	   and	   then	  
segmenting	  various	  regions	  by	  their	  relative	  density.	  It	  was	  shown	  that	  the	  region	   -­‐1024	  to	  -­‐917HU	  
corresponded	   to	   major	   airways	   and	   cavities	   (figure	   52).	   Since	   the	   major	   airways	   do	   not	   change	  
significantly	   in	  volume	  during	  the	  experiment,	  changes	   in	  this	   region	  were	  strongly	  associated	  with	  
cavity	   formation.	   The	   region	   from	   -­‐917	   to	   -­‐855HU	   represents	   hyperexpanded,	   but	   not	   cavity	  
containing	   tissue.	   This	   hyperexpansion	   occurs	   in	   all	   regions	   except	   the	   directly	   infected	   area,	  
suggesting	  that	  the	  lung	  compensates	  for	  the	  affected	  region	  mechanically.	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4.7.5. High	  density	  changes	  in	  rabbit	  CT	  scans	  and	  their	  correlation	  with	  pathology	  
Next	  the	  high	  density	  peak	  (-­‐184	  to	  53HU)	  was	  examined.	  Conceptually,	  one	  must	  remember	  that	  a	  
CT	  density	  results	  from	  the	  given	  proportion	  of	  a	  tissue	  to	  air	  within	  a	  voxel.	  As	  such,	  an	  increase	  in	  
regions	   of	   density	   can	   reflect	   either	   an	   increase	   in	   the	   amount	   of	   tissue	   at	   a	   given	   density,	   or	   an	  
increase	  in	  the	  amount	  of	  air	  in	  the	  same	  mass	  of	  tissue.	  With	  dense	  tissue,	  the	  interest	  is	  not	  in	  the	  
amount	  of	  aeration,	  but	   instead	  the	   increase	   in	  actual	   tissue	  mass	  resulting	   from	   infiltration	  of	   the	  
airspace	   and	   fibrosis,	   CT	   density	   readings	   converted	   into	   tissue	   mass.	   This	   took	   place	   using	   the	  
simple	  equation	  (191):	  
𝑇𝑖𝑠𝑠𝑢𝑒  𝑚𝑎𝑠𝑠 = 1 − 𝐶𝑇1000   ×  𝑉𝑜𝑙𝑢𝑚𝑒	  
	  
Where	   the	   CT	   number	   is	   the	   density	   of	   a	   voxel	   in	   Hounsfield	   units,	   and	   volume	   is	   the	   number	  
of	  voxels	  containing	  this	  density.	  This	  equation	  is	  derived	  from	  the	  fact	  that	  water	  has	  a	  density	  of	  
0HU	   and	   air	   of	   -­‐1000HU	   and	   the	   assumption	   that	   a	   voxel	   with	   a	   density	   between	   0HU	   and	   -­‐
1000HU	  are	  composed	  of	  a	  proportion	  of	  tissue	  (that	  has	  a	  density	  equal	  to	  water)	  and	  air.	  





This	  analysis	  revealed	  a	  small	  but	  significant	  increase	  in	  the	  abundance	  of	  high-­‐density	  tissues	  (figure	  
53).	   Since	   there	   was	   an	   increase	   in	   mass	   of	   all	   tissue	   densities	   post	   infection,	   the	   proportional	  
increase	  in	  each	  zone	  was	  compared	  (figure	  54).	  




Analysing	  the	  proportional	  changes	  showed	  that	  a	  subset	  of	  the	  regions	  with	  density	  between	  -­‐200	  
and	  200	  Hounsfield	  units	  increased	  as	  a	  proportion	  of	  the	  entire	  lung	  mass.	  This	  region;	  -­‐184	  to	  156,	  
corresponds	  with	  vasculature	  and	  consolidated	   tissue	   (figure	  52).	  As	  with	   the	  cavity	   signature,	   this	  
information	  was	  used	  to	  generate	  a	  false	  colour	  scale	  and	  map	  the	  region.	  This	  confirmed	  that	  the	  
increase	  in	  proportion	  of	  this	  region	  correlated	  with	  the	  regions	  of	  consolidation.	  
	  
4.7.6. Visual	  representation	  of	  pathological	  changes	  
Regions	   of	   consolidation,	   hyperexpansion	   and	   cavitation	   were	   identified.	   By	   combining	   all	   this	  
information,	  a	  3D	  colour	  map	  that	  highlights	  these	  pathologies	  was	  generated.	  When	  combined	  with	  
the	   segmentation	   method,	   this	   allows	   for	   rendering	   of	   pathology	   within	   the	   lung	   field	   which	  
complement	  the	  quantitative	  information	  (figures	  27	  and	  28)	  produced.	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This	   map	   successfully	   rendered	   major	   changes,	   but	   did	   not	   allow	   for	   rendering	   of	   more	   subtle	  
pathologies,	  which	  occur	  in	  densities	  that	  did	  not	  necessarily	  change	  in	  overall	  volume,	  but	  may	  have	  
changed	   in	   distribution	   (figure	   55).	   For	   example,	   tissue	   with	   a	   density	   of	   -­‐300	   units	   is	   found	  
distributed	   throughout	   the	   lung,	   and	   may	   not	   change	   in	   absolute	   or	   relative	   amount	   during	  
infection.	  However,	  despite	  the	  absence	  of	  an	  overall	  change,	  changes	  in	  distribution	  of	  this	  density	  
would	  indicate	  pathological	  change	  (i.e.	  nodule	  development).	  As	  a	  result,	  the	  scale	  was	  modified	  to	  
allow	  clearer	  representation	  of	  disease	  pathology	  (figure	  56).	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4.8. Assessing	  transmission	  from	  rabbits	  
Cavity	   formation	   is	   associated	   strongly	   with	   bacterial	   transmission	   (184,	   185).	   Preliminary	   studies	  
were	  conducted	  to	  investigate	  whether	  transmission	  could	  be	  modelled	  using	  the	  rabbit	  as	  a	  source.	  
Animal	   to	   animal	   transmission	   of	  M.	   bovis	   has	   been	   demonstrated	   by	   Lurie	   (205).	   However,	   this	  
required	  large	  amounts	  of	  bedding	  to	  be	  added	  to	  the	  cages,	  and	  though	  the	  bacteria	  appeared	  to	  
be	  inhaled,	  it	  could	  not	  be	  established	  if	  infection	  could	  was	  being	  expelled	  via	  the	  respiratory	  tract.	  
A	  series	  of	  experiments	  were	  conducted	   in	  order	   to	   investigate	   if	   rabbits	  exhaled	  virulent	  M.	  tb	   in	  
the	  presence	  of	  cavitary	  lung	  disease.	  
	  
4.8.1. Bacterial	  collection	  using	  hydrophobic	  HEPA	  grade	  filters	  
First,	  the	  breath-­‐hold	  chamber	  was	  modified	  to	  allow	  placement	  of	  a	  filter	  in	  the	  expiratory	  limb	  of	  
the	  respiratory	  circuit	  (figure	  57).	  After	  exposure,	  the	  filter	  was	  removed,	  rinsed	  in	  40ml	  of	  PBS	  and	  
0.05%	  tween	  and	  plated	  on	  selective	  7H11	  plates	   (500ul	  per	  plate;	  12	  plates	  per	   filter).	  12	  animals	  
were	   used	   for	   this	   experiment.	   Filters	   were	   cultured	   from	   all	   animals,	   6	   animals	   had	   not	   yet	  
developed	  cavities	  at	  the	  first	  time	  point,	  and	  6	  animals	  had	  cavities.	  The	  procedure	  was	  repeated	  7	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No	  colonies	  were	  found	  on	  any	  plates.	  This	  suggests	  that	  large	  amounts	  of	  viable	  bacteria	  were	  not	  
exhaled	  by	  rabbits,	  however,	  a	  number	  of	  alternative	  explanations	  for	  this	  observation	  are	  possible.	  
Technically,	  there	  are	  a	  number	  of	  problems	  with	  this	  experiment.	  M.	  tb	  may	  not	  survive	  in	  exhaled	  
droplets	   for	   a	   long	   time;	   since	   the	  droplets	  would	   theoretically	  be	   collected	  on	   the	   filter	   and	   then	  
exposed	   to	  high	   concentrations	   of	   unhumidified	   oxygen,	   containing	   1%	   isoflurane	   for	   up	   to	  	  45	  
minutes,	  which	  may	   lead	   to	   desiccation	   (although	   the	   ability	   for	  M.	   tb	   to	   survive	   on	   surfaces	   for	  
periods	  of	  up	  to	  six	  months	  is	  well	  documented).	  Secondly,	  the	  bacteria	  may	  become	  trapped	  in	  the	  
filter.	  The	  filter	  membranes	  are	  hydrophobic	  and	  extraction	  was	  performed	  with	  very	  mild	  detergent	  
(0.05%	   tween	   80)	  which	  may	   not	   release	   bacteria.	   Attempts	  were	  made	   to	   develop	   a	   protocol	   to	  
homogenise	   filters,	   but	   none	   were	   successful	   (data	   not	   shown).	   Also,	   one	   would	   expect	   that	   the	  
hydrophobic	  nature	  of	  the	  filters	  should	  mean	  that	  droplets	  containing	  bacilli	  should	  be	  found	  on	  the	  
surface	  and	  not	  embedded	  in	  the	  membrane.	  
	  
This	   experiment	   by	   no	   means	   demonstrates	   that	   rabbits	   do	   not	   exhale	   bacteria.	   Conceptually,	  
exhalation	   of	   bacteria	   may	   be	   dependent	   on	   specific	   mechanics	   (for	   	   example	   coughing)	   –	   and	  
although	   the	   animals	  were	   subject	   to	   significant	   changes	   in	   respiratory	  pressure,	   the	   rapid	  airflow	  
generated	  by	  coughing	  was	  not	  recapitulated.	  Bacterial	  entry	  from	  the	  parenchyma,	  into	  the	  airway,	  
may	  be	  sporadic,	  for	  example	  if	  it	  coincides	  with	  cavity	  formation.	  If	  this	  were	  the	  case,	  in	  a	  singular	  
event,	  many	  millions	  of	  bacteria	  may	  be	  simultaneously	  released,	  rather	  than	  a	  constant	  stream	  of	  
bacteria.	   It	   should	  be	  noted	  however,	   that	   filters	  on	   the	  expiratory	   circuits	  of	   rabbits	  with	   cavities	  
were	   exposed	   for	   a	   total	   of	   36	   hours	   –	   and	   that	   the	   absence	   of	   any	   culturable	   bacteria	   strongly	  
suggests	  that	  rabbits	  in	  general	  are	  not	  highly	  infectious.	  
	  
4.8.2. Bacterial	  collection	  using	  gelatin	  filters	  
A	   second	   experimental	   setup	   using	   only	   3	   animals	   yielded	   identical	   results.	   This	   time	   air	   was	  
sampled	   directly	   onto	   a	   gelatin	   filter,	   using	   a	   commercially	   available	   bacterial	   sampling	   device	  
(Sartorius	  MD8	   Air	   Sampler).	   In	   this	   experiment	   all	   animals	   had	   cavities	   and	  were	   between	   42-­‐49	  
days	  post	   infection.	   The	   concept	  was	   that	   the	   gelatin	   collection	  method	  would	   reduce	   the	   risk	  of	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desiccation.	  This	  method	  of	  capturing	  aerosolised	  M.	  tb	  has	  been	  used	  to	  assess	   the	  prevalence	  of	  
aerosolised	  M.	  bovis,	  did	  not	  yield	  any	  culturable	  bacteria	  from	  badger	  sets	  (206).	  The	  machine	  was	  
modified	  to	  ensure	  sampling	  of	  all	  exhaled	  gas	  (figure	  58).	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4.8.3. Rabbit	  to	  guinea-­‐pig	  transmission	  
Simultaneously	   to	   these	  experiments	   a	   ‘natural’	   transmission	   study	  was	  designed	   to	   see	   if	   guinea-­‐	  
pigs	   could	   be	   used	   as	   sentinels	   for	   the	   detection	   of	   exhaled	   viable	   bacteria.	   Since	   as	   few	   as	   10	  
bacteria	   can	  establish	  progressive	   disease	   in	   the	   guinea	   pig	   it	  was	   thought	   that	   animal	   co-­‐housing	  
could	  demonstrate	  if	  sporadic	  infectious	  events	  occur	  (146,	  207).	  A	  custom	  caging	  setup	  was	  used	  to	  
prevent	   direct	   animal	   contact,	   and	  maintain	   animal	  well	   being	   (figure	  59).	   A	   rabbit	  with	   extensive	  
cavities	  disease	  was	  housed	  with	  a	  guinea	  pig	  for	  8	  weeks.	  At	  the	  end	  of	  this	  period	  the	  guinea	  pig	  
was	   sacrificed	   and	   the	  entire	   lung	  homogenised	   in	   12ml	  of	  PBS.	   The	  entire	   volume	  was	   plated	  on	  
selective	  7h11	  agar	  (500ul	  per	  plate).	  No	  bacteria	  were	  grown	  from	  the	  guinea	  pig	  lung.	  
	  
 





It	  should	  be	  noted	  that	  whilst	  this	  experiment	  does	  not	  exclude	  the	  possibility	  of	  animal	  to	  animal	  
	  
transmission,	  it	  suggests	  that	  it	  would	  be	  at	  best	  a	  rare	  event.	  A	  number	  of	  technical	  improvements	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could	  be	  made	  to	  enhance	  the	  chance	  of	  transmission.	  First,	  air	  flow	  in	  the	  caging	  could	  be	  reduced.	  
High	   air-­‐turnover	   has	  been	  demonstrated	   to	   reduce	   the	   risk	  of	   contracting	  M.	   tb	   infection	   in	  man	  
(24).	  Secondly,	  larger	  numbers	  of	  animals	  could	  be	  used.	  Thirdly,	  a	  method	  to	  induce	  coughing	  could	  
be	  developed	  –	  procedures	  such	  as	  nebulised	  citric	  acid	  have	  been	  used	  to	   induce	  this	   response	   in	  
rabbits	  (208,	  209).	  This	  modification	  would	  probably	  best	  be	  applied	  to	  direct	  bacterial	  collection	  on	  
filters;	   although	   a	   design	   for	   a	   chamber	  which	   allowed	   for	   coughing	   and	   airflow	   from	   a	   rabbit	   to	  
guinea-­‐pig	  could	  be	  used.	  
	  
It	   should	  be	  remembered	  that	  a	  practical	   transmission	  model	  would	  allow	  quantitative	  assessment	  
the	   effect	   of	   interventions	   in	   preventing	   transmission.	   Since	   the	   mechanism	   of	   transmission	   is	  
exhalation	  of	  aerosol	  droplets,	  an	  ideal	  model	  would	  recapitulate	  this	  process	  in	  a	  quantifiable	  and	  
predictable	  manner.	  Currently	  this	  model	  does	  not	  readily	  demonstrate	  this;	  however,	  since	  reliable	  
cavity	   formation	   is	   possible	   (figure	   23),	   and	   cavities	   are	   strongly	   associated	   with	   TB	   transmission	  
(184,	   185),	   safely	   trialled	   anti-­‐cavity	   therapies	   could	   be	   translated	   to	   human	   studies,	   without	   the	  
proof	  that	  they	  prevent	  transmission	  in	  the	  animal	  model,	  but	  with	  the	  expectation	  that	  this	  may	  a	  
beneficial	  result	  of	  treatment	  in	  humans.	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4.9. Summary	  
This	  work,	  though	  very	  simplistic	  in	  nature,	  provides	  entirely	  novel	  options	  in	  assessing	  outcomes	  in	  
rabbit	  experiments.	  By	  combining	  multiple	  biological	  samples	  and	  high	  quality	  CT	  images,	  we	  can	  see	  
that	   virtual	  	  necropsy	  is	   possible,	   and	  	  hence	  reduce	  animal	  	  and	  	  drug	  	  usage,	   allowing	  	  expanded	  
research	   in	   multiple	   areas.	   CT	   scanning	   can	   be	   used	   to	   measure	   levels	   of	   lung	   involvement	   and	  
disease	  extent,	  and	  uniquely	  allows	  longitudinal	  follow-­‐up	  of	  animals	  before	  and	  after	  interventions.	  
Although	   this	   does	   not	   replace	   the	   need	   for	   studying	   animal	   bacterial	   burdens,	   it	   also	   gives	  
previously	  undetectable,	  quantitative	  and	  highly	  clinically	   relevant	   information	  about	   the	  extent	  of	  
lung	  involvement.	  There	  is	  also	  potential	  for	  comparison	  of	  disease	  to	  any	  marker	  in	  biological	  fluids,	  
rudimentary	  detail	  of	  regional	  compliance	  of	   the	   lung	  and	  the	  ability	   to	  compare,	   for	   the	  first	  time	  
within	   the	  same	  animal,	   these	  details	  over	   time.	  A	   few	  simple	  modifications	  could	  greatly	   improve	  
the	  power	  of	  the	  tools	  developed	  here.	  Automated	  radiology	  techniques	  could	  allow	  for	  non-­‐biased	  
image	   analysis,	   with	   rapidly	   availability	   of	   results.	   Advanced	   respiratory	   monitoring	   using	   devices	  
such	  as	  the	  SciReq	  Flexivent	  in	  combination	  with	  CT	  imaging	  could	  be	  used	  to	  examine	  the	  detailed	  
mechanical	   properties	   of	   the	   lung	   during	   infection	   (210,	   211).	   The	   techniques	   described	   here	   are	  
easily	  modifiable	  to	  other	  large	  animal	  species.	  
	  
The	  application	  of	  these	  technologies	  to	  the	  70	  day	  model	  of	  TB	  described	  in	  the	  section	  3.8	  of	  this	  
thesis	  mean	  that	  trials	  involving	  drugs	  aimed	  at	  targeting	  cavity	  formation	  are	  possible	  using	  1	  group	  
of	   animals	   in	   the	   control	   and	   treatment	   arm.	   As	   a	   result	   of	   this	   work,	   a	   short-­‐duration,	   highly	  
relevant	  model	  of	  TB	  cavity	  formation	  is	  available	  for	  investigating	  novel	  therapies	  in	  the	  context	  of	  
human-­‐like	  pathology.	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5. Molecular	   Characterisation	   of	   the	  Rabbit	  Cavity	  Model	  of	  Tuberculosis	  
	  
Tissue	  destruction	  is	  an	  important	  process	  in	  active	  tuberculosis	  (TB).	  The	  molecular	  mechanisms	  are	  
poorly	   understood.	   Since	   destruction	   of	   the	   collagen	   ECM	   is	   central	   to	   the	   process,	   collagen	  
degrading	   enzymes	   are	   likely	   involved	   (84,	   85,	   171).	   The	   model	   was	   investigated	   to	   better	  
understand	  the	  molecular	  similarities	  and	  differences	  between	  what	  is	  known	  about	  human	  disease	  
and	  the	  rabbit	  model.	  
	  
Because	  MMPs,	  especially	  MMP-­‐1,	  have	  been	  identified	  as	  potential	  targets	  for	  anti-­‐cavitary	  therapy	  
in	   TB	   (53,	   54,	   84,	   85,	   105,	   107,	   109-­‐111,	   114-­‐118,	   171),	   the	   investigations	   focussed	   primarily	   on	  
these	   enzymes.	   Elkington	   et	   al.	  proposed	   a	   selective	   inhibitor	   of	  MMP-­‐1	  may	   be	   able	   to	  mediate	  
cavitary	   pathology,	   however,	   have	   not	   been	   able	   to	   perform	   preclinical	   	   trials	   of	   the	   drug	   	   in	   	   a	  
relevant	  animal	  model	  (109).	  Since	  the	  newly	  developed	  rabbit	  model	  described	  in	  section	  3.8	  of	  this	  
thesis	  closely	   resembles	  the	  pathological	  phenotype	  of	  TB,	  we	  sought	   to	   investigate	  whether	  there	  
were	  molecular	   correlates	   of	   human	  disease.	  Having	   confirmed	  a	   number	   of	  molecular	   correlates,	  
we	  then	  investigated	  if	  this	  model	  could	  predict	  unidentified	  mediators	  of	  ECM	  degradation	  in	  man.	  
Cathepsin	   K	   was	   predicted	   and	   confirmed	   as	   a	   potential	   mediator,	   via	   identification	   in	   a	   whole	  
transcriptome	  screen,	  and	  was	  subsequently	  confirmed	  as	  being	  associated	  of	  tissue	  destruction	   in	  
TB.	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5.1. Selection	   of	   reference	   genes	   for	   quantitative	   real	   time	   polymerase	  
chain	  reactions	  
Since	   quantitative	   real-­‐time	   polymerase	   chain	   reactions	   (qRT-­‐PCR)	   had	   not	   been	   utilised	   for	   the	  
	  
assessment	  of	   rabbit	   pulmonary	   tissue	   infected	  with	  M.	   tb	  at	   the	   initiation	  of	   this	   thesis,	   the	   first	  
step	   in	   assessing	   the	   gene	   expression	   was	   to	   establish	   suitable	   reference	   genes	   (although	  
publications	  with	  rabbit	  gene	  expression	  from	  granuloma	  expression	  have	  since	  been	  published,	  the	  
process	  of	  reference	  gene	  analysis	  was	  not	  published	  (156,	  167)).	  A	  vast	  number	  of	  strategies	  have	  
been	  used	   to	   identify	   reference	  genes	   (172).	  Conceptually,	   the	   idea	  of	   a	   reference	  gene	   is	   that	  by	  
comparing	  expression	  of	  genes	  of	  interest	  to	  a	  known	  reference	  gene,	  for	  which	  expression	  does	  not	  
change	   in	   the	   conditions	   of	   interest,	   the	   relative	   expression	   of	   the	   gene	   of	   interest	   can	   be	  
determined.	  Since	  the	  principal	   focus	  of	   this	  study	  was	   to	   identify	  whether	  genes	  of	   relatively	  high	  
expression	   (i.e.	   the	  MMPs)	  matched	   findings	   observed	   in	   human	   cells	   and	   samples,	   an	   exhaustive	  
search	  for	  stable	  reference	  was	  not	  conducted,	   instead,	  a	  small	  panel	  of	  potential	   reference	  genes	  
were	   identified	   from	   the	   literature	   (212),	   and	   primers	   designed	   according	   to	   the	   available	   rabbit	  
reference	  genome	  (oryCun2	  [GCA_000003625.1]).	  
	  










NCA0127 CTGAACCCCAAGGCCAACC Rabbit Beta actin Forward 
NCA0128 AGAGGCGTACAGGGACAGC Rabbit Beta actin Reverse 
AKP001 GGCATCGTGACCAACTGGGA Rabbit Beta Actin (2) Forward 
AKP002 CCGGCGTGTTGAACGTCT Rabbit Beta Actin (2) Reverse 
AKP013 GTTCAACACGCCGGCCATGT Rabbit Beta Actin (3) Forward 
AKP014 AGCGCGTAGCCCTCGTAGAT Rabbit Beta Actin (3) Reverse 
AKP021 GTTCAACACGCCGGCCATGT Rabbit Beta Actin (3) Forward 
AKP022 AGCGCGTAGCCCTCGTAGAT Rabbit Beta Actin (3) Reverse 
AKP025 CGCTTCCGTTGCCCCGAG Rabbit Beta Actin (4) Forward 
AKP026 GCCGCCCGACAGCACCGT Rabbit Beta Actin (4) Reverse 
AKP171 CGATCATGAAGTGCGACGTGG Rabbit Beta Actin (5) Forward 
AKP172 TCTTCATGGTGCTGGGCG Rabbit Beta Actin (5) Reverse 
NCA0129 TTGTTCCCCTGCCTGGAGT Rabbit B-2 Microglobulin Forward 
NCA0130 GATGAAACCCAGATAC Rabbit B-2 Microglobulin Reverse 
AKP027 TGCTCGCGCTAGTCTTGTTCCC Rabbit B-2 Microglobulin (2) Forward 
AKP028 TCTGGGGCGGATGAAACC Rabbit B-2 Microglobulin (2) Reverse 
AKP193 ACGCCCAATGATAAGGAT Rabbit B-2 Microglobulin (3) Forward 
AKP194 CCTCCATGCTGTTGATTA Rabbit B-2 Microglobulin (3) Reverse 
AKP219 TCCATGTTTTCTGTACTTCTGG Rabbit B-2 Microglobulin (4) Forward 
AKP220 AACTATGGATTCCCACCC Rabbit B-2 Microglobulin (4) Reverse 
NCA0131 CGTCTTCACCACCATGGAG Rabbit GAPDH Forward 
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NCA0132 CAATCTTGAGAGAGTTGTC Rabbit GAPDH Reverse 
AKP003 AAGTGGATGTTGTCGCCA Rabbit GAPDH (2) Forward 
AKP004 ATGGCCTTCCCGTTGATG Rabbit GAPDH (2) Reverse 
AKP017 AAGTGGATGTTGTCGCCA Rabbit GAPDH (2) Forward 
AKP018 ATGGCCTTCCCGTTGATG Rabbit GAPDH (2) Reverse 
AKP041 TTCCAGTATGATTCCACCCACG Rabbit GAPDH (3) Forward 
AKP042 CACTTGATGTTGGCGGGA Rabbit GAPDH (3) Reverse 
AKP177 CAAGAAGGTGGTGAAGCAGGC Rabbit GAPDH (4) Forward 
AKP178 GCCCCAGCATCGAAGGTAGA Rabbit GAPDH (4) Reverse 
NCA0133 GCTCGAGATGTGATGAAGG Rabbit HPRT1 Forward 
NCA0134 GTCATAGGAATGGATCTATC Rabbit HPRT1 Reverse 
AKP005 AATCATTACGTCGAGGAC Rabbit HPRT1 (2) Forward 
AKP006 ATAATCCAGCAGGTCAGC Rabbit HPRT1 (2) Reverse 
AKP033 AAGTTCTTTGCTGACCTGCTGG Rabbit HPRT-1 (3) Forward 
AKP034 CATCTCCACCGATTACTTT Rabbit HPRT-1 (3) Reverse 
AKP045 GCTCGAGATGTGATGAAGGAGA Rabbit HPRT-1 (4) Forward 
AKP046 TCCCCTGTTGACTGGTCATTAC Rabbit HPRT-1 (4) Reverse 
NCA0135 CAAGAGCCTGACCAACGAC Rabbit HSP-90 Forward 
NCA0136 TCAAACAGGTCAAACG Rabbit HSP-90 Reverse 
AKP179 CTCCCAGAACCGCAAGAAGC Rabbit HSP-90 (2) Forward 
AKP180 TGGTCCTTGGTCTCACCTGTGA Rabbit HSP-90 (2) Reverse 
AKP181 ACGAAGTTCGAGAACCTCTGCA Rabbit HSP-90 (3) Forward 
AKP182 CCGTACGTGCTTGTGACGATG Rabbit HSP-90 (3) Reverse 
AKP031 TGCCGTCAACAACACTCTCACA Rabbit GUSB Forward 
AKP032 TCCCGCGTAGTTGAAGAAGTCA Rabbit GUSB Reverse 
AKP195 TTTCCATGGGGTCAACAAGCAC Rabbit GUSB (2) Forward 
AKP196 TGCATCACCTCCTCCGCAT Rabbit GUSB (2) Reverse 
AKP197 TGCGCCGGGACAAGAATCA Rabbit GUSB (3) Forward 
AKP198 TGGTCACAAAGGTCACGGGC Rabbit GUSB (3) Reverse 
NCA0139 GGTTCCTGCTTTCACAGG Rabbit PPIA Forward 
NCA0140 CATCCTCGAACTTCTCTC Rabbit PPIA Reverse 
AKP029 CTGAGCACCGGAGAGAAAGGA Rabbit PPIA (2) Forward 
AKP030 ATAGATGGACTTGCCGCCGG Rabbit PPIA (2) Reverse 
AKP173 CCCAACACAAACGGCTCCCA Rabbit PPIA (3) Forward 
AKP174 TGCTGGTCTTGCCGTTCTCG Rabbit PPIA (3) Reverse 
AKP175 GGTTCCTGCTTTCACAGG Rabbit PPIA (4) Forward 
AKP176 CATCCTCGAACTTCTCTC Rabbit PPIA (4) Reverse 
AKP035 CTCTGCTACGCGATGGTTGCTA Rabbit TFRC Forward 
AKP036 TCCGCGTTTTCTGACTGCTC Rabbit TFRC Reverse 
AKP199 TCCAGACGATTTCCAGAGAGGC Rabbit TFRC (2) Forward 
AKP200 CAGCACGTTGTTCACAGTGAGC Rabbit TFRC (2) Reverse 
AKP201 TGCTGCTTTCCCTTTCCTTGCT Rabbit TFRC (3) Forward 
AKP202 CCCGGGCCATTTTGTTCA Rabbit TFRC (3) Reverse 
AKP037 TGGGTCTGTCATCCTGCTGG Rabbit PGK-1 Forward 
AKP038 TTGGCTGGTTCCGCTTTA Rabbit PGK-1 Reverse 
AKP203 TTGGTCGGGCGAAGCAGATTGT Rabbit PGK-1 (2) Forward 
AKP204 TCTCCACCGCCGATGATGGT Rabbit PGK-1 (2) Reverse 
AKP205 AGTCCGTTGTCTTGATGAGCCA Rabbit PGK-1 (3) Forward 
AKP206 GGGCCCACACAATCCTTTAAGA Rabbit PGK-1 (3) Reverse 
AKP039 GCAGCAGTGTCGTCCGCAAA Rabbit ALAS Forward 
AKP040 CCACTGGGGTCCTCTCCGT Rabbit ALAS Reverse 
AKP207 TGTGGCCAACGACTCAACCC Rabbit ALAS (2) Forward 
AKP208 CGTCGTTGTGGCGGAAGATGTA Rabbit ALAS (2) Reverse 
AKP209 GAATTGGTGATCGGGACGGAGT Rabbit ALAS (3) Forward 
AKP210 TGAAGATGAAGCCAGCCGC Rabbit ALAS (3) Reverse 
NCA0137 TGGACCTGGTGGTTCAC Rabbit PBGD Forward 
NCA0138 TGAAAGACAACAGCATCGCAG Rabbit PBGD Reverse 
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AKP211 AGTGCTATCATCCTGGCTGTGG Rabbit PBGD (2) Forward 
AKP212 TCGAACTTCCACTCCCAGGG Rabbit PBGD (2) Reverse 
AKP213 AGGAGTCTGGAGTCTGGATGGC Rabbit PBGD (3) Forward 
AKP214 TCCTCGTGGAATGTTCCGG Rabbit PBGD (3) Reverse 
AKP015 GAATGAGTCCACTTTAAATC Rabbit 18S rRNA Forward 
AKP016 GATCCAACTACGAGCTTT Rabbit 18S rRNA Reverse 
AKP215 CAGTTATGGTTCCTTTGGTCGC Rabbit 18S rRNA (2) Forward 
AKP216 AGGCTGACCGGGTTGGTTT Rabbit 18S rRNA (2) Reverse 
AKP217 GCAAGACGGACCAGAGCGAA Rabbit 18S rRNA (3) Forward 
AKP218 GTCATGGGAATAACGCCGC Rabbit 18S rRNA (3) Reverse 
Table 4. Potential reference gene primers for qRT-PCR. 
	  
	  
From	   this	   list	   primers,	   those	   pairs	   which	   had	   an	   average	   efficiency	   of	   1.8	   to	   2.2	   (as	   evaluated	   by	  
Ramakers	  linear	  regression	  method	  (172))	  and	  generated	  products	  with	  a	  singular	  melt	  point,	  were	  
used	   to	   establish	   reference	   gene	   stability	   in	   5	   paired	  RNA	   isolates	   from	  cavity	  wall	   grossly	   normal	  










AKP025 CGCTTCCGTTGCCCCGAG Rabbit Beta Actin (4) Forward 
AKP026 GCCGCCCGACAGCACCGT Rabbit Beta Actin (4) Reverse 
NCA0129 TTGTTCCCCTGCCTGGAGT Rabbit B-2 Microglobulin Forward 
NCA0130 GATGAAACCCAGATAC Rabbit B-2 Microglobulin Reverse 
AKP041 TTCCAGTATGATTCCACCCACG Rabbit GAPDH (3) Forward 
AKP042 CACTTGATGTTGGCGGGA Rabbit GAPDH (3) Reverse 
AKP005 AATCATTACGTCGAGGAC Rabbit HPRT1 (2) Forward 
AKP006 ATAATCCAGCAGGTCAGC Rabbit HPRT1 (2) Reverse 
AKP181 ACGAAGTTCGAGAACCTCTGCA Rabbit HSP-90 (3) Forward 
AKP182 CCGTACGTGCTTGTGACGATG Rabbit HSP-90 (3) Reverse 
AKP031 TGCCGTCAACAACACTCTCACA Rabbit GUSB Forward 
AKP032 TCCCGCGTAGTTGAAGAAGTCA Rabbit GUSB Reverse 
AKP029 CTGAGCACCGGAGAGAAAGGA Rabbit PPIA (2) Forward 
AKP030 ATAGATGGACTTGCCGCCGG Rabbit PPIA (2) Reverse 
AKP035 CTCTGCTACGCGATGGTTGCTA Rabbit TFRC Forward 
AKP036 TCCGCGTTTTCTGACTGCTC Rabbit TFRC Reverse 
AKP037 TGGGTCTGTCATCCTGCTGG Rabbit PGK-1 Forward 
AKP038 TTGGCTGGTTCCGCTTTA Rabbit PGK-1 Reverse 
AKP207 TGTGGCCAACGACTCAACCC Rabbit ALAS (2) Forward 
AKP208 CGTCGTTGTGGCGGAAGATGTA Rabbit ALAS (2) Reverse 
AKP213 AGGAGTCTGGAGTCTGGATGGC Rabbit PBGD (3) Forward 
AKP214 TCCTCGTGGAATGTTCCGG Rabbit PBGD (3) Reverse 
Table 5. Reference gene primers for qRT-PCRs to establish reference gene stability. 





Having	  identified	  BACT	  and	  PPIA	  were	  clearly	  the	  most	  stable	  genes	  (figure	  61),	   it	  was	  decided	  that	  
these	   should	   be	   used	   as	   reference	   genes.	   GAPDH	   was	   included	   in	   all	   experiments	   as	   there	   is	   a	  
precedent	   for	   its	   use	   in	   comparing	   RNA	   from	   M.	   tb	   infected	   rabbit	   lungs	   (156,	   163,	   167).	  
Subsequently,	  multiple	  primers	  for	  each	  of	  the	  MMPs	  mapped	  in	  the	  rabbit	  genome	  as	  well	  as	  the	  4	  
TIMPs	  were	  selected	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5.2. Selection	  of	  MMP	  primers	  for	  qRT-­‐PCR	  
Below	   is	   a	   list	   of	   primer	   pairs	   that	  were	   trialled	   for	   each	   identifiable	  MMP	   in	   the	   rabbit	   genome	  
(Table	  6).	  
	  
Target	   Forward	  Primer	  ID	  
Forward	  Primer	  Sequence	  
(5'	  →	  3')	  
Reverse	  
Primer	  ID	  
Reverse	  Primer	  Sequence	  
(5'	  →	  3')	   Product	  Size	  (bp)	  
	   	   	   	   	   gDNA	   cDNA	  
MMP-­‐1	   NCA0212	   CAACTCTGGAGTAATGTCACACC	   NCA0213	   GAACATCCCCTCCAATGC	   408	   172	  
MMP-­‐2	   NCA0214	   GCAATACCTGAACACCTTCTACG	   NCA0215	   TATAGTTGGCCACATCC	   179	   179	  
MMP-­‐3	   NCA0216	   GCTCATGCTTATGCACCTGG	   NCA0217	   TACATCAGCGCTTCAGGGTTGG	   1720	   167	  
MMP-­‐7	   NCA0218	   AGGAGATGCAGAAGTTCTTTGG	   NCA0219	   TCTGGAAGTCCACTTCGG	   143	   143	  
MMP-­‐8	   NCA0220	   ATTTTATTTCCCTGTTCTGGCC	   NCA0221	   TTCATAGCCATTCAGAGC	   696	   122	  
MMP-­‐9	   NCA0222	   ACCTGTTCCGCTATGGTTACACC	   NCA0223	   TGGAATTTGCCCACGTCC	   181	   181	  
MMP-­‐10	   NCA0224	   CTACAACACCTTCACAGACCTGGC	   NCA0225	   GCATCGAAGGACAAAGCC	   373	   177	  
MMP-­‐11	   NCA0226	   GACCTTCACTGAGGTGCATGAGG	   NCA0227	   TTGGGGAAGAAGGCATGG	   207	   123	  
MMP-­‐12	   NCA0228	   TCAAGTATGGAGCGATGTGACC	   NCA0229	   TCCAATACCAGGTCCAGGC	   248	   163	  
MMP-­‐13	   NCA0230	   CTCATTCTGAAGTTGAAAAGGC	   NCA0231	   TCAAATGGGTAGAAGTCGC	   584	   148	  
MMP-­‐14	   NCA0232	   CAAAGCAACAGCTTCAGCC	   NCA0233	   TCATGGTGTCTGTATCGG	   3829	   172	  
MMP-­‐15	   NCA0234	   AGATGCAGCGCTTCTACGG	   NCA0235	   TTGGCTTTCACGTGCACC	   654	   118	  
MMP-­‐16	   NCA0236	   CAAGGAAAAATGACAGGCC	   NCA0237	   AAAACAAACATCTCACGGC	   130	   130	  
MMP-­‐17	   NCA0238	   ACGCAAGAGGAACTGTCCAAGGC	   NCA0239	   TTGTTCCACTTGGTCGG	   519	   185	  
MMP-­‐19	   NCA0240	   AAGGACCTCAGGTCTTCAGGC	   NCA0241	   GGGTCTTCTGATTGAAGG	   1342	   159	  
MMP-­‐20	   NCA0242	   AGCTACAAGCGTTCTTTGGC	   NCA0243	   GGAAGAGACGATAGTTCGC	   114	   114	  
MMP-­‐21	   NCA0244	   GATGATGACGAACACTTCACACCG	   NCA0245	   ACCAGTCCAACTCGAACGC	   404	   169	  
MMP-­‐24	   NCA0246	   CTGAAGCTCCATTTTCCCAGG	   NCA0247	   TTGTCTGATCCAGCACGC	   3110	   168	  
MMP-­‐27	   NCA0248	   CAAAGAGCCTTGATGTTCC	   NCA0249	   ATCCTGTGTCACAGGCATGG	   832	   160	  
MMP-­‐28	   NCA0250	   TACAAGCAGCACCTCTCCTACCG	   NCA0251	   CTTGGAAGAAGGTGAGGC	   172	   172	  
TIMP-­‐1	   NCA0264	   TGTCTGCTCTGCACACTTCGGC	   NCA0265	   GCAGGTTTGGAATCAGGGGC	   -­‐	   120	  
TIMP-­‐2	   NCA0266	   CGGAGAAGAACATCAACGGG	   NCA0267	   CCAGAAACTCCTGCTTGGGG	   111	   111	  
TIMP-­‐3	   NCA0268	   AAGCCTCTGAGAGTCTCTGTGGCC	   NCA0269	   TCCACGAAGTTGCACAGCCC	   475	   112	  
TIMP-­‐4	   NCA0270	   ACACTCAGAGAATGATCCGG	   NCA0271	   CACCACAGAGAGAAGAGTCA	   544	   114	  
MMP-­‐10(2)	   NCA0274	   ATGAACCATCTTGTCCTC	   NCA0275	   CCTTCTTTTGTGAGGTTG	   809	   143	  
TIMP-­‐3(2)	   NCA0278	   CTCTGAGAGTCTCTGTGG	   NCA0279	   TAGCGATAGTTCAGC	   522	   159	  
MMP-­‐3(2)	   AKP007	   GAGCCTCAAGGGATGCAGA	   AKP008	   AGCCAAGGAACTTCTGCA	   649	   156	  
MMP-­‐9(2)	   AKP009	   GTGACGCCACTCACCTTCAC	   AKP010	   TCGTCGAAGTGGGCATCTCC	   399	   167	  
MMP-­‐14(2)	   AKP011	   CACTGTCAGCTGCCATTG	   AKP012	   TCGGACATTGGCCTTGAT	   414	   146	  
MMP-­‐1	   AKP023	   CAACTCTGGAGTAATGTCACACC	   NCA0213	   GAACATCCCCTCCAATGC	   408	   172	  
MMP-­‐1	   AKP043	   CCCTGAAGATGATGAAGCAACC	   AKP044	   ACATCTGCCCTTGACAGGTCTG	   234	   142	  
HPRT-­‐1	   AKP045	   GCTCGAGATGTGATGAAGGAGA	   AKP046	   TCCCCTGTTGACTGGTCATTAC	   -­‐	   191	  
MMP-­‐2	   AKP047	   AGCCCAAGTGGGACAAGAATCA	   AKP048	   TTCGAGAAAACCGCAGCGG	   916	   138	  
MMP-­‐3	   AKP049	   AGGTGATACGCAAGCCCAGGTG	   AKP050	   CAATGGCAGCATCAACAGCA	   241	   150	  
MMP-­‐7	   AKP051	   TACTCACCACTCCCAAGCAGCC	   AKP052	   CCACAAGTTGAAAGCCTTTGCC	   218	   135	  
MMP-­‐8	   AKP053	   TCCTTGCCCATGCCTTTCAGCC	   AKP054	   TGAGCGAGCCCCAAGGAAT	   4478	   145	  
MMP-­‐9	   AKP055	   ACGTCAGGGGCATCCAGCAT	   AKP056	   GGTAGTGGGGTGCTCGGAGG	   1095	   146	  
MMP-­‐10	   AKP057	   GGAGGTGATACGCAAGCCCA	   AKP058	   GCATCTCTTGGCAGATCTGGTG	   226	   144	  
MMP-­‐11	   AKP059	   GTCACGCCACTGACCTTCACTG	   AKP060	   CCCCAGGCCCATCAAAGG	   190	   106	  
MMP-­‐12	   AKP061	   CTCGATGTGGAGTGCCTGATGT	   AKP062	   GCTTCATGTCTGGAGTGT	   1049	   111	  
MMP-­‐13	   AKP063	   TCCTCGAACACTCAAATGGTCC	   AKP064	   GGCCTTTTCAACTTCAGA	   1052	   91	  
MMP-­‐14	   AKP065	   TTCGATGGCGAGGGTGGCTT	   AKP066	   GCTCATGCACAGCCACCAGG	   646	   148	  
MMP-­‐1	   AKP067	   ACCTTCCCAAAATCCCAGTCAG	   AKP068	   GATTTGCCCGCATGTAGAACC	   1979	   137	  
MMP-­‐1	   AKP069	   ATTGACGCTGCTGTTTCTGAGG	   AKP070	   CCTTGTTTCCAATTCCTGGGA	   1991	   148	  
MMP-­‐2	   AKP071	   CCGCAGTGATGGCAAGATGTG	   AKP072	   GGGCTGCCACGAGGAACA	   1789	   107	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MMP-­‐2	   AKP073	   GACATCAAGGGCATTCAAGAGC	   AKP074	   GCGATGCCATCGAAGACGAT	   1177	   134	  
MMP-­‐3	   AKP075	   TCTCAAGATGATGTGGATGGCA	   AKP076	   AGTGCTGATTGCATCGAAGGAC	   337	   153	  
MMP-­‐3	   AKP077	   TGGCCATCTCTTCCTTCAGCA	   AKP078	   TGCTTCTTGGGTAACCAGCTTG	   878	   130	  
MMP-­‐7	   AKP079	   AGGAAACACACTGGCTCACGC	   AKP080	   CCAAGTTCATGAGTTGCCACGT	   2183	   135	  
MMP-­‐7	   AKP081	   CCACAGTGGGAACAGGCTCA	   AKP082	   CCAGTTATAGGCAGGCCAAAGA	   3114	   128	  
MMP-­‐8	   AKP083	   CAAGCACGTTTTCACTCCCTCA	   AKP084	   TGGTGGCAGCATCAAAGG	   2260	   138	  
MMP-­‐9	   AKP085	   ACCGCCAGCTACGACAAGGA	   AKP086	   TTGCCCAGGAAGACGAAGG	   429	   119	  
MMP-­‐9	   AKP087	   TCGCCGAGATAGGGAACAAGC	   AKP088	   GTCGGCGATGAGGAAGGG	   224	   104	  
MMP-­‐10	   AKP089	   TACCCAAAAGACATCCACACCC	   AKP090	   TCGCTCCATAGACTGGCTGC	   1173	   147	  
MMP-­‐10	   AKP091	   GCACGAAGGAGAGGCTGACA	   AKP092	   AACATCTCCATAAAGCCCAGGC	   557	   130	  
MMP-­‐11	   AKP093	   GGACACCAATGAGATAGCACCG	   AKP094	   GCGCAGCCTCCACACAAA	   237	   130	  
MMP-­‐11	   AKP095	   TGAGAGCCAGCAACCGACAG	   AKP096	   TGAGAGCCAGCAACCGACAG	   865	   92	  
MMP-­‐12	   AKP097	   CCCATGCCAAAACCTGACAATC	   AKP098	   ACGGACACTGGTCGTTGAACTC	   1313	   150	  
MMP-­‐12	   AKP099	   CCTGGGCTTCCCTGACTTTGTG	   AKP100	   TCAGCTTGGGATAACCAGCATC	   1941	   143	  
MMP-­‐13	   AKP101	   ACTCATTGCTGGTCCCTGCC	   AKP102	   TCCCGCAGGATTCAGAGGA	   212	   120	  
MMP-­‐13	   AKP103	   GAAGACCCCAACCCTAAACACC	   AKP104	   AGCTCTGCATCCACCTGCTGAG	   763	   149	  
MMP-­‐14	   AKP105	   CTGCCTGCGTCCATCAACA	   AKP106	   AGCCTCGTCAAACACCCA	   216	   90	  
MMP-­‐14	   AKP107	   GATCGATGCCGCTCTCTTCTG	   AKP108	   CGCTGTCCACTGCCCTGA	   522	   101	  
MMP-­‐15	   AKP109	   GCGGGGAGATGTTCGTGTTC	   AKP110	   AAACGGCCATCTTGGCGCTC	   410	   148	  
MMP-­‐15	   AKP111	   TTCGACGCCGATGAGCCC	   AKP112	   ATCCACTGGTAGAACGGCGC	   471	   149	  
MMP-­‐15	   AKP113	   GCTACCCCAAGCCCATCAGTGT	   AKP114	   GCGCTCGTTGTCGAATTTCC	   1178	   128	  
MMP-­‐16	   AKP115	   AACAGGACAGAAGTGGCAGCAT	   AKP116	   CATCAAAGGCACGGCGAA	   4939	   107	  
MMP-­‐16	   AKP117	   AGCACTGGAAGACGGTTGGAT	   AKP118	   AATACTGCTCCGTTCCGC	   103	   103	  
MMP-­‐16	   AKP119	   GGACTTTATGGGCTGTGATGGA	   AKP120	   GGCCAAGATGCAGGGAATGAC	   142	   142	  
MMP-­‐17	   AKP121	   CGCACCAGCGACCACAAGAT	   AKP122	   GCCGCGGGTATCCTTCCT	   3379	   88	  
MMP-­‐17	   AKP123	   TCTCCAAGGCCGACCACAA	   AKP124	   GGCCTCGTCGTCATCAAA	   123	   123	  
MMP-­‐17	   AKP125	   ATTGGGCTGGGCCATGTTG	   AKP126	   GGACACAGACTCCCGTACACCA	   1335	   144	  
MMP-­‐19	   AKP127	   GGCCCTCATGGCTCCTGTCTAT	   AKP128	   TGGGCAGCTCTGTCTCTTCTTC	   527	   140	  
MMP-­‐19	   AKP129	   GAATCGGATCGAGCCTAACCTG	   AKP130	   TTGGGGTAGCGGCTGAAGTC	   295	   129	  
MMP-­‐20	   AKP131	   TGAAAGGGATCCAGGCGTTGTA	   AKP132	   TCCCAGCATCGTCACAGCA	   2250	   140	  
MMP-­‐20	   AKP133	   CATGCATTTGCACCTGGAGAAG	   AKP134	   TTCATGAGCAGCGACCGT	   908	   111	  
MMP-­‐21	   AKP135	   AATGCAGCCCAACTACACTCCC	   AKP136	   CCTCCCCAAACTGGTTTCTCTC	   1225	   149	  
MMP-­‐21	   AKP137	   GTCAACAGGAACCAAGTGCCG	   AKP138	   AGAAGAGCGAGCCGTGCG	   133	   133	  
MMP-­‐24	   AKP139	   CCGTAGGCGGAGAAACAAGC	   AKP140	   TCAAAGGCCTGGCGAATAGC	   1576	   135	  
MMP-­‐24	   AKP141	   CCAAGGGGCCTTCATCAGCAAA	   AKP142	   TGCAGCCCATCCAGTCACG	   2595	   137	  
MMP-­‐27	   AKP143	   GCACTGGAAGTATGGAGCAACG	   AKP144	   TGACGAGGACATCGGCCA	   201	   133	  
MMP-­‐27	   AKP145	   CAAATCCATCCATACGCTCGGC	   AKP146	   CCATGGTTTGGGTCATCTCATC	   729	   137	  
MMP-­‐28	   AKP147	   AGGTGGCAGCAGACGGCAAT	   AKP148	   TCTCCAGCACCGACTCCCTT	   669	   140	  
MMP-­‐28	   AKP149	   CACAACGATGGGCTGGGCAA	   AKP150	   AGCACCACGAACAGGTTGCG	   2474	   149	  
TIMP-­‐1	   AKP151	   GTGGGGGCTCCAGAAGTCAATC	   AKP152	   TGCCCCAAGGCGTCAAAT	   631	   92	  
TIMP-­‐1	   AKP153	   ACTCCCACAAATCCCAGAACCG	   AKP154	   CGGAACGTTGAGAGAAGCTCAG	   404	   129	  
TIMP-­‐1	   AKP155	   GCCCGGACAGACGCTAGAGAAT	   AKP156	   TGAGGTGGGACACAGGTGCA	   1002	   116	  
TIMP-­‐2	   AKP157	   AGGTGGACTCTGGGAACGACA	   AKP158	   CGGGGCCTTTGAACATCT	   1128	   89	  
TIMP-­‐2	   AKP159	   CTGGACGTGGGAGGCAAGAA	   AKP160	   GGTTCAGGCTCTTCTTCTGCGT	   5747	   153	  
TIMP-­‐3	   AKP161	   ACGCCTTCTGCAACTCCGACAT	   AKP162	   ACGTGGGGCATCTTGGTGA	   -­‐	   139	  
TIMP-­‐3	   AKP163	   AGAATGAGTGCCTTTGGACCG	   AKP164	   TGCAGTAGCCGCCCTTTT	   99	   99	  
TIMP-­‐4	   AKP165	   TTAGAAGCCAACAGCCAGAAGC	   AKP166	   GGCTTTCCCTCTGCACCAAG	   2982	   127	  
TIMP-­‐4	   AKP167	   GCTGTTGCTGCGGCTGCT	   AKP168	   ACGTGCTGCTGGGGGTGC	   87	   87	  
EMMPRIN	   AKP183	   TGAAGAAGTCGGAGCACGCC	   AKP184	   TGGGAGCCGTTCTGGATGAC	   -­‐	   136	  
EMMPRIN	   AKP185	   GCTGGCTGAAAGGGAAGGAA	   AKP186	   TTGCCAAACCTGTCGTCC	   -­‐	   91	  
EMMPRIN	   AKP187	   CGGAGCTGCACATCAAGGAC	   AKP188	   CCACGATGCCCAGGAAGG	   -­‐	   150	  
TIMP-­‐1	   AKP189	   GGCCTTCTGCAACTCCGA	   AKP190	   TGCCCCAAGGCGTCAAAT	   1857	   126	  
MMP-­‐9	   AKP191	   CGCCAGCTACGACAAGGACA	   AKP192	   AAGTGGTGGCACACCAGAGG	   -­‐	   -­‐	  
CTSK	   AKP221	   TGGGGACTCAAGGTTCTGCTG	   AKP222	   CCCAAATTAAACGCCGAGAGA	   1589	   148	  
HO1	   AKP223	   TGAAGGAGGCCACCAAGGA	   AKP224	   TCCAGGGCCACGTAGATGTG	   2124	   136	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HO1	   AKP225	   CAGCTTGCCCCAGGATTTGTC	   AKP226	   TGGTACAGGGAGGCCATCACCA	   972	   147	  
HO1	   AKP227	   ATCGCCAGCGCCACCAAGTT	   AKP228	   GCAGCTCCTGCAACTCCTCAA	   1215	   148	  
Table 6. Primer pairs trialed prior to qRT-PCR analysis. 
	  
	  
From	  these	  primers,	  those	  that	  most	  reliably	  produced	  a	  single	  peak	  under	  melt-­‐curve	  analysis,	  and	  
an	  efficiency	  of	  between	  1.8	  and	  2.2	  by	  Ramaker’s	  linear	  regression	  analysis	  (172)	  were	  selected	  to	  
carry	   out	   preliminary	   analysis	   of	   MMP	   expression	   in	   cavity	   vs	   non-­‐cavity	   tissue	   (table	   7):
	  
Table 7. Primer pairs used preliminary analysis qRT-PCR analysis. 
	  
	  
This	  preliminary	  data	  is	  shown	  in	  figure	  62.	  





This	  preliminary	  data,	  which	   is	  not	   intended	  to	  be	  used	  to	  draw	  conclusions	  about	  expression,	  was	  
used	   instead	  to	   refine	  the	  assays	   for	   future	  experiment	  but	  also	  allowed	  for	  several	  conclusions	  to	  
be	  drawn.	  Most	  importantly,	  although	  primers	  had	  previously	  shown	  amplification	  of	  certain	  MMPs,	  
the	   primers	   did	   not	   regularly	   amplify	   product	   for	   a	   number	   of	   amplicons:	   MMP-­‐8,	   MMP-­‐10	   and	  
MMP-­‐27.	  Very	  low	  levels	  of	  MMP21	  and	  24	  were	  detected.	  MMPs	  -­‐1,	  -­‐2,	  -­‐3,	  -­‐7,	  -­‐9,	  -­‐12,	  -­‐13,	  -­‐14,	  -­‐15,	  
-­‐16,	   -­‐17	   and	   -­‐19	   and	   TIMPs	   -­‐1,-­‐2,-­‐3	   and	   -­‐4	  were	   detected	   reliably	   detected	   in	   cavity	   samples.	   Of	  
	  
these,	  only	  MMP-­‐9,	  -­‐12,	  -­‐14,	  -­‐15,	  -­‐16,	  -­‐17	  and	  -­‐19	  and	  the	  TIMPs	  were	  detected	  in	  normal	  tissue.	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5.3. Preliminary	  evaluation	  of	  MMP	  expression	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Different	  experimental	  modalities	  and	  dissection	  techniques	  were	  used	  in	  each	  of	  these	  preliminary	  
studies.	   The	   primary	   observation	   from	   these	   data	   is	   that	   there	   is	   significant	   variation	   in	   the	  
expression	  levels	  of	  genes	  in	  rabbit	  tissue,	  and	  that	  the	  method	  of	  dissection	  can	  make	  a	  significant	  
difference	   in	   attempting	   to	   define	   these	   differences.	   Figure	   63B	   demonstrates	   that	  when	   tissue	   is	  
dissected	   from	   the	   cavity	   immediately	   after	   cavitation	   and	   compared	   to	   tissue	   from	   distant	   sites,	  
MMP-­‐1,	   -­‐3	  and	   -­‐13	   are	  highly	  upregulated.	   Figure	  63C	  demonstrates	   that	   the	  expression	  of	  MMPs	  
remains	  constant	  between	  closely	   related	  but	  normal	   tissue	  as	  compared	  to	  cavity	  wall	   tissue,	  and	  
suggests	   that	   either	   the	   imprecise	   dissection	   method	   confounds	   results,	   or	   the	   adjacent	   tissue	  
grossly	  healthy	  tissue	  may	  have	  a	  similar	  pattern	  of	  MMP	  and	  TIMP	  expression	  to	  cavity	  tissue.	  
	  
Having	   established	   that	   the	   dissection	   technique	   used	   in	   figure	   63B	   was	   most	   ideally	   suited	   for	  
examining	   differences	   in	   gene	   expression	   between	   affected	   and	  unaffected	   tissue;	  we	  went	  on	   to	  
further	   examine	   these	   tissues	   by	   RNA-­‐Seq	   –	   a	   non-­‐biased,	   next-­‐generation	   whole-­‐transcriptome	  
sequencing	  approach,	  that	  allows	  for	  determination	  of	  the	  concentration	  of	  each	  RNA	  species	  within	  
a	  sample.	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5.4. RNA-­‐Seq	   analysis	   of	   cavitary	   lung	   tissue,	   non-­‐cavitary	   infected	   lung	  
tissue,	  and	  uninfected	  lung	  tissue	  
RNA	  	  was	  	  isolated	  	  from	  	  lung	  	  tissue	  	  from	  	  animals	  	  infected	  	  with	  	  M.	  	  tb	  	  immediately	  	  after	  	  cavity	  
	  
formation	   (as	   identified	  by	  CT).	   Cavity	  wall	  was	  paired	  with	  healthy	  RNA	   from	  each	  of	  3	   rabbits,	  a	  
comparison	  was	   also	  made	   between	   the	   three	   healthy	   tissue	   samples	   and	   tissue	   from	   uninfected	  
rabbit	   lung.	   The	   mRNA	   was	   sequenced	   on	   the	   ABI	   Solid	   platform,	   and	   mapped	   to	   the	   oryCun2	  
(GCA_000003625.1)	  sequence.	  More	  than	  17000	  transcripts	  were	  mapped.	  





The	   transcriptome	   analysis	   suggested	   2	   main	   things.	   First,	   that	   the	   expression	   pattern	   in	   these	  
animals	   is	   relatively	   reproducible;	  as	  shown	  by	   the	   large	  number	  genes	  which	  differed	  significantly	  
between	  healthy	  and	  cavity	  tissue	  but	  not	  between	  similar	  tissue	  types	  in	  different	  animals.	  Second,	  
that	  healthy	  tissue	  from	  infected	  animals	  is	  very	  similar	  to	  uninfected	  tissue,	  as	  shown	  by	  the	  limited	  
fold	  change	  across	  all	  genes	  assessed	  (figure	  64).	  The	  remaining	  analysis	  was	  conducted	  by	  making	  
comparisons	  between	  paired	  infected	  cavity	  and	  non-­‐cavity	  tissues.	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To	  better	  understand	  the	  nature	  of	   the	  genes	   involved,	  pathway	  analysis	  was	  performed	  using	  the	  
‘Consensus	   Pathway	   Database’	   (CPDB)	   (213,	   214).	   This	   allows	   for	   investigation	   of	   enrichment	   and	  
over	   representation	   analysis	   of	   a	   number	   of	   different	   pathway	   reference	   sources.	   Amongst	   these,	  
KEGG	  (Kyoto	  Encyclopedia	  of	  Genes	  and	  Genomes)	  pathways	  are	  perhaps	  the	  most	  commonly	  used	  
when	  assessing	  disease	  processes.	  The	  KEGG	  database	  is	  a	  collection	  of	  manually	  curated	  pathways,	  
which	   ‘represent	   our	   knowledge	   on	   the	  molecular	   interaction	   and	   reaction	   networks’	   for	  multiple	  
processes	   (215,	  216).	   48	  pathways	  were	   found	   to	  be	   significantly	   enhanced	   in	  cavity	   vs	  non-­‐cavity	  
tissue.	   Genes	   involved	   in	   the	   response	   to	   tuberculosis	   in	   man	   were	   highly	   enriched;	   more	   genes	  
associated	   with	   this	   process	   were	   enriched	   than	   from	   any	   other	   mapped	   process	   (figure	   65).	   A	  
second	  pathway	   database,	   Reactome,	  was	   used	   to	   further	   assess	   the	   genes	   involved.	   Reactome	   is	  
also	  an	  open-­‐source,	  open	  access,	  manually	  curated	  and	  peer-­‐reviewed	  database	  (217-­‐219).	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Using	  two	  separately	  curated	  databases	  to	  assess	  this	  data	  set	   independently	  suggested	  that	  many	  
genes	  involved	  in	  human	  reponses	  to	  M.	  tb	  were	  found	  to	  change	  in	  this	  infection	  model	  (figure	  65	  
and	  66).	  Clearly	  pathway	  analysis	  is	  of	  limited	  practical	  value,	  especially	  when	  there	  are	  limited	  data	  
sets,	   and	   limited	   correlation	   (presently)	   between	   rabbit	   and	  human	   databases.	  However,	   the	   data	  
presented	  above	  is	  a	  useful	  summary	  of	  the	  types	  of	  gene	  expression	  changes	  seen	  within	  the	  tissue.	  
Making	  strong	  claims	  based	  on	  such	  data	  is	   inappropriate,	  but	  does	  facilitate	  description	  of	  general	  
changes.	  Such	  curated	  databases	  are	  subject	  to	  editor	  bias,	  as	  well	  as	  field	  bias.	  
	  
These	  general	   changes	   show	  a	   strong	   involvement	  of	   immune	   repsonses	   to	   infection,	   complement	  
activation,	  and	  a	  degree	  of	  auto-­‐inflammatory	  activity.	  Finally,	  a	  number	  of	  pathways	  related	  to	  ECM	  
turnover	  are	  described.	  This	  was	  of	  great	   interest	  given	  the	  hypothesis	  that	  such	  processes	  may	  be	  
therapeutically	   targetable	   (84,	   109,	   118,	   171),	   but	   previously	   have	   not	   been	   identified	  models	   of	  
disease	  where	  therapeutic	  trials	  could	  occur.	  
	  
Because	  the	  process	  of	  collagen	  turnover	  does	  not	  have	  a	  well-­‐curated	  pathway,	  the	  RNA-­‐Seq	  data	  
was	   manually	   mined	   for	   expression	   of	   genes	   involved	   in	   collagen	   turnover.	   First,	   MMPs	   were	  
identified	  (figure	  67).	  





As	   expected	   there	   was	   increased	   transcription	   of	   the	   collagenase	   members	   of	   the	   MMP	   family	  
MMP-­‐1,	   -­‐13,	   and	   -­‐14	   (only	   3	   MMP-­‐8	   transcripts	   were	   detected).	   Additionally,	   there	   was	   high	  
expression	  of	  MMP-­‐12	  (macrophage	  metalloelastase).	  Suprisingly	  no	  reads	  were	  mapped	  for	  MMP-­‐	  
9.	  





The	  strong	  divergence	  in	  the	  types	  of	  collagens	  expressed	  between	  apparently	  normal	  and	  cavitary	  
tissue	   was	   unexpected.	   Increases	   in	   fibrillar	   types	   I	   and	   III	   collagen	   are	   associated	   with	   fibrotic	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processes,	   but	   the	   decrease	   in	   expression	  of	   all	  mapped	   components	   of	   type	   IV	   collagen,	   suggest	  
that	  maintenance	  of	  the	  basement	  membrane	  ECM	  is	  disrupted.	  
	  
Next,	  peptidases	  were	  identified	  by	  Gene	  Ontology	  (GO)	  number	  (GO:0008233)	  (220),	  in	  an	  attempt	  
to	   identify	   other	   matrix	   regulating	   proteases	   that	   may	   be	   upregulated	   in	   cavity	   as	   compared	   to	  
normal	  tissue.	  





This	  unbiased	  approach	  also	  revealed	  signficant	  increases	  in	  cathepsin	  expression	  (CTS-­‐)	  and	  caspace	  
expression	  	  (CASP-­‐)	  	  as	  	  well	  	  as	  	  the	  	  already	  	  discussed	  	  MMPs	  	  (MMP-­‐).	  	  Cathepsin	  	  K	  	  (CTSK),	  	  which	  
functions	  as	  a	  fibrillar	  collagenase	  at	  acidic	  pH	  (221,	  222)	  was	  an	  interesting	  and	  novel	  finding.	  The	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remaining	  proteases	  do	  not	  have	  identified	  collagenolytic	  activty	  (221,	  222).	  To	  confirm	  the	  presence	  
of	   proteolytic	   activity,	   we	   designed	   a	   small	   experiment	   in	   order	   to	   observe	   whether	   collagen	  
degradation	  was	  occuring.	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5.5. Evaluation	   of	   collagen	   degradation	   as	   a	   biomarker	   in	   the	   rabbit	  
model	  
Having	  	  identified	  	  that	  	  collagen	  	  turnover	  	  and	  	  MMP	  	  activity	  	  were	  	  strongly	  	  associated	  	  with	  	  the	  
	  
development	   of	   cavities,	   it	   became	   rational	   to	   investigate	   if	   collagen	   turnover	   could	   be	   used	   as	   a	  
biomarker	   of	   cavitary	   disease.	   By	   examining	   serum,	   plasma	   and	   urinary	   levels	   of	   collagen	  
degradation	  products,	  it	  became	  clear	  that	  even	  with	  a	  small	  sample	  size,	  changes	  in	  pulmonary	  lung	  
collagen	   are	   likely	   reflected	   in	   peripheral	   breakdown	   products	   (figure	   70).	   Although	   only	   a	   few	  
samples	  were	  available	   for	  this	  study,	  the	  data	  strongly	   indicate	   that	  collagen	  breakdown	  products	  
are	   indicative	  of	   cavity	   specific	  process	   in	  M.	   tb	   infection	  of	   rabbits.	  Further	   investigation	  of	   this	   is	  
warranted,	  since	  this	  may	  allow	  for	  a	  marker	  of	  effectiveness	  of	  ECM-­‐protective	  therapies	  in	  TB,	  or	  
may	  be	  a	  marker	  for	  disease	  severity	  in	  clinical	  trials.	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Having	  confirmed	  that	  collagen	  turnover	  was	  indeed	  occurring,	  we	  set	  out	  to	  refine	  the	  observations	  
of	  gene	  expression	  changes	  in	  the	  rabbit	  model	  of	  cavitary	  tuberculosis,	  by	  conducting	  a	  larger	  scale	  
analysis	   of	   time-­‐matched	  animals,	   looking	   at	   differences	   in	  expression	   between	   cavity,	   near	   cavity	  
and	  distant	  tissue.	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5.6. Characterisation	  of	  collagen	  degrading	  MMPs,	  CTSK	  and	  TIMPs	  in	  the	  
70	  day	  cavity	  model	  of	  tuberculosis	  
To	  characterise	  MMP	  expression	  in	  rabbit	   lungs,	  real	  time	  qRT-­‐PCR	  primers	  were	  designed	  with	  an	  
	  






Table 8. Primers utilised for qRT-PCR analysis of MMPs, TIMPs, CTSK and HO1 in rabbit 
pulmonary tissue: NCBI gene references are listed, primers listed in 3’ to 5’ direction.
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Table 9. Sanger sequenced products from qRT-PCR reactions with the primers for MMP, TIMP, 
CTSK and HO1 expression analysis in rabbit pulmonary tissue:  Products of the qRT-PCR 
reactions were first subjected to electrophoresis to determine size, prior to extraction and Sanger 
sequencing at the GeneWiz facility. Sequences were reassembled using Vector NTI.  
	  
These	  high	  quality	  primer	  sets	  were	  used	  to	  assess	  gene	  expression	  (figure	  71-­‐74).	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MMP-­‐1,	  MMP-­‐13	   and	   CTSK	   were	   all	   substantially	   and	   significantly	   unregulated	   in	   cavity	   tissue	   as	  
compared	  to	   infected	  normal	  tissue.	  MMP-­‐8	  was	  not	  detected	  at	  the	  transcript	   level,	  although	  this	  
does	   not	   rule	   out	   is	   involvement,	   because	  MMP-­‐8	   is	   commonly	   stored	   as	   a	   protein	   in	   neutrophils	  
(223),	  and	  so	   transcription	  may	  not	  occur	  at	   the	  site	  of	  activity.	  MMP-­‐14	  expression	  was	   relatively	  
high	   in	   all	   tissue	   types,	   and	   a	   trend	   towards	   increased	   expression	   in	   more	   diseased	   tissue	   was	  
observed,	   the	   two	   outlying	   points	   in	   the	   cavity	   and	   non-­‐cavity	   samples,	   (which	   are	   not	   statistical	  
outlier’s	  by	  Grubb’s	  test),	  result	  from	  high	  MMP-­‐14	  expression	  in	  the	  normal	  tissue	  of	  this	  animal.	  





Interestingly,	   there	   was	   no	   significant	   increase	   in	  MMP-­‐9	   expression	   dependent	   on	   sampling	   site.	  
MMP-­‐2	  expression	  was	  statistically	  significantly	  lower	  in	  the	  near	  cavity	  tissue.	  MMP-­‐3	  showed	  very	  
high	  expression	  associated	  with	  tissue	  pathology.	  MMP-­‐10	  showed	  an	  upwards	  trend.	  MMP-­‐7	  and	  -­‐	  
12	  were	  both	  significantly	  upregulated	  in	  pathological	  as	  compared	  to	  grossly	  normal	  tissue.	  





TIMP-­‐1	  expression	  was	  significantly	  increased	  in	  cavity	  as	  compared	  to	  other	  tissues,	  whereas	  TIMP-­‐	  
3	  was	   down-­‐regulated.	   TIMP-­‐2	   and	   -­‐4	   did	   not	   change	   significantly.	   (TIMP-­‐4	   levels	  were	   extremely	  
low	  as	  estimated	  by	  CT	  value	  –	   figure	  71).	   It	   is	   surprising	   that	  despite	   increases	   in	  MMPs-­‐1,	   -­‐3,	   -­‐7,	  
and	  -­‐12	  in	  near	  cavity	  tissue,	  TIMP’s	  do	  not	  significantly	  increase.	  This	  imbalance	  in	  TIMP:MMP	  ratio	  
would	   suggest	   that	   a	   collagenolytic	   environment	  occurs	   in	   infected	   tissue.	   The	  down-­‐regulation	  of	  
TIMP-­‐3	   is	   surprising.	   TIMP-­‐3	   is	  known	  to	   inhibit	  angiogenesis	   (224),	  and	   its	  down	  regulation	  would	  
suggest	   there	   may	   be	   neovascularisation	   in	   this	   region.	   Although	   further	   investigation	   of	   this	  
hypothesis	   is	  beyond	  the	  scope	  of	   this	   thesis,	   this	  may	  have	  ramifications	   for	   immune	  cell	  delivery	  
and	  tissue	  hypoxia.	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Since	   gene	   expression	   does	   not	   correlate	   directly	   with	   protein	   levels,	   confirmation	   of	   protein	  
expression	  was	  sought.	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5.7. MMP-­‐1	  protein	  levels	  are	  increased	  in	  cavity	  as	  compared	  to	  normal	  







































MMP-­‐1	   protein	   levels	   in	   snap-­‐frozen,	   homogenized	   and	   filtered	   lung	   tissue	   were	   assayed	   by	   a	  
commercially	   available	   ELISA.	   This	   demonstrated	   that	   MMP-­‐1	   was	   indeed	   upregulated	   at	   the	  
protein	  level	  in	  cavity	  wall	  tissue	  as	  compared	  to	  normal	  tissue	  from	  infected	  animals	  (figure	  75).	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5.8. Identification	   of	   enzymatically	   active	  MMP-­‐1	   in	   rabbit	   tissue	   which	  





























Protein	  was	  extracted	  from	  infected	  rabbit	  lung	  homogenate	  and	  analysed	  by	  substrate	  zymography	  
(figure	   76).	   This	   method	   involves	   distribution	   of	   protein	   through	   a	   substrate	   containing	   gel	   by	  
electrophoresis,	   followed	  by	   incubation	   in	  a	  neutral	  buffer,	  which	  facilitates	  enzymatic	  degradation	  
of	   the	  substrate	   (225).	   Staining	  of	   the	   gel	   reveals	  enzyme	  activity	   as	  uncoloured	   regions	  devoid	  of	  
the	   substrate.	   Enzymatic	   digestion	   of	   both	   casein	   and	   gelatin	   corresponding	   to	   the	   molecular	  
weights	  of	  pro	  and	  active	  MMP-­‐1	  indicated	  that	  the	  protein	  has	  proteolytic	  activity.	  MMP-­‐1	  activity	  
was	   challenging	   to	   visualise	   due	   to	   high	   levels	  of	  protein	   in	   the	   samples.	  MMP-­‐1	   activity	   could	  be	  
inhibited	   by	   Ro32-­‐3555,	   a	   collagenase	   specific	   MMP	   inhibitor	   (figure	   76B).	   This	   drug	   completed	  
phase	  III	  trials	  for	  treatment	  for	  rheumatoid	  arthritis	  but	  was	  withdrawn	  due	  to	  lack	  of	  efficacy	  (226,	  
227).	  The	  drug	  has	  potential	  to	  be	  trialled	  in	  the	  70	  day	  rabbit	  model,	  to	  evaluate	  the	  role	  of	  MMP-­‐1	  
in	  cavity	  formation.	  Similarly,	  Cathepsin	  K	  is	  also	  the	  target	  of	  novel	  inhibitor,	  Odanacatib,	  which	  has	  
demonstrable	   efficacy	   in	   man	   (228-­‐233).	   However,	   cathepsin	   K	   expression	   had	   not	   yet	   been	  
confirmed	  in	  man.	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5.9. Cathepsin	  K	  is	  associated	  with	  TB	  pathology	  in	  man	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To	   confirm	   the	   presence	   of	   Cathepsin	   K	   in	   human	   tissue	   associated	  with	  M.	   tb	   infection,	   human	  
tissue,	   resected	   for	   diagnosis	   of	   suspected	   malignancy,	   and	   discovered	   instead	   to	   be	   TB	   (by	  
pathology	   and	   acid	   fast	   staining),	   was	   stained	   for	   cathepsin	   K	   (figure	   77).	   This	   demonstrated	   that	  
cathepsin	   K	   was	   abundantly	   expressed	   and	   is	   associated	   with	   TB	   pathology.	   In	   particular,	   its	  
expression	   localised	   to	   the	  periphery	  of	   large	  necrotic	   regions	  and	  multinucleate	  giant	   cells.	  These	  
pathologies	  have	   a	   known	  association	  with	  high	  bacterial	   burdens,	   and	   this	   localisation	   suggests	   a	  
specific	  relationship	  between	  cathepsin	  K	  expression	  and	  infection.	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5.10. Summary	  
These	  studies	  demonstrate	   that	  MMP-­‐1,	  at	   the	  transcriptional,	  protein	  and	  enzymatic	  activity	   level	  
were	   found	   in	   the	   rabbit	   model.	   Both	   hypothesis	   driven,	   and	   unbiased	   screening	   approaches,	  
identified	  a	  role	  for	  MMP-­‐1	  and	  collagen	  turnover.	  This	  reflects	  what	   is	  seen	  in	  human	  disease	   (99,	  
105,	  107,	  109,	  110,	  114).	  In	  addition	  to	  this,	  cathepsin	  K,	  identified	  by	  whole	  genome	  sequencing	  in	  
rabbits,	   was	   shown	   to	   be	   associated	   with	   TB	   pathology,	   other	   than	   multinucleate	   giant	   cells	   (as	  
shown	  very	  recently	  by	  Halushka	  et	  al.	  (173)).	  Like	  MMP-­‐1,	  this	  enzyme	  is	  also	  easily	  targetable	  with	  
a	   drug,	   Odanacatib,	  with	   demonstrable	   safety	   in	   humans	   even	   after	   upwards	  of	   5	   years	   exposure	  
(228-­‐233).	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6. The	  Role	  of	  cAMP	  in	  M.	  tuberculosis	  	  Induced	  MMP-­‐1	  Secretion	  
	  
	  
Having	  identified	  that	  MMP-­‐1	  expression	  was	  present	  in	  the	  rabbit	  model	  of	  TB,	  further	  methods	  for	  
targeting	  its	  secretion	  and	  activity	  were	  investigated.	  Whilst	  the	  drug	  Ro32-­‐3555	  can	  prevent	  MMP-­‐1	  
activity,	  its	  failure	  to	  complete	  clinical	  trials	  has	  meant	  that	  there	  are	  no	  longer	  manufacturers	  of	  the	  
drug.	   Custom	   synthesis	   is	   available,	   but	   it	   is	   costly	   to	  manufacture.	   Previous	   experiments	   suggest	  
that	   pathways	   targeted	   by	   commonly	   available	   and	   cheap	   drugs	  may	   alter	  MMP-­‐1	   secretion	   and	  
therefore	  negate	  such	  cost	  (116,	  117).	  
	  
M.	  tb	  may	  deregulate	  host	  cellular	  pathways	  to	  induce	  excessive	  MMP-­‐1	  secretion.	  MMP-­‐1	  secretion	  
is	  substantially	  greater	   in	  response	  to	  M.	  tb	  than	  non-­‐pathogenic	  M.	  bovis	  BCG	  (116),	  and	  this	  may	  
benefit	  the	  bacteria	  by	  allowing	  transmission	  (53,	  54,	  109).	  Volkman	  et	  al.	  have	  shown	  that	  ESAT-­‐6	  
secretion	  modulates	  MMP-­‐9	  secretion	  by	  host	  epithelial	  cells	  (111)	  but	  as	  of	  yet	  no	  bacterial	  factor	  
has	  been	   identified	   that	   specifically	   upregulates	  MMP-­‐1	   activity.	  Agarwal	  et	  al.	  demonstrated	   that	  
the	  M.	  tb	  gene	  Rv0386,	  which	  encodes	  an	  adenylate	  cyclase	  (an	  enzyme	  that	  converts	  ATP	  to	  cAMP),	  
was	  required	  for	  virulence	  (234).	  They	  proposed	  that	  this	  adenylate	  cyclase	  was	  part	  of	  a	  mechanism	  
that	   delivered	   cAMP	   into	   the	   host	   macrophage	   (cAMP	   is	   polarised	   and	   cannot	   diffuse	   across	  
membranes)	  to	  alter	  TNFα	  secretion	  (234).	  cAMP	  synthesis	   is	  required	  for	  MMP-­‐1	  secretion	  during	  
M.	   tb	   infection	   (116).	   It	   has	   also	   been	   observed	   that	   exogenous	   cAMP	   can	   augment	   collagenase	  
secretion	   from	   lipopolysaccharides	   (LPS)	   stimulated	   macrophages	   (235).	   Inhibition	   of	   COX	  
enzymes	   results	   in	   decreased	   MMP-­‐1	   secretion	   that	   can	   subsequently	   be	   restored	   by	   adding	  
dibutyryl	  cAMP	  (dbcAMP);	  a	  membrane	  permeable	  cAMP	  analogue	  (114,	  117).	  cAMP	  plays	  this	  role	  
as	  part	  of	  a	  p38	  mitogen	  activated	  protein	  kinase	  (MAPK)	  dependent	  signalling	  cascade:	  p38	  MAPK	  
signalling	   leads	   to	   increased	   levels	   of	   cyclo-­‐oxygenase	   (COX)	   enzymes	   which	   synthesise	  
prostaglandin	  	  E2	  	  	  (PGE2),	  	  PGE2	  	  	  accumulation	  	  leads	  	  to	  	  host	  	  adenylate	  	  cyclase	  	  activity	  	  and	  	  cAMP	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production.	  cAMP	  regulates	  a	  number	  intracellular	  signalling	  pathways,	  most	  notably	  protein	  kinase	  
A	  (PKA).	  We	  hypothesised	  that	  M.	  tb	  secretes	  cAMP	  to	  drive	  MMP-­‐1	  secretion.	  A	  number	  of	  readily	  
available	   and	   safe	   drugs	   are	   approved	   for	   altering	   cAMP	   levels	   (COX	   inhibitors	   and	  
phosphodiesterase	  inhibitors).	  
	  
To	   investigate	   the	   relationship	   between	   MMP-­‐1	   and	   this	   promising,	   straightforward,	   therapeutic	  
intervention,	  a	  series	  of	  in	  vitro	  experiments	  were	  designed	  to	  establish	  the	  role	  of	  cAMP	  in	  MMP-­‐1	  
secretion	  by	  macrophages	  infected	  with	  M.	  tb.	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6.1. Experimental	  protocol	  
Human	  blood	  monocytes	  were	  isolated	  by	  ficoll	  centrifugation	  and	  adhesion	  purification.	  They	  were	  
then	  matured	   into	  macrophages.	   Infection	  was	   simulated	   either	   by	   the	   addition	   of	   sterile-­‐filtered	  
culture	  supernatant	  (TB	  Sup)	  or	  infection	  with	  M.	  tb	  H37Rv	  at	  a	  MOI	  of	  1.	   If	  live	  infection	  was	  used,	  
the	  supernatant	  was	  changed	  2	  hours	  after	   infection	  to	  remove	  any	  non-­‐phagocytosed	  bacteria.	  At	  
72	  hours	  cell	  supernatant	  was	  harvested.	  MMP	  content	  was	  analysed	  using	  either	  ELISA	  or	  multiplex	  
bead-­‐array	   analysis	   (Luminex).	   The	  data	  below	  are	   representative	  of	  3	   experiments	   and	  error	  bars	  
represent	  standard	  deviations.	  We	  have	  previously	  observed	  that	  donor-­‐to-­‐donor	  variation	  leads	  to	  
inter-­‐experimental	   variation	   in	   absolute	   MMP	   secretion,	   but	   that	   changes	   in	   MMP	   secretion	   are	  
reproducible	  (114,	  116).	  
	  
Sterile-­‐filtered	   culture	   supernatant	   from	   logarithmically	   growing	   M.	   tuberculosis	   (TB	   Sup)	   was	  
utilised	  to	  model	  infection	  in	  the	  absence	  of	  live	  bacteria.	  TB	  Sup	  contains	  a	  number	  of	  TB	  antigens	  
capable	   of	   driving	   MMP	   secretion	   and	   its	   use	   means	   that	   alterations	   in	   host	   responses,	   can	   be	  
investigated	   without	   confounding	   alterations	   in	   bacterial	   behaviour	   or	   growth	   leading	   to	   indirect	  
alterations	  to	  host	  cell	  behaviour.	  
	  
Cyclic	  AMP	  (cAMP)	   is	  not	  membrane-­‐permeable,	  so	  a	  permeable,	  water-­‐soluble	  analogue	  of	  cAMP,	  
dibutyryl	   cAMP	   (dbcAMP)	   is	   used	   to	   model	   the	   effect	   of	   exogenous	   cAMP.	   The	   first	   experiment	  
aimed	   to	   establish	   whether	   cAMP	   alone	   induced	   MMP-­‐1	   secretion	   from	   primary	   human	  
macrophages.	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6.2. Exogenous	   cAMP	   does	   not	   increase	   MMP-­‐1	   secretion	   from	   non-­‐	  
stimulated	  or	  highly-­‐stimulated	  macrophages:	  
First,	   the	   effect	   of	   adding	   exogenous	   cAMP	   to	   macrophages	   with	   and	   without	  	  M.	   tuberculosis-­‐	  
	  
derived	  stimulation	  was	  investigated.	  MMP-­‐1	  secretion	  did	  not	  increase	  in	  the	  presence	  of	  dbcAMP	  
alone,	  which	  is	  in-­‐keeping	  with	  previous	  observations	  (235).	  MMP-­‐1	  was	  significantly	  upregulated	  by	  
a	   1:40	   dilution	   of	   TB	   Sup	   (Figure	   79).	   This	   dilution	   was	   used	   because	   our	   group	   has	   shown	   that	  
similar	   dilutions	   of	   supernatant	   from	   M.	   tuberculosis	   infected	   monocytes	   (CoMtb)	   drive	   MMP-­‐1	  
secretion	   from	  primary	  macrophages	   (114).	   The	   high	   level	   of	  MMP-­‐1	   secretion	   demonstrates	   that	  
this	  dilution	  of	  TB	  Sup	  is	  a	  very	  potent	  stimulus	  for	  the	  induction	  of	  MMP-­‐1	  secretion.	  Unexpectedly,	  
when	  dbcAMP	  was	  added	  to	  this	  stimulus	  MMP-­‐1	  secretion	  was	  unchanged	  at	   low	  concentrations,	  
and	   decreased	   at	   higher	   concentrations.	   At	   10uM	   dbcAMP	  MMP-­‐1	   secretion	  was	   50%	   lower	   than	  
with	  TB	   Sup	  alone	  and	  at	   50uM	  dbcAMP	  a	  90%	   reduction	   in	  MMP-­‐1	   secretion	  was	  observed.	  This	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6.3. Even	   in	   minimally	   stimulated	   cells,	   exogenous	   cAMP	   does	   not	  
increase	  MMP-­‐1	  secretion	  
McCarthy	  et	  al.	  had	  previously	  described	  that	  very	  high	  levels	  (100-­‐500μM)	  of	  dbcAMP	  resulted	  in	  a	  
	  
decreased	   in	   collagenase	   secretion	   in	   LPS	   stimulated	   macrophages	   (235).	   Elkington	   et	   al.	  
demonstrated	   that	  M.	   tb	   infection	  of	  macrophages	   leads	   to	   PGE2	  production,	  which	   then	   leads	   to	  
increased	  host	  adenylate	  cyclase	  activity	  and	   increased	  host	  cAMP	  production	   (114).	  The	  results	   in	  
section	   6.3	   suggested	   that	   perhaps	   endogenous	   cAMP	   was	   already	   reaching	   a	   level	   that	   led	   to	  
maximal	   MMP-­‐1	   secretion.	   It	   was	   hypothesised	   that	   reducing	   this	   stimulus,	   may	   allow	   for	   easier	  
identification	   of	   a	   role	   for	   exogenous	   cAMP	   in	   	   driving	   	  MMP-­‐1	   secretion.	   In	   order	   to	   select	   an	  





This	  demonstrated	  that	  increasing	  the	  concentration	  of	  TB	  Sup	  resulted	  in	  more	  MMP-­‐1	  secretion	  in	  
a	  dose	  dependent	  fashion.	  It	  was	  decided	  that	  a	  TB	  Sup	  dilution	  of	  1:200	  should	  be	  used	  for	  further	  
experiments,	   as	   this	   allows	   for	   an	   observable	   increase	   in	   MMP-­‐1	   secretion.	   Additionally,	   a	   larger	  
range	  of	  dbcAMP	  concentrations	  was	  used	  to	  evaluate	   the	  effect	  of	  cAMP	  on	  MMP-­‐1	  secretion	   in	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this	   low-­‐stimulation	  model.	   Figure	   80B	   shows	   that	   exogenous	   cAMP	  did	   not	   substantially	   increase	  
MMP-­‐1	  secretion	  from	  TB	  Sup	  stimulated	  cells,	  even	  when	  the	  stimulus	  was	  reduced	  to	  allow	  for	  an	  
increase	   in	   MMP-­‐1	   secretion.	   A	   significant	   but	   small	   increase	   in	   MMP-­‐1	   secretion	   at	   low	  
concentrations	  of	  dbcAMP	  (0.1-­‐5.0μM)	  may	  be	  masked	  in	  this	  data	  by	  the	  increased	  variability	  of	  the	  
TB	   only	   stimulated	   cells	   in	   this	   experiment	   (black	   bar).	   This	   data	   does	   not	   suggest	   that	   cAMP	  
contributes	  substantially	  to	  MMP-­‐1	  secretion,	  and	  also	  confirms	  that	  at	  high	  concentrations	  MMP-­‐1	  
secretion	  is	  inhibited	  by	  the	  presence	  of	  exogenous	  cAMP.	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6.4. Artificially	   increasing	   host	   derived	   cAMP,	   by	   utilising	   the	  
phosphodiesterase	  inhibitor	  IBMX,	  does	  not	  increase	  MMP-­‐1	  secretion	  
In	  order	  to	  confirm	  the	  observation	  that	  increasing	  cytoplasmic	  levels	  of	  cAMP	  were	  not	  associated	  
	  
with	   increased	   MMP-­‐1	   secretion,	   the	   phosphodiesterase	   inhibitor	   IBMX	   (3-­‐isobutyl-­‐1-­‐	  
methylxanthine),	   was	   utilised	   to	   indirectly	   increase	   endogenous	   cAMP	   levels.	   Eight	   PDEs	   regulate	  
host	  cAMP	  levels	  by	  converting	  cAMP	  to	  AMP.	  IBMX	  inhibits	  all	  but	  one	  of	  these	  PDEs	  and	  has	  been	  
shown	  to	  reliably	  increase	  intracellular	  cAMP	  levels	  (236).	  IBMX	  was	  placed	  onto	  the	  macrophages	  2	  








It	  was	  observed	  that	  in	  both	  in	  live	  infection,	  and	  in	  TB	  Sup	  stimulated	  cells,	  increasing	  endogenous	  
cAMP	  did	  not	  increase	  MMP-­‐1	  secretion.	  It	  was	  again	  observed	  that	  at	  high	  concentrations	  of	  IBMX	  
(which	  correspond	  to	  high	  endogenous	  cAMP	  levels),	  MMP-­‐1	  secretion	  was	  decreased.	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6.5. dbcAMP	   cannot	   be	   used	   to	   enhance	   MMP-­‐1	   secretion	   even	   with	   a	  
cAMP	  free	  stimulus	  
Broth	   culture	  of	  M.	   tb	   contains	   cAMP	   derived	   from	   the	   bacteria	   (234).	   This	   experiment	   aimed	   to	  
	  
provide	  an	  entirely	  cAMP	  free	  stimulus	  in	  which	  cAMP	  concentrations	  could	  be	  absolutely	  controlled	  
by	  supplementing	  with	  dbcAMP.	  M.	  tb	  H37Rv	  killed	  by	  UV	  irradiation	  (UVTB)	  was	  spun	  at	  10000g	  for	  
5	  minutes,	  prior	   to	  washing	  3x	   in	  PBS	  and	  then	  resuspended	   in	  either	  7H9	  (wUVTB)	  or	   the	  original	  
supernatant	   (UVTB).	   The	  wUVTB	   should	   contain	  whole	  bacteria	  devoid	  of	   any	   secreted	  mediators.	  
The	  UVTB	  served	  as	  a	  positive	  control.	  MMP-­‐7,	  which	   is	  upregulated	  by	  M.	  tb	   infection	   in	  a	  cAMP	  
independent	  manner	  (114)	  was	  also	  measured.	  






The	  addition	  of	  dbcAMP	  did	  not	  alter	  MMP-­‐1	  secretion,	  suggesting	  that	  exogenous	  cAMP	  does	  not	  
increase	   MMP-­‐1	   secretion	   (figure	   82A).	   In	   the	   same	   samples	   MMP-­‐3	   and	   -­‐7	   did	   not	   change	  
significantly	  suggesting	  that	  a	  component	  of	  the	  supernatant	  (Figure	  82B	  and	  C),	  which	  is	  not	  cAMP	  
specifically	  up-­‐regulates	  MMP-­‐1	  secretion.	  The	  observation	  that	  MMP-­‐1	  secretion	   is	  dependent	  on	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both	  a	  cellular	  and	  supernatant	  component	  of	  the	  stimulus,	  but	  that	  MMP-­‐3	  and	  -­‐7	  secretion	  is	  not,	  
indicated	  that	  enhanced	  MMP-­‐1	  secretion	  is	  dependent	  on	  a	  component	  of	  TB	  sup	  that	  is	  not	  cAMP.	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PKA	   is	   a	   downstream	   signalling	   molecule	   from	   cAMP	   (via	   PGE2).	  The	   PKA	   inhibitor	   H89	   caused	   a	  
dose	  dependent	   reduction	   in	  MMP-­‐1	  secretion	  occurs	   (Figure	  83),	   indicating	  that	  MMP-­‐1	  secretion	  
from	  M.	   tb	   infected	  macrophages	   is	   likely	   regulated	   in	   a	   cAMP	   dependent	  manner;	   although	   it	   is	  
possible	  that	  cAMP	  independent	  mechanism	  for	  PKA	  activation	  may	  exist.	  
229	  |	  P	  a	  g	  e	  	  
6.7. TNF	  secretion	  is	  reduced	  by	  dbcAMP	  in	  primary	  human	  macrophages	  
Because	   Agarwal	   et	   al.	   demonstrated	   that	   bacteria	   derived	   cAMP	   led	   to	   an	   increase	   in	   TNFα	  
secretion	   (234)	   an	   investigation	   into	   whether	   TNFα	   secretion	   was	   increased	   in	   the	   presence	   of	  
additional	   dbcAMP	  was	   performed.	   Agarwal	   had	   demonstrated	   this	   effect	   in	  mouse	   bone-­‐derived	  
monocyte-­‐macrophages,	   and	   the	   human	  monocytic	   cell	   line	   THP-­‐1.	   Surprisingly,	   in	   human	   blood-­‐	  
derived	   macrophages,	   TNFα	   secretion	   was	   decreased	   by	   increasing	   concentrations	   of	   dbcAMP	  
(Figure	   83),	   both	   at	   24	   and	   48	   hours	   post	   infection.	   These	   time	   points	   were	   used	   to	   match	   the	  





This	  data	   suggests	   that	  despite	   the	   involvement	  of	   cAMP	   in	   regulating	  MMP-­‐1	   secretion,	   bacterial	  
derived	   cAMP	   is	   not	   the	  main	   contributor	   to	  MMP-­‐1	   secretion	   during	   TB	   infection.	   However,	   the	  
observations	   in	   figure	   81,	   that	   the	   cultured	   supernatant	   led	   to	   a	   substantial	   increase	   in	   MMP-­‐1	  
secretion,	  indicate	  that	  some	  mediator	  in	  this	  supernatant	  alters	  MMP-­‐1	  secretion.	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6.8. MMP-­‐1	   and	   -­‐3	   secretion	   are	   specifically	   augmented	   by	   culture	  
supernatant,	  whereas	  MMP-­‐7	  secretion	  remains	  unchanged	  
To	   confirm	  whether	   the	   culture	   supernatant	   contained	   a	  mediator	   (which	   could	   be	   protein,	   lipid,	  
	  
nucleotide	   or	   a	   small	   molecule)	   with	   the	   potential	   to	   augment	   MMP-­‐1	   secretion,	   the	   following	  
experiment	  was	   performed:	   Differing	   concentrations	   of	   UVTB	   and	  wUVTB	  were	   used	   to	   stimulate	  
primary	  macrophages	  (figure	  84).	  A	  dose	  response	  effect	  was	  observed	  with	  both	  UVTB	  and	  wUVTB	  
(Figure	  84A	  and	  B).	  Surprisingly	  a	  dose	  response	  effect	  was	  not	  seen	  with	  MMP-­‐7	  secretion.	  This	   is	  
most	   likely	   due	   to	  MMP-­‐7	   secretion	   being	  maximal,	   even	   at	   the	   lowest	   dose	   of	   UVTB	   used.	   This	  
speculation	  is	  supported	  by	  the	  observation	  that	  a	  downwards	  trend	  is	  observed	  in	  MMP-­‐7	  secretion	  
with	   decreasing	   concentration	   of	   the	   stimulus	   (Figure	   84C).	   MMP-­‐1	   and	   -­‐3	   secretion	   differed	  
significantly	  between	  equal	  concentrations	  of	  UVTB	  and	  wUVTB	  at	  all	  concentrations	  tested	  (p<0.01)	  
whereas	  MMP-­‐7	  secretion	  was	  unchanged.	  This	  is	  a	  strong	  indicator	  that	  both	  cellular	  and	  secreted	  
components	  of	  M.tb	  act	  synergistically	  to	  cause	  MMP-­‐1	  and	  -­‐3,	  but	  not	  MMP-­‐7	  secretion.	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6.9. Summary	  
In	   this	   model	   M.	   tb	   infection,	   which	   uses	   primary	   human	   macrophages,	   it	   was	   unexpectedly	  
observed	   that	   exogenous	   cAMP,	   in	   the	   form	   of	   dbcAMP	   does	   not	   alter	  MMP-­‐1	   secretion.	   At	   high	  
concentrations,	   it	   appears	   that	   exogenous	   cAMP	   can	   even	   reduce	  MMP-­‐1	   secretion	   from	   primary	  
macrophages	   in	  the	  context	  of	  M.	  tb	   infection.	  The	  reduction	   in	  MMP-­‐1	  secretion,	  occurs	  at	  cAMP	  
concentrations	  greater	  than	  those	  observed	  during	  M.	  tb	   infection	  (234),	  and	  so	  is	  unlikely	  to	  be	  of	  
relevance	   in	   vivo.	   cAMP	   can	   restore	   the	   reduction	   in	   MMP-­‐1	   production	   during	   M.	   bovis	   BCG	  
infection	  to	  the	  levels	  seen	  during	  M.	  tb	  infection	  of	  macrophages	  (116).	  cAMP	  can	  also	  restore	  the	  
reduction	  in	  MMP-­‐1	  secretion	  caused	  COX	  inhibition	  in	  M.	  tb	  infected	  macrophages	  (114).	  The	  data	  
presented	  here	  shows	  that	  M.	  tb	  induced	  MMP-­‐1	  secretion	  is	  PKA	  dependent.	  Suggesting	  that	  cAMP	  
(as	  a	  key	  mediator	  of	  PKA)	  may	  be	  required	  for	  MMP-­‐1	  secretion.	  However,	  the	  data	  presented	  here	  
also	   suggest	   that	   exogenous	   cAMP	   alone	   cannot	   augment	  MMP-­‐1	   secretion.	   It	  would	   appear	   that	  
cAMP	   has	   a	   role	   in	   MMP-­‐1	   secretion,	   but	   that	   bacterial	   cAMP	   does	   not	   feed	   directly	   into	   this	  
pathway.	   This	   is	   confirmed	   by	   the	   observation	   that	   the	   Rv0386	   transposon	  mutant	   (which	   lacks	   a	  
functional	  adenylate	  cyclase	  shown	  to	  be	  involved	  in	  the	  secretion	  of	  cAMP	  into	  the	  host	  cell	  (234))	  
induces	   an	   equal	   amount	   of	  MMP-­‐1	   secretion	   to	   its	   parent	   strain	  M.	   tb	   CDC1551	   (PTG	   Elkington,	  
unpublished	  observation).	  
	  
Agarwal	   et.	   al	  demonstrated	   that	   picomolar	   increases	   in	   cAMP	   altered	   early	   TNFα	   secretion	   from	  
both	   the	   human	  monocytic	   cell	   line,	   THP-­‐1,	   and	  mouse	  macrophage-­‐like	   cell	   line,	   J774	   as	   well	   as	  
mouse	  bone	  derived	  monocyte-­‐macrophages	  (234).	  However,	  the	  data	  presented	  here	  show	  that	  in	  
primary	   human	   macrophages	   stimulated	   with	   M.	   tb,	   exogenous	   cAMP	   appears	   to	   reduce	   TNFα	  
secretion	   (figure	   84).	   The	   fact	   that	   increased	   levels	   of	   cAMP	   appear	   to	   be	   associated	   with	   anti-­‐	  
inflammatory,	  rather	  than	  pro-­‐inflammatory	  changes,	  is	  in-­‐keeping	  with	  a	  large	  body	  of	  work	  on	  the	  
subject	   (237-­‐244).	   This	   raises	   questions	   as	   to	  why	   the	   two	   cellular	  models	   differ.	   The	  primary	   cell	  
model	  acts	  as	  the	  most	  representative	  in	  vitro	  model	  of	  human	  responses	  to	  M.	  tb,	  but	  the	  inherent	  
variability	  makes	   it	  unsuitable	   for	  studying	  extremely	  small	  changes	   in	  cell	  behaviour.	  As	  such,	  the	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results	   shown	   here	   do	   not	   exclude	   the	   possibility	   that	   bacterial	   cAMP	   plays	   a	   role	   in	   MMP-­‐1	  
secretion,	   but	   instead	   suggest	   that	   this	   ‘exogenous’	   cAMP	   source	   is	   not	   likely	   to	   be	   a	   major	  
contributor	  to	  MMP-­‐1	  secretion	  in	  man.	  Interestingly,	  the	  data	  suggests	  that	  a	  mediator	  secreted	  by	  
M.	  tuberculosis	  may	  specifically	  drive	  MMP-­‐1	  secretion	  (figures	  82	  and	  85).	  
	  
	  
The	  data	  show	  repeatedly	  that	  filtered	  supernatant	  from	  M.	  tb	  culture	  can	  induce	  MMP-­‐1	  secretion.	  
In	  addition	  to	  this,	  supernatant	  from	  UV-­‐killed	  M.	  tb	  augments	  secretion	  of	  MMP-­‐1	  and	  -­‐3,	  but	  not	  
MMP-­‐7,	   from	   macrophages.	   This	   suggests	   that	   MMP-­‐1/-­‐3	   are	   specifically	   up-­‐regulated	   by	   some	  
component	   of	   the	   supernatant	   of	  M.	   tb	   broth	   culture.	   The	   possibility	   of	   such	   a	   virulence	   factor	  
warrants	   further	   investigation.	   This	   is	   particularly	   pertinent	   as	   ESAT-­‐6	   has	   been	   linked	   to	  MMP-­‐9	  
secretion	  and	  cellular	   recruitment	   in	   the	   zebrafish	  model	  of	   TB	   (111).	   Induction	  of	  MMPs	  has	   also	  
been	  suggested	  as	  a	  pathogenic	  mechanism	  in	  both	  Pseudomonas	  aeruginosa	  (245)	  and	  Helicobacter	  
pylori	  (246,	  247).	  The	  ‘secretome’	  of	  M.	  tb	  has	  been	  thoroughly	  assessed	  by	  the	  vaccine	  community,	  
looking	   to	   identify	   antigenic	   peptides	   (248).	   Few	   people	   have	   identified	   functional	   activities	   for	  
components	   of	   the	   secretome.	   However,	   the	   possibility	   that	   secreted	   products	   modulate	   host	  
immune	  responses	  has	  been	  explored	  by	  several	  groups	  who	  have	  identified	  small	  molecules	   (234),	  
lipids	  (249),	  and	  proteins	  (111)	  that	  mediate	  specific	  immune	  responses.	  
	  
Finally,	   and	   perhaps	  most	   clinically	   pertinent	   is	   that	   increasing	   the	   production	  of	   cAMP	   (the	  main	  
function	   of	   commonly	   used	   phosphodiesterase	   inhibitors)	   may	   reduce	   MMP-­‐1	   secretion	   in	   the	  
context	  of	  TB.	  This	  effect	  would	  not	  be	  revealed	  by	  mouse	  studies.	  Mouse	  trials	  have	  suggested	  that	  
PDE	   inhibition	  may	  be	  effective	  adjunctive	  therapy	   (250,	  251),	  and	  so	   it	   is	  possible,	   that	   this	  effect	  
may	   be	   underestimating	   potential	   clinical	   benefit.	   It	   would	   be	   interesting	   to	   investigate	   if	   similar	  
divergences	  in	  cAMP	  signalling	  occurred	  in	  rabbits,	  a	  mechanism	  which	  may	  explain	  why	  trials	  of	  PDE	  
inhibitors	  in	  rabbits	  infected	  with	  M.	  tb	  reduced	  pathology	  and	  facilitated	  isoniazid	  activity	  (167).	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7. Discussion	  and	  Future	  Directions	  
	  
	  
Tuberculosis	  is	  a	  preventable	  cause	  of	  death,	  and	  yet	  it	  kills	  more	  than	  1.4	  million	  people	  each	  year	  
(1).	  10	  million	  children	  are	  orphaned	  each	  year	  by	  disease	  (2).	  It	  is	  estimated	  that	  the	  disease	  has	  a	  
total	   economic	   cost	   of	   $519	   billion	   in	   sub-­‐Saharan	   Africa	   alone	   (4).	   Clearly,	   a	   monumental,	   co-­‐	  
ordinated	   effort	   is	   required	   to	   improve	   preventative	   measures	   and	   facilitate	   diagnosis	   and	  
treatment,	  especially	  in	  the	  complex	  social	  settings	  where	  TB	  is	  most	  prevalent.	  Novel	  preventative,	  
diagnostic	  and	  therapeutic	  approaches	  must	  be	  developed	  if	  we	  are	  to	  combat	  TB	  in	  the	  developing	  
world.	  
	  
Tissue	  destruction,	   in	  particular	  cavity	   formation,	   is	  a	  common	  phenotype	  of	  active	  tuberculosis	   (9,	  
10,	  39,	  60,	  69,	  71,	  85,	  118)	  and	  rarely	  occurs	  in	  other	  diseases	  (88).	  It	  contributes	  to	  morbidity	  (176-­‐	  
179),	  mortality	   (180-­‐183),	   transmission	   (184,	   185),	   and	   treatment	   failure	   (71,	   86,	   186).	   It	   is	   poorly	  
understood,	  largely	  due	  to	  the	  paucity	  of	  animal	  models	  in	  which	  it	  can	  be	  rigorously	  studied.	  
	  
Animal	  models	  provide	  proof-­‐of-­‐concept	  and	  safety	  information	  prior	  to	  performing	  trials	  in	  human	  
beings.	  Reducing	  the	  risk	  of	  newly	  trialled	  therapies	  is	  especially	   important	  in	  tuberculosis,	  which	  is	  
readily	   cured	   in	   the	   individual,	   with	   a	   suboptimal,	   but	   still	   relatively	   easily	   administered	   and	  
tolerated,	  course	  of	  antibiotics.	  Combating	  the	  TB	  problem	  in	  regions	  with	  limited	  resources	  requires	  
more	  easily	  implemented	  interventions,	  but	  the	  trial	  of	  novel	  strategies	  is	  challenging	  where	  it	  is	  the	  
ethical	   duty	   of	   the	   researcher	   to	   ensure	   that	   those	  within	   a	   cohort	   receive	   at	   least	   optimal	   care.	  
Careful	   use	   and	   interpretation	   	   of	   animal	   models	   can	   	   be	   used	   to	   select	   the	   best	   interventional	  
candidates.	  In	  depth	  analysis	  of	  animal	  models	  may	  provide	  insight	  into	  mechanisms	  of	  disease.	  
	  
This	  thesis	  describes	  modifications	  to,	  and	  investigations	  of,	  a	  cavity	  model	  of	  tuberculosis	  that	  can	  
be	  used	  for	  preclinical	  trials.	  It	  describes	  the	  development	  of	  modalities	  to	  better	  assess	  this	  model,	  
and	  the	  confirmation	  that	  collagen	  degrading	  enzymes	  are	  associated,	  at	  a	  tissue	   level,	  with	  cavity	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formation.	   The	   hope	   is	   that	   this	  work	  will	   facilitate	   investigation	   of	   novel	   therapies	   to	   tackle	   this	  
global	  epidemic.	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7.1. A	   cavity	   model	   that	   recapitulates	   human	   pathology,	   in	   a	   manner	  
which	  makes	  interventional	  trials	  feasible	  
The	  key	  contribution	  of	  the	  work	  outlined	  here	   is	  the	  introduction	  of	  a	  modified	  model	  of	  cavitary	  
	  
tuberculosis	  that	  rapidly	  and	  reliably	  recapitulates	  the	  cavitary	  phenotype	  in	  man	  (185,	  252).	  Despite	  
the	   highly	   artificial	   process	   that	   leads	   to	   cavity	   formation	   in	   this	   model,	   the	   endpoint	   is	  
representative	   of	   human	   disease.	   The	   histology	   is	   similar	   (71,	   73,	   155);	   there	   is	   a	   fibrotic	   layer	  
surrounded	   by	   lymphocytes,	   within	   which	   lies	   a	   layer	   of	   epithelioid	   macrophages	   which	   become	  
increasingly	  necrotic	  towards	  the	  centre	  of	   the	  cavity.	   In	  the	  necrotic	   region	  high	  numbers	  of	  acid-­‐	  
fast	  bacteria	  are	  found.	  Multinucleate	  giant	  cells	  and	  foam	  cells	  are	  observed;	  although	  perhaps	  less	  
commonly	  than	  in	  human	  specimens,	  perhaps	  because	  such	  cell	  types	  form	  at	  later	  time	  points.	  CT	  
findings	  are	  similar	  to	  those	  found	  in	  human	  disease	  (252-­‐254)	  –	  cavities	  they	  are	  thick-­‐walled,	  with	  
surrounding	  infiltrate	  and	  are	  associated	  with	  airway	  change.	  Crucially,	  viable	  bacteria	  localise	  to	  the	  
cavity	   surface,	   as	   in	   human	   disease	   (69,	   71,	   83).	   The	   cavities	   developed	   in	   the	   model	   do	   not	  
significantly	   differ	   in	   phenotype	   from	   those	   seen	   in	   ‘natural’	   models,	   where	   aerosol	   infection	   is	  
followed	   by	   chronic	   disease	   (155,	   162,	   163,	   189).	   It	   is	   therefore	   logical	   to	   investigate	   the	   process	  
cavity	  development	  in	  the	  new	  model,	  because	  it	  may	  reflect	  the	  process	  of	  natural	  cavity	  formation	  
in	   man.	   Conveniently,	   the	   short	   time	   course	   in	   cavity	   development	   means	   that	   well	   matched	  
comparisons	  can	  be	  made.	  
	  
Experimental	  techniques	  designed	  to	  investigate	  if	  cavity	  formation	  correlates	  with	  transmission	  did	  
not	   yield	   positive	   results.	   However,	   further	   modifications	   to	   these	   methods,	   or	   perhaps	   careful	  
examination	  of	  the	  pattern	  of	  dissemination	  after	  cavity	   formation,	  may	  reveal	  whether	  this	  model	  
can	  be	  used	  to	  better	  understand	  the	  role	  of	  cavity	  formation	  in	  transmission.	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7.2. Simple	  imaging	  modalities	  allow	  for	  the	  monitoring	  of	  progression	  of	  
disease	  in	  a	  single	  animal	  
In	  	  man,	   the	  	  severity	   of	  	  TB	  	  can	  	  be	   measured	   in	   many	  	  ways;	   mortality,	  	  symptom	  	  scores,	   DALYs	  
	  
(disability	  adjusted	  life	  years),	  QALYs	  (quality	  adjusted	  life	  years),	  sputum	  bacillary	  count,	  structural	  
extent	   of	   disease,	   respiratory	   function,	   weight,	   immunological	   parameter	   change,	   transmissibility	  
and	  many	  so	  forth.	  It	  is	  essential	  to	  remember	  that	  the	  aim	  in	  treating	  an	  individual,	  is	  to	  achieve	  the	  
absence	  of	  disease	  (i.e.	  symptoms)	  in	  both	  the	  short	  and	  long-­‐term,	  and	  that	  at	  a	  community	  level,	  
(be	   it	   local	   or	   global)	   the	  aim	   is	   to	   prevent	   disease	   in	  unaffected	   individuals,	   either	   by	   preventing	  
acquisition	   directly,	   or	   by	   preventing	   transmission	   from	   infectious	   sources	   (i.e	   treating	   infected	  
individuals).	   If	   treatment	   strategies	   are	   to	   achieve	   this,	   better	   correlates	   for	   symptomatic	   disease	  
and	  transmission	  must	  be	  found	  in	  animal	  models.	  Current	  readouts	  of	  TB	  models	  include	  mortality,	  
histology,	   bacterial	   burden,	   immunological	   marker	   change	   and	   weight-­‐change.	   All	   of	   these	  
measures,	  are	  highly	  correlative	  with	  bacterial	  burden,	  which	  is	  only	  partially	  responsible	  for	  disease	  
outcome	  in	  man	  (69,	  71,	  74,	  75).	  These	  measures	  can	  therefore	  predict	  the	  efficacy	  of	  antibacterial	  
agents,	  and	  the	   importance	  of	  bacterial	  virulence	  factors	  required	  for	  survival	   in	  the	  context	  of	  the	  
model	  species’	  immune	  response	  (which	  is	  often	  largely	  ineffective	  against	  the	  pathogen).	  However,	  
they	   still	   cannot	   universally	   predict	   antibiotic	   effectiveness	   in	  man	   (128,	   255-­‐257).	   They	  may	   also	  
predict	  how	  well	  vaccines	  enhance	  clearance	  of	  infection	  by	  the	  host	  species;	  although	  it	  is	  clear	  that	  
immune-­‐mediated	  clearance	  in	  many	  animal	  species	  does	  not	  often	  predict	  outcome	  in	  humans	  (22,	  
258-­‐260).	  
	  
This	   thesis	   presents	   a	   structural	   imaging	   	  method	   	   to	   assess	   a	   functional	   	   correlate	   of	   disease	   in	  
rabbits.	   Evaluation	   of	   novel	   therapeutic	   strategies	   in	   this	   model	   may	   help	   us	   better	   understand	  
current	  clinical	  strategies,	  and	  design	  similarly	  efficacious	  strategies.	  Occasionally,	  functional	  imaging	  
has	  been	  used	   to	  assess	   local	   inflammation	   in	  animal	  models	  of	  TB	   (133,	  134,	  165,	  261);	  however,	  
evaluation	  of	   disease	   extent	   by	   CT	   has	   not	   previously	   been	  performed.	   This	   is	   surprising	   since	  we	  
observed	  that	  in	  our	  model,	  CT	  changes	  better	  predict	  disease	  outcome	  than	  PET	  (262,	  263).	  
238	  |	  P	  a	  g	  e	  	  
The	  breath-­‐hold	  technique	  allows	  for	  quantification	  of	  pathology	   in	  vivo,	  and	   is	  a	  modification	  of	  a	  
similar	   technique	   used	   in	   neonates	   (202).	   The	   analysis,	   which	   was	   a	   modification	   of	   methods	  
previously	   used	   in	   humans	   (191),	   demonstrated	   clear	   changes	   in	   lung	   involvement,	   even	   over	   the	  
short	  duration	  of	  these	  experiments.	  The	  presence	  of	  such	  readily	  measurable	  changes	  suggests	  that	  
observable	   difference	   would	   occur	   with	   effective	   therapeutics.	   Additionally,	   an	   estimate	   of	  
recruitable	   lung	   can	   be	   achieved	   by	   varying	   lung	   pressure,	   again,	   by	   modification	   a	   previously	  
published	   technique	   (191).	   Finally,	   a	   disease	   specific	   method	   was	   developed	   to	   assess,	   in	   a	   non-­‐	  
biased	  manner,	  regions	  in	  which	  pathological	  change	  is	  observed,	  before	  and	  after	   infection.	  These	  
give	  accurate	  measures	  of	  specifically	  diseased	  regions	  –	  which	  can	  then	  be	  visualised,	  allowing	  for	  
subjective	  analysis	  of	   the	  quantified	  regions.	  This	   technique	   is	  clearly	  unrefined	  when	  combined	  to	  
cutting	  edge	  regional	  pulmonary	   function	  analysis	   (210,	  211),	  but	   represents	  a	  conceptual	  advance	  
in	  the	  use	  of	  animal	  models	  for	  TB	  research.	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7.3. Hypersensitivity	  to	  PPD	  is	  correlated	  with	  cavity	  development	  
The	  data	  presented	  here	  suggests	  that	  in	  rabbits,	  sensitisation	  as	  measured	  by	  TST	  reactivity	  (type	  IV	  
hypersensitivity	   (39)),	   to	  PPD	   (as	  opposed	  to	  old	   tuberculin),	   increases	   the	  risk	  of	  cavity	   formation.	  
This	  is	  in-­‐keeping	  with	  previous	  investigations	  where	  sensitisation	  resulted	  in	  cavity	  formation	  (157-­‐	  
161,	  168,	  169,	  264,	  265).	   It	   is	  unclear	  how	  this	  observation	  correlates	   to	   sporadic	   cavity	   formation	  
during	  chronic	  infection	  in	  rabbits	  (155,	  162,	  163,	  165).	  A	  unifying	  theory	  is	  that	  chronic	  infection	  in	  
itself	  causes	  sensitisation	  (189),	  and	  that	  when	  bacterial	  burden	  is	  sustained	  after	  sensitisation,	  then	  
cavity	   formation	  occurs.	   This	  would	  explain	   the	  variety	  of	  outcomes	   seen	   in	   chronic	   infection.	  This	  
would	   suggest	   that	   sensitised	   animals	   also	   mount	   a	   bactericidal	   immune	   response	   that	   is	  
simultaneously	   protective	   in	   certain	   regions	   but	   destructive	   in	   others.	   Currently,	   little	   is	   known	  
about	  why	  certain	  strains	  produce	  chronic	   infection	  when	  others	  (particular	  CDC1551)	  do	  not	   (156,	  
266).	  The	  best	  characterised	  strains	  which	  causes	  chronic	  infection	  in	  rabbits	  is	  HN878,	  and	  the	  only	  
suggested	  mechanisms	   for	   its	   increased	   virulence	   in	   animal	  models	   are	   contradictory;,	   suggesting	  
alternative	  roles	  for	  IFNα	  and	  β	  induction	  and	  delay	  in	  Th1	  responses	  (163,	  267-­‐269).	  
	  
This	   hypothesis	   is	   in-­‐keeping	   with	  molecular	   data	   from	   other	  model	   systems	   in	   which	   apparently	  
paradoxical	   roles	   for	   a	   number	   of	   mediators	   of	   inflammation	   occur.	   TNF	   (136,	   141,	   270),	  
Leukotriene	  A4	  (142,	  143,	  271),	  PD-­‐1	  (272-­‐274)	  and	  cAMP	  (167,	  234,	  250,	  275)	  have	  all	  been	  shown	  
to	   be	   associated	   with	   divergent	   disease	   outcomes.	   Sensitisation	   probably	   results	   in	   disruption	   of	  
many	   of	   these	   responses,	   which	   will	   vary	   subtly	   in	   a	   lesion-­‐to-­‐lesion	   manner.	   The	   high-­‐dose	  
sensitisation	   regimen	   administered	   as	   part	   of	   these	   experiments,	   as	  well	   as	   consistent	   delivery	   of	  
equal	  bacterial	  burdens,	  may	  provide	  a	  consistency	  in	  responses	  that	  does	  not	  occur	  with	  lower	  dose	  
sensitisations,	   or	   aerosol	   infection.	   Careful	   dissection	   of	   the	   relevant	   pathways	   is	   warranted,	   and	  
conveniently,	   pharmaceutical	   inhibitors	   and	  modulators	   of	   many	   of	   these	   pathways	   are	   available	  
(276-­‐279).	   Introduction	   of	   such	   inhibitors	   into	   the	   model	   system	   presented	   here	   may	   reveal	  
functional	  outcomes	  that	  other	  animal	  models	  may	  not	  predict.	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Finally,	  it	  is	  worth	  considering	  that	  Dannenberg	  claims	  that	  humans	  are	  ‘100	  times	  more	  sensitive	  to	  
tuberculin’	  than	  rabbits	  (189),	  if	  this	  estimate	  is	  true,	  lower	  dose	  exposure	  to	  mycobacterial	  products	  
in	  man	  may	  have	  a	  dramatic	  effect	  in	  inducing	  hypersensitivity.	  The	  experimental	  data	  presented	  in	  
this	   thesis	   suggest	   that	   TST-­‐positivity	   is	   a	   risk	   factor	   for	   active	   TB,	   rather	   than	   a	   simple	  marker	   of	  
exposure	  (9,	  39,	  280).	  Were	  this	  to	  be	  true	  in	  people,	  it	  would	  imply	  that	  latent	  disease	  (rather	  than	  
latent	   infection)	   is	   indicated	  by	  a	  positive	  TST,	  and	   that,	   logically,	   subclinical	   infection	  need	  not	  be	  
accompanied	  by	   a	  positive	  TST.	   Such	  subclinical	   infection	   is	  a	   low	   risk	   for	   active	  disease.	  This	   logic	  
would	  explain	  why	   it	   is	  well	  documented	  that	  TST/IGRA	  negative	   individuals	  may	  develop	  active	  TB	  
without	  a	  discernible	  new	  exposure	  when	  given	  anti-­‐TNF	  therapy	   (281-­‐284).	  This	  hypothesis	  would	  
also	   provide	   an	   explanation	   for	   the	   surprising	   absence	   of	   TST-­‐positivity	   in	   some	   highly	   exposed	  
individuals	  (37,	  285),	  and	  why	  TST-­‐negative	  immunocompetent	  individuals	  have	  a	  low	  risk	  of	  disease.	  
If	   this	   is	   true,	   then	  reinterpretation	  of	  studies	  where	  persistent	   lack	  of	  conversion	  was	  assumed	  to	  
be	   the	   protective	   from	   infection	   (285)	   is	   needed.	   This	   consideration	   is	   extremely	   important	   in	   the	  
context	   of	   vaccine	   use	   and	   development,	   since	   it	   would	   suggest	   that	   developing	   certain	   immune	  
responses	  may	  dispose	  to	  more	  destructive	  disease,	  even	  if	  the	  vaccine	  is	  initially	  protective.	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7.4. Pulmonary	   disease	   in	   the	   rabbit	   resulting	   from	   M.	   bovis	   and	   M.	  
tuberculosis	  infection	  are	  phenotypically	  different	  from	  each	  other	  
The	  work	  in	  this	  thesis	  also	  investigated	  infection	  of	  rabbits	  with	  Mycobacterium	  bovis	  ravenel	  after	  
	  
sensitisation.	  It	  is	  apparent	  that	  M.	  bovis	  infection	  results	  in	  a	  fundamentally	  different	  disease	  from	  
that	  caused	  by	  M.	  tb	  in	  rabbits	  (73-­‐75).	  This	  difference	  is	  often	  overlooked	  (74,	  75).	  M.	  bovis,	  but	  not	  
M.	   tb,	   rapidly	   disseminates	   and	   establishes	   infection	   in	   multiple	   organ	   sites.	   This	   observation	   is	  
important	   to	  consider	  because	  M.	  bovis	  has	  not	  been	  sustained	   in	  human	  populations	  whereas	  M.	  
tuberculosis	   has,	   implying	   that	   intra-­‐host	   dissemination	   in	   the	   life-­‐cycle	   of	  M.	   tb	   is	   questionable	  
importance.	   However,	   the	   data	   here	   also	   suggest	   that	   despite	   being	   less	   capable	   of	   causing	  
disseminated	   disease,	   M.	   tb	   infection	   results	   in	   cavity	   formation	   more	   often.	   Because	   cavity	  
formation	   is	   associated	   with	   disease	   transmission	   (184,	   185),	   the	   preponderance	   for	   M.	   tb	   to	  
develop	  cavitary	  disease,	  instead	  of	  disseminated	  disease,	  indicates	  a	  direct	  link	  between	  cavitation	  
and	  M.	   tb,	   and	   strongly	   indicates	   that	   cavity	   formation	   is	   a	   bacterial	   driven	   process.	  M.	   bovis	   is	  
primarily	   found	   in	   domestic	   animal	   populations,	   where	   the	  mechanism	   of	   transmission,	   although	  
often	   assumed	   to	   be	   ‘aerosol’,	  may	   be	   uro/faecal-­‐respiratory	   transfer,	   and	   through	   contaminated	  
milk.	  
	  
The	   data	   presented	   here	   suggest	   that	   the	   immune	   responses	   to	   M.	   bovis	   ravenel	   are	   highly	  
inflammatory	  when	   compared	   to	   equivalent	   infection	  with	  M.	   tb	   H37Rv.	  This	   suggests	   that	   cavity	  
formation	  is	  a	  distinct	  process	  from	  inflammation,	  and	  suggests	  that	  cavity	  formation,	  as	  opposed	  to	  
general	  necrotic	  or	  inflammatory	  pathways,	  is	  driven	  by	  M.	  tb.	  This	  is	  evidenced	  by	  the	  observation	  
that	  M.	  tb	  secretes	  a	  mediator	  that	  drives	  MMP-­‐1	  secretion	  by	  macrophages.	  
	  
Although	   the	   focus	  of	   this	   thesis	   is	   on	   the	   importance	   of	  M.	   tb	  as	   a	   human	   pathogen,	   it	  must	   be	  
remembered	  that	  the	  economic	  burden	  of	  M.	  bovis	  in	  livestock	  is	  an	  important	  subject	  (57,	  58,	  286-­‐	  
293).	  No	   conclusive	   evidence	   for	   aerosol	   transmission	  of	  M.	  bovis	   could	  be	   found,	   an	  observation	  
that	  is	   in-­‐keeping	  with	  the	  finding	  that	  human-­‐to-­‐human	  transmission	  is	  very	  rare;	  human	  infection	  
is	   primarily	  	  through	  	  ingestion	  	  of	  	  contaminated	   milk	  	  or	  	  occupational	  	  exposure	  	  (294,	  	  295).	  	  Lurie	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demonstrated	   transmission	   of	  M.	   bovis	   from	   one	   rabbit	   to	   another	   across	   an	   air-­‐gap,	   however,	  
transmission	  did	  not	  occur	  if	  cages	  were	  regularly	  cleaned	  and	  less	  bedding	  was	  used	  (74,	  75,	  205),	  
suggesting	   that	   the	   primary	   mechanism	   of	   transmission	  	  was	   via	   contaminated	   bedding	   and	   not	  
direct	  exhalation	  of	  bacteria.	  
	  
The	  differences	  between	  the	  M.	  bovis	  and	  M.	  tb	  must	  explain	  why	  M.	  bovis	   is	  not	  epidemic	  in	  man	  
whereas	  M.	  tb	   is.	  This	  observation,	  and	  the	  data	  presented	  here,	  suggest	  that	  M.	  bovis	  lacks	  crucial	  
traits	  required	  for	  successful	  transmission	  in	  man	  (since	  it	   is	  clearly	  virulent	  within	  man(295))	  –	  and	  
is	   therefore	  a	   very	   separate	  disease.	   Since	  M.	   tb	  strains	   can	   sustain	   infection	   in	   rabbits	   (155,	  163-­‐	  
165),	   it	   seems	   that	   the	   use	   of	   the	   different	   M.	   bovis	   infection	   model	   for	   investigating	   TB	   is	  
unwarranted.	   However,	   it	   is	   important	   that	   an	   understanding	   of	   the	   mechanisms	   involved	   in	   the	  
pathogenesis	  of	  TB,	  and	  the	  disease	  caused	  by	  M.	  bovis	  are	  sought.	  By	  comparing	  the	  two	  infections,	  
specific	  mechanisms	  that	  underlie	   their	   respective	  successes	   in	   the	  populations	   they	  affect	  may	  be	  
revealed.	  Understanding	   such	  mechanisms	  may	   reveal	   novel	   therapeutic	   targets,	  which	  may	   be	  of	  
particular	  interest	  to	  those	  seeking	  to	  prevent	  disease	  transmission.	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7.5. Molecular	   characterisation	   of	   the	   modified	   cavity	   model	   suggests	  
parallels	  to	  human	  disease	  and	  reveals	  potential	  therapeutic	  targets	  
The	   final	   component	  of	   the	   studies	   in	   this	   thesis	  examined	  molecular	   correlations	  between	   rabbit	  
	  
and	   human	   disease,	   focussing	   specifically	   on	   ECM-­‐degrading	   enzymes.	   The	   correlates	   between	  
disease	   in	  man	  and	  this	  model	  occur	  were	   impressive,	  with	  the	  model	  showing	  similar	   increases	   in	  
MMP	   expression	   to	   that	   observed	   in	   humans	   (105,	   107,	   109).	   In	   particular,	   MMP-­‐1,	   which	   is	  
increased	   during	   active	   TB	   (105,	   107,	   109,	   110,	   114-­‐117),	   was	   found	   to	   increase	   at	   both	   the	  
transcriptional	  and	  protein	  level	   in	  cavitary	  rabbit	  disease.	  This	  correlated	  with	  transcriptional	  data	  
from	  rabbit	  aerosol	   infection	  models	  with	  M.	   tb	  HN878	   (163,	  275).	  Since	   this	  enzyme	   is	   targetable	  
with	  an	  inhibitor	  (Ro32-­‐3555/Trocade/Cipemastat)	  of	  proven	  safety	  in	  man	  (226,	  296),	  the	  suggested	  
trials	  of	  this	  drug	  (53,	  84,	  107,	  109)	  can	  now	  be	  carried	  out	  in	  a	  relevant	  preclinical	  model	  of	  disease.	  
Perhaps	   more	   pertinent	   to	   clinical	   use,	   the	   commonly	   used	   antibiotic	   doxycycline	   is	   an	   FDA	  
approved	  inhibitor	  of	  MMP-­‐1	  (297-­‐301),	  with	  partial	  antibiotic	  effectiveness	  against	  M.	  tb	  (107),	  and	  
may	  represent	  a	  more-­‐cost	  effective	  adjunctive	  therapy	  for	  TB.	  Other	  options	  may	  exist	  for	  reducing	  
tissue	  damage,	  particularly	  by	  identifying	  the	  pathways	  involved	  in	  regulating	  MMP-­‐1	  expression.	  
	  
In	   vitro	   regulation	   of	   MMP-­‐1	   was	   examined	   using	   a	   blood-­‐derived	   human	   macrophage	   culture	  
model.	   Having	   hypothesised	   that	   bacterial	   derived	   cAMP	   (234)	  may	   be	   a	   key	  mediator	   promoting	  
MMP-­‐1	  secretion,	  it	  was	  discovered,	  surprisingly,	  that	  high	  levels	  of	  cAMP	  reduced	  MMP-­‐1	  secretion	  
by	   infected	  macrophages.	   In	  keeping	  with	  this	  observation	  the	  experiments	  demonstrated	  that	  the	  
pan-­‐PDE	  inhibitor	  IBMX	  (which	  should	  cause	  an	  increase	  in	  intracellular	  cAMP)	  also	  decreased	  MMP-­‐	  
1	   secretion.	   This	   data	   supports	   the	   observation	   that	   CC-­‐3052,	   a	   PDE4	   inhibitor,	   reduced	   MMP-­‐1	  
expression	  in	  a	  rabbit	  model	  of	  TB	  (275).	  PDE	  inhibitors	  have	  shown	  adjunctive	  therapeutic	  potential	  
for	  treatment	  of	  M.	  tb	  infection	  in	  mice	  (250,	  251)	  and	  rabbits	  (167,	  275).	  The	  benefit	  derived	  in	  the	  
treatment	   of	   mice,	   suggests	   an	   MMP-­‐1	   independent	   mechanism,	   since	   mice	   do	   not	   express	   a	  
functional	   homologue	   of	   MMP-­‐1	   in	   lung	   tissue	   (130).	   There	   benefit	   in	   the	   rabbit	   model	   may	   be	  
MMP-­‐1	  dependent,	  but	  since	  extensive	  ECM	  degradation	  does	  not	  occur	   in	  this	  model	  at	  the	  time	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points	  studied,	  this	  reduction	  does	  not	  establish	  if	  MMP-­‐1	  inhibition	  is	  important.	  Further	  to	  this,	  the	  
data	  presented	  here	  also	  suggest	  that	  M.	  tb	  secretes	  a	  mediator	  that	  enhances	  MMP-­‐1	  secretion	  by	  
macrophages.	   Further	   understanding	   of	   such	   a	   mechanism	   would	   be	   of	   great	   interest,	   as	   it	   may	  
reveal	   a	   virulence	   factor	   essential	   for	   continued	   disease	   progression	   and	   transmission.	   One	   could	  
speculate	  that	  neutralisation	  of	  such	  a	  factor	  could	  prevent	  disease	  progression,	  and	  would	  make	  a	  
worthy	  vaccine	  target.	  
	  
In	   addition	   to	   MMP-­‐1,	   this	   study	   also	   identified	   Cathepsin	   K	   as	   another	   potential	   mediator	   	   of	  
collagenolysis	  in	  TB.	  Cathepsin	  K	  is	  a	  cysteine	  protease	  with	  fibrillar	  collagenase	  activity	  at	  acidic	  pH	  
(221)	  and	  the	  only	  non-­‐MMP,	  type-­‐I	  collagenase.	  Coincidently,	  cathepsin	  K	  was	  demonstrated	  to	  be	  
associated	  with	   TB	   pathology	   by	   another	   group	   observing	   the	   role	   of	  multi-­‐nucleate	   giant	   cells	   in	  
various	  pathologies	  (173),	  although	  the	  data	  in	  this	  thesis	  confirms	  that	  cathepsin	  K	  expression	  is	  not	  
limited	   to	   these	   cell	   types.	   Although	   cathepsin	   D	   has	   previously	   been	   associated	   with	   tissue	  
destruction	   in	   rabbits	   (162)	   –	   this	   structurally	   related	   enzyme,	   has	   no	   known	   function	   in	   tissue	  
destruction.	   There	   is	   a	   clinically	   safe	   drug,	   Odanacatib,	   awaiting	   FDA-­‐approval,	   which	   targets	   this	  
enzyme	  specifically	  (228-­‐233).	  
	  
Taken	   together	   the	   data	   suggests	   that	   the	   70-­‐day	   rabbit	   model	   represents	   tissue	   destructive	  
processes	   in	   active	   TB.	   The	  work	   identifies	   a	   number	   of	   potential	   targets,	   for	  which	   clinically	   safe	  
drugs	  can	  be	  repurposed	  for	  rapid	  clinical	  deployment.	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7.6. Summary	  
This	  work	  documents	  the	  modification	  of	  a	  rabbit	  model	  of	  cavitary	  tuberculosis,	  to	  a	  point	  where	  it	  
can	   easily	   be	   used	   for	   therapeutic	   trials.	   The	  model	   is	   representative	   of	   a	   number	   of	   features	   of	  
human	   disease,	   in	   particular;	   bacterial	   localisation	   to	   the	   cavity	   surface,	   cellular	   organisation	   in	  
response	  to	  M.	  tb	   infection	  and	  ECM	  changes	  associated	  with	  TB.	  This	  thesis	  also	  outlines	  a	  simple	  
way	   to	   collect,	   analyse	   and	   present	   imaging	   data	   in	   this	  model.	   Several	  molecular	   correlates	  with	  
human	   disease	  were	   identified	   in	   this	  model,	   of	  which,	   at	   least	   two,	   are	   therapeutically	   relevant.	  
This	  thesis	  presents	  a	  model	  for	  trialling	  these	  (and	  other)	  therapies	  for	  TB.	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7.7. Future	  Directions	  
There	   are	   numerous	   future	   directions	   for	   this	   work,	   however,	   with	   the	   development	   of	   such	   a	  
specific	  model	  of	  cavitary	  disease	  a	  number	  of	  investigations	  are	  imminently	  possible.	  Although	  this	  
thesis	  followed	  a	  hypothesis	  surrounding	  the	  role	  of	  collagenases	  in	  tuberculosis,	  the	  applications	  for	  
the	   model	   and	   technologies	   developed	   during	   the	   thesis	  are	   perhaps	   more	   relevant	   to	  	  several	  
fundamental	  questions	  in	  tuberculosis	  treatment.	  
	  
7.7.1. Understanding	  and	  improving	  antibiotic	  therapy	  
Investigating	  the	  relative	  contributions	  of	  antibiotics	  to	  the	  clearance	  of	  bacteria	  from	  cavities,	  may	  
help	  us	  to	  understand	  why	  certain	  antibiotic	  regimens	  outperform	  others	  in	  man,	  despite	  similar	   in	  
vitro	  activity	   (87,	  126,	  127,	  164).	  One	   long-­‐standing	  hypothesis	   is	  that	  the	  cavity	  microenvironment	  
alters	   local	   antibiotic	   penetration	   and	   efficacy.	   This	   hypothesis	   has	   already	   been	   confirmed	   in	  
granulomas	  during	  M.	   tb	   infection	  of	   rabbits	   (164,	   166)	  using	  multiple-­‐reaction-­‐monitoring	  matrix-­‐	  
assisted	   laser	   desorption-­‐ionisation	   mass	   spectrometry	   imaging	   (MRM-­‐SELDI-­‐MSI),	   to	   investigate	  
relative	  drug	  concentrations	  in	  rabbit	   lesions.	  As	  of	  yet,	  no	  formal	  study	  of	  the	  cavity	  compartment	  
has	   been	   completed.	   This	   method	   is	   fraught	   with	   challenges,	   as	   it	   provides	   only	   relative	  
concentrations,	   and	   even	   with	   the	   establishment	   of	   such	   concentrations	   –	   it	   still	   does	   not	   give	  
compartmental	   information	   (for	   example	   whether	   the	   antibiotic	   concentrates	   in	   macrophage	  
vacuoles,	  where	  M.	   tuberculosis	  may	   persist).	   The	   current	  model	   allows	   for	   antibiotic	   exposure	   in	  
the	  cavity	  setting	  to	  be	  monitored	  using	  either	  MRM-­‐SELDI-­‐MSI,	  or	  more	  conveniently,	  by	  evaluating	  
bacterial	  burdens	  after	  antibiotic	  treatment	  -­‐	  a	  measure	  of	  actual	  efficacy,	  rather	  than	  regional	  drug	  
distribution.	  Such	  studies	  may	  help	  design	  novel	  therapeutic	  regimens	  that	  provide	  optimal	  cover	  of	  
all	  compartments	  in	  which	  bacteria	  are	  found	  in	  man.	  
	  
7.7.2. Protease	  inhibition	  as	  a	  therapeutic	  strategy	  
The	  next	  obvious	  investigation	  is	  the	  trial	  of	  these	  highly	  specific	  drugs	  Odanacatib	  and	  Cipemastat;	  
such	   trials	   will	   establish	  whether	   cathepsin	   K	   and	  MMP-­‐1	   contribute	   to	   tissue	   destruction,	   or	   are	  
merely	   associated	   with	   tissue	   destruction.	   If	   these	   therapies	   do	   prevent	   tissue	   destruction	   they	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could	   potentially	   be	   used	   therapeutically	   in	   XDR-­‐TB	   –	   where	   such	   drugs	   may	   reduce	   morbidity.	  
Secondly,	   trialling	   such	   drugs	   may	   reveal	   mechanisms	   by	   which	   these	   enzymes	   regulate	   immune	  
function,which	  may	  be	  relevant	  not	  only	  to	  understanding	  TB,	  but	  immunopathology	  in	  general.	  This	  
may	   be	   especially	   relevant	   to	   inflammatory	   conditions	   where	   tissue	   destruction	   is	   the	   hallmark.	  
Thirdly,	   these	   drugs	   could	   be	   trialled	   in	   combination	   with	   antibiotic	   regimens,	   as	   alterations	   to	  
pathology	  may	  improve	  antibiotic	  penetration.	  
	  
7.7.3. Understanding	  the	  bacterial	  factors	  involved	  in	  cavity	  formation	  
The	   final	   consideration	   is	   whether	   the	   model	   can	   be	   used	   to	   investigate	   bacterial	   factors	   which	  
contribute	   to	  cavity	   formation,	  and	   thus	   identify	  cavity	   specific	  virulence	   factors.	  The	   identification	  
of	   bacterial	   factors	   which	   contribute	   to	   cavitary	   disease	   either	   through	   direct	   induction	   of	   ECM-­‐	  
degrading	   factors,	  or	   through	  enhancing	  hypersensitivity	   reactions	  can	  now	  be	  tested	   in	  a	   relevant	  
animal	  model.	   Further	   exploration	   of	   this	   concept,	  may	   provide	   novel	   vaccine	   targets	   that	   aim	   to	  
neutralise	  the	  disease,	  rather	  than	  the	  bacteria	  itself.	  Although	  it	  is	  unlikely	  to	   lead	  to	  total	  disease	  
eradication,	  this	  efficacy	  may	  be	  enough	  to	  break	  the	  cycle	  of	  epidemic	  transmission,	  or	  accelerate	  
bacterial	   clearance	   in	   conjunction	   with	   antibiotic	   therapy,	   and	   thus	   shorten	   the	   duration	   of	  
treatment.	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